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Abstract
In the field of neuroimaging genetics, brain images are used as phenotypes in the search
for genetic variants associated with brain structure or function. This search presents a
formidable statistical challenge, not least because of the very high dimensionality of geno-
type and phenotype data produced by modern SNP (single nucleotide polymorphism) ar-
rays and high resolution MRI. This thesis focuses on the use of multivariate sparse regres-
sion models such as the group lasso and sparse group lasso for the identification of gene
pathways associated with both univariate and multivariate quantitative traits.
The methods described here take particular account of various factors specific to path-
ways genome-wide association studies including widespread correlation (linkage disequi-
librium) between genetic predictors, and the fact that many variants overlap multiple path-
ways. A resampling strategy that exploits finite sample variability is employed to provide
robust rankings for pathways, SNPs and genes. Comprehensive simulation studies are pre-
sented comparing one proposed method, pathways group lasso with adaptive weights, to a
popular alternative. This method is extended to the case of a multivariate phenotype, and
the resulting pathways sparse reduced-rank regression model and algorithm is applied to a
study identifying gene pathways associated with structural change in the brain characteris-
tic of Alzheimer’s disease. The original model is also adapted for the task of ’pathways-
driven’ SNP and gene selection, and this latter model, pathways sparse group lasso with
adaptive weights, is applied in a search for SNPs and genes associated with elevated lipid
levels in two separate cohorts of Asian adults.
Finally, in a separate section an existing method for the identification of spatially ex-
tended clusters of image voxels with heightened activation is evaluated in an imaging ge-
netic context. This method, known as cluster size inference, rests on a number of assump-
tions. Using real imaging and SNP data, false positive rates are found to be poorly con-
trolled outside of a narrow range of parameters related to image smoothness and activation
thresholds for cluster formation.
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6Chapter 1
Introduction
1.1 Gene association mapping
Since the publishing of the first draft of the human genome, a huge amount of effort has
been expended in the hunt for genetic variation associated with human disease. Much of
this work has focused on the identification of single points of variation, known as single
nucleotide polymorphisms or SNPs, where common variation is observed in the human
population (see Figure 1.1). Parallel advances in sequencing technology and the detailed
cataloguing of SNPs for diverse human populations have led to the identification of 100s of
SNPs affecting an array of common diseases and traits (Green et al., 2011; Altshuler, Daly,
and Lander, 2008).
In modern genome-wide association studies (GWAS), 100s or 1000s of individuals are
genotyped at up to a million or more SNPs across the genome. This ‘hypothesis-free’ ap-
proach to searching for genetic variants in GWAS has been greatly aided by the ability to
exploit patterns of widespread correlation or linkage disequilibrium (LD) between genetic
markers belonging to unrelated individuals. Different human sub-populations can be char-
acterised by these distinctive LD patterns, which have a block-like structure, arising from
the relatively few sexual recombination events that have occurred throughout recent hu-
man history (see Figure 1.2). For a given human sub-population, the presence of these LD
blocks or haplotypes enables single ‘tagging’ SNPs to be used as proxies for other, ungeno-
typed variants, dramatically decreasing the number of variants that need to be genotyped
Introduction 7
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Figure 1.1: Schematic representation of points of common genetic variation between individuals.
Letters ACGT represent single nucleotides that make up the human genome. Extended stretches
of nucleotides can be grouped into genes, broadly classified as functional units within the genome.
Single nucleotide polymorphisms or SNPs, are genetic loci at which there is common variation
between individuals in the human population, typically defined as variants whose minor ‘allele’
(here marked in red) occurs with a frequency > 1%. An individual has two copies of each allele,
and so may possess 0, 1 or 2 minor alleles. SNPs may occur within genes (SNP 1) or between genes
(SNP 2).
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(The International HapMap Consortium, 2005). Variants identified using this approach will
however typically have only an indirect relationship to the true causal variant(s) that they
tag (Hirschhorn and Daly, 2005). For this reason, this approach may also come at the cost
of reduced power, compared to fine-mapping studies that include all SNPs in a genomic
region of interest. The presence of LD can also lead to inflated numbers of false positives,
due to spurious associations arising from SNPs in LD with causal SNPs.
Figure 1.2: Pairwise correlation (LD) patterns between 420 SNPs on a 500kb stretch of human
chromosome 5. High pairwise correlation in the sample population is marked in brown. Blocks of
strong correlation, known as haplotypes, are marked by the black outline. Plot taken from Altshuler,
Daly, and Lander (2008).
Genetic variation between subjects is generally measured by recording the number of
minor alleles possessed by each individual, a SNP’s minor allele being defined as the less
common variant in the sample (variants marked in red in Figure 1.1). Since individuals
inherit two copies of each allele, one from the mother and one from the father, each subject
may possess zero, one or two minor alleles. Thus in a study with N subjects genotyped
at P SNPs, we can denote the minor allele count for SNP j observed on individual i as
xij ∈ {0, 1, 2}, i = 1, . . . , N ; j = 1, . . . , P .
The standard statistical approach is then one of mass univariate testing, where the hy-
pothesis that minor alleles are associated with a particular trait or phenotype is tested, one
SNP at a time. In a case-control study for example, we might test the hypothesis that minor
alleles are more likely to be found in cases than controls by testing for independence of
rows and columns in a 2 × 2 contingency table, using a χ21 test (see Table 1.1). Different
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xj 0 1, 2 total
cases d0 d12 D
controls c0 c12 C
total n0 n12 N
(a) Observed
xj 0 1, 2 total
cases n0D/N n12D/N D
controls n0C/N n12C/N C
N
(b) Expected
Table 1.1: Association test for SNP j in a case-control study. (a) d0, d12 represent observed number
of cases with xj = 0, or xj ∈ {1, 2}, respectively. c0, c12 represent the same for controls. (b)
Expected values under the null, i.e. where rows and columns in (a) are independent. The hypothesis
that minor alleles are associated with disease status is tested by observing that
∑
(Observed −
Expected)2/Expected ∼ χ21 under the null.
genetic models, assuming for example recessive or dominant genetic effects can be tested
by changing the column categories. An alternative strategy for testing associations in case-
control studies is to code phenotypes as yi ∈ {0, 1} for cases and controls respectively, and
use a logistic regression model, logit(pii) = β0 + β1xij , where logit(pii) = log(pii/(1− pii)
and pii is the disease risk of the ith individual. Here we assume an additive genetic model,
whereby disease risk increases in proportion with the number of minor alleles. We can test
the null hypothesis that there is no association between disease status, H0 : βˆ1 = 0, using a
likelihood-ratio test. The use of a logistic regression model has the advantage of allowing
easy incorporation of model covariates, such as age or sex.
The search for SNPs, known as ‘quantitative trait loci’ (QTL), influencing quantitative
traits, i.e. those that vary continuously, for example blood pressure or blood lipid levels,
is also gaining momentum as a potentially more powerful way to study the underlying
causes of complex disease (Plomin, Haworth, and Davis, 2009). For quantitative traits, the
association of SNP minor alleles with a phenotype is established using a quantitative trait
test of association (QTT). For example by assuming a linear model yi = β0 + xijβj + i,
we can perform a t-test on the SNP regression coefficient βj to test the null hypothesis
H0 : βj = 0. Once again this model can easily be extended to include covariates.
A major limitation of the mass univariate testing approach in GWAS arises from the
very large number of SNPs, and hence hypotheses that must be tested. In order for the
number of false positives to be adequately controlled, some correction to the single-SNP
threshold for significance, α, corresponding to the probability that a single test will yield a
false positive association, must be applied. If we perform P such tests across the genome,
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and further assume that each test is independent, the corresponding chance, genome-wide,
for such a false positive finding is then αGW = 1 − (1 − α)P . This leads to the familiar
Bonferroni correction, αGW = α/P , which at the α = 0.05 level yields a significance
threshold, αGW = 10−7 for a typical GWAS with P = 500, 000 . Such a stringent thresh-
old for the achieving of genome-wide significance substantially reduces the power to detect
associations (Altshuler, Daly, and Lander, 2008). The presence of widespread correlation
between markers due to LD means that tests are in fact not independent, so that the Bon-
ferroni correction is likely to be too conservative. One solution is to approximate the false
positive rate by comparing empirical p-values with a null distribution generated from the
same dataset, but with multiple phenotype permutations. Here LD patterns are preserved
while the phenotype-genotype association is broken (Balding, 2006). Another approach is
to increase power by accepting a higher risk of false positives by controlling the expected
number of false discoveries as a proportion of positive tests, using the false discovery rate
(FDR) (Benjamini and Hochberg, 1995).
In contrast to univariate, ‘one SNP at a time’ methods, multivariate or multilocus meth-
ods allow all SNPs to be considered in the model at the same time, which can aid the
identification of weak signals while diminishing the importance of false ones. Multilo-
cus or haplotype methods test the association of haplotypes, rather than individual SNPs,
with phenotypes, and are thus able to implicitly exploit dependencies between SNPs, while
reducing the number of tests to be performed (Duggal et al., 2008; Balding, Waldron,
and Whittaker, 2006). Another approach is to extend the previous, single SNP regression
model described earlier, to a multiple regression model, in which all SNPs are modelled
together. Thus for a quantitative trait we have the multiple linear regression (MLR) model,
yi = β0 +
∑P
j=1 xijβj + i. The use of multiple regression models in GWAS, while the-
oretically attractive, is however problematic in practice. Firstly, in GWAS, the number of
SNPs is typically much greater than the sample size, so that estimates for the SNP regres-
sion coefficients βj, j = 1, . . . , P , are not uniquely defined. Secondly, even where SNP
coefficients are estimable, LD or multicollinearity between SNPs renders such estimates
unreliable (Hastie, Tibshirani, and Friedman, 2008).
One solution is to use some form of regularisation or constraint on the coefficient vector
β = (β1, . . . , βP ). Types of regularisation include ridge regression (Hoerl and Kennard,
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1970), lasso regression (Tibshirani, 1996) and the elastic net (Zou and Hastie, 2005), each
of which provides coefficient estimates with different characteristic properties (see Sec-
tion 2.1). The lasso is a particularly attractive option for GWAS, since the lasso constraint
imposes sparse estimates for β, in that many individual coefficient estimates are precisely
zero. For this reason, the lasso, and related approaches such as stepwise regression (Hester-
berg et al., 2008) are often described as performing ‘model selection’, since they highlight
a subset of important predictors. Since its first application in GWAS (Wu et al., 2009), the
lasso and related sparse regression models have been used to tackle a variety of problems
in biomarker discovery. Of particular note in the present context is their use in imag-
ing genetics for the identification of SNPs associated with high-dimensional neuroimaging
phenotypes (Bunea et al., 2011; Kohannim et al., 2012a; Vounou, Nichols, and Montana,
2010).
1.2 The gene pathways approach
Gene variants identified in GWAS have so far uncovered only a relatively small part of
the known heritability of most common diseases (Visscher et al., 2012). This has focused
attention on the need to develop new methodological approaches. A number of factors that
might explain this ‘missing heritability’ have been suggested, including the failure of many
current models to capture the presence of gene-gene and gene-environment interactions, of
multiple SNPs with small effect and of rare variants (Visscher et al., 2012; Manolio et al.,
2009; Goldstein, 2009).
One promising approach uses prior information on functional structure present within
the genome. This is motivated by the observation that in many cases disease states are likely
to be driven by multiple genetic variants of small to moderate effect, mediated through their
interaction in molecular networks or pathways (Figure 1.3), rather than by the effects of a
few, highly penetrant mutations (Schadt, 2009). Where this assumption holds, the hope is
that by considering the joint effects of multiple variants acting in concert, pathways gene
association studies (PGAS) will reveal aspects of a disease’s genetic architecture that would
otherwise be missed when considering variants individually (Wang, Li, and Hakonarson,
2010; Fridley and Biernacka, 2011). Other potential benefits of PGAS include:
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Figure 1.3: Schematic of genes acting together in a functional pathway. Coloured nodes represent
genes, and edges represent possible interactions between genes. Note that pathways can interact,
and genes may belong to multiple pathways.
• the ability to accommodate genetic heterogeneity, where causal markers accumulate
within genes or pathways, but vary between individuals, so that marginal effects are
reduced across the sample as a whole (Holmans et al., 2009)
• the ability to compare results across studies genotyping different variants, that may
nonetheless be mapped to common pathways (Cantor, Lange, and Sinsheimer, 2010;
Ma and Kosorok, 2010)
• better elucidation of disease mechanisms by providing a biological interpretation of
association results (Cantor, Lange, and Sinsheimer, 2010)
• identification of targets for drug or other therapeutic interventions through the iden-
tification of disease implicated pathways (Hirschhorn, 2009).
First developed in the context of gene expression studies (Mootha et al., 2003), pathways-
based methods have more recently been extended to the analysis of GWAS data (Holmans
et al., 2009; Luo et al., 2010; Lango Allen et al., 2010; Lambert et al., 2010). This has led
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to the identification of putative causal pathways for a number of diseases including Parkin-
son’s Disease (Lesnick et al., 2007), Crohn’s Disease (Wang et al., 2009b) and rheumatoid
arthritis (Eleftherohorinou et al., 2011).
PGAS methods rely on prior information mapping SNPs to functional networks or path-
ways. Since pathways are typically defined as groups of interacting genes, SNP to pathway
mapping is a two-part process, requiring both the mapping of genes to pathways, and of
SNPs to genes. A consistent strategy for this mapping process has however yet to be es-
tablished, a situation compounded by a lack of agreement on what constitutes a pathway in
the first place (Cantor, Lange, and Sinsheimer, 2010).
The number and size of databases devoted to classifying genes into pathways is grow-
ing rapidly, as is the range and diversity of gene interactions considered (see for exam-
ple http://www.pathguide.org/). Databases such as those provided by KEGG (http://www.
genome.jp/kegg/pathway.html), Reactome (http://www.reactome.org/) and Biocarta (http:
//www.biocarta.com/) classify pathways across a number of functional domains, for ex-
ample apoptosis, cell adhesion or lipid metabolism; or crystallise current knowledge on
specific disease-related molecular reaction networks. Strategies for pathways database as-
sembly range from a fully-automated text-mining approach, to that of careful curation by
experts. Inevitably therefore, there is considerable variation between databases, in terms
of both gene coverage and consistency (Soh et al., 2010), so that the choice of database(s)
will itself influence results in PGAS.
The mapping of SNPs to genes adds a further layer of complexity, since although many
SNPs may occur within gene boundaries, in a typical GWAS, the vast majority of SNPs will
reside in inter-genic regions (see Figure 1.1). In an attempt to include variants potentially
residing in functionally significant regions lying outside gene boundaries, SNPs may be
mapped to nearby genes using various distance thresholds. Various values for SNP to
gene mapping distances, measured in thousands of nucleotide base pairs (kb), have been
suggested in the literature, ranging from mapping SNPs to genes only if they fall within a
specific gene, to the attempt to encompass upstream promoters and enhancers by extending
the range to 10, 20 or even 500kb and beyond (Wang et al., 2009b; Eleftherohorinou et al.,
2009; Cantor, Lange, and Sinsheimer, 2010). This process is illustrated schematically in
Figure 1.4. Notable features of the SNP to pathway mapping process include the fact that
1.2 The gene pathways approach 14
genes (and therefore SNPs) may map to more than one pathway, and also that many SNPs
and genes do not currently map to any known pathway (Fridley and Biernacka, 2011).
	  
	  
pathways	  
genes	  
genotyped	  SNPs	  
	  
Figure 1.4: Schematic illustration of the SNP to pathway mapping process. (i) Genes (green circles)
are mapped to pathways using information on gene-gene interactions (top row), obtained from a
gene pathways database. Many genes do not map to any known pathway (unfilled circles). Also,
some genes may map to more than one pathway. (ii) Genes that map to a pathway are in turn mapped
to genotyped SNPs within a specified distance. Many SNPs cannot be mapped to a pathway since
they do not map to a mapped gene (unfilled squares). Note SNPs may map to more than one
gene. Some SNPs (orange squares) may map to more than one pathway, either because they map to
multiple genes belonging to different pathways, or because they map to a single gene that belongs
to multiple pathways.
In common with standard statistical analysis methods in GWAS (see section 1.1), the
majority of existing PGAS methods begin with a univariate test of association, in which
individual SNPs are scored according to their degree of association with disease status or
a quantitative trait. Various techniques are then used to combine these univariate statistics
into pathway scores. For example, the GenGen method (Wang, Li, and Bucan, 2007) first
ranks all genes according to the value of the highest-scoring SNP within 500kb of each
gene, using the SNP’s χ2 statistic. Pathway significance is then assessed by determining
the degree to which high-ranking genes are over-represented in a given gene set, in com-
parison with the genomic background. The PLINK toolkit (Purcell et al., 2007) features a
‘set-based test’, in which pathway significance is measured by taking the average, marginal
p-value of a pre-determined maximum number of ‘uncorrelated’ SNPs within the pathway.
Here, uncorrelated SNPs are defined as those whose pairwise linkage disequilibrium (LD)
is below a certain threshold value. As a final step, where more than one pathway is consid-
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ered a correction for multiple testing is generally made.
Few multivariate PGAS methods that jointly model genetic predictors currently exist,
and at the time of writing, to the best of our knowledge there are none that model a quanti-
tative response. Just as with gene or SNP mapping, a multivariate or multilocus approach to
pathway mapping has the potential to increase power by fully accounting for LD structure
within SNP data (Chen et al., 2010; Hoggart et al., 2008). For example, the PoDA method
(Braun and Buetow, 2011) assesses pathway significance by computing a multilocus dis-
tance measure between cases and controls, from all SNPs mapped to a pathway. This is
expected to emphasise epistatic interactions between SNPs, over purely marginal effects on
disease status. A number of penalized regression techniques that allow prior information on
the relationship between SNP markers to be incorporated into the model selection process
have recently been proposed. For example, Zhou et al. (2010) group SNPs into genes, and
utilise a useful property of the group lasso (Yuan and Lin, 2006) to aid the detection of rare
variants within genes. The GRASS method (Chen et al., 2010) uses a combination of lasso
and ridge regression to assess the significance of association between a candidate pathway
and a dichotomous (case-control) phenotype. Comparisons with other PGAS methods us-
ing simulated data suggests that this regularised approach may be more powerful. Finally,
Zhao et al. (2011) use a combination of PCA and lasso regression to identify pathways as-
sociated with disease status. A review of existing PGAS methods is presented in Appendix
A.
In Chapter 2, we describe a group-sparse, multiple regression model, with SNPs grouped
into pathways, to identify causal pathways associated with a quantitative trait. Our method,
which we call ‘Pathways Group Lasso With Adaptive Weights’ (P-GLAW), includes all
pathways together in a single regression model, since we expect to gain a better measure of
the relative importance of different pathways by ensuring they compete against each other.
Other notable features of our method include an adaptive pathway weighting procedure that
accounts for factors biasing pathway selection, and the use of a subsampling procedure for
the ranking of important pathways. Our method additionally takes account of the presence
of SNPs overlapping multiple pathways and uses a novel combination of techniques to opti-
mise model estimation, making it fast to run, even on whole genome datasets. We conclude
Chapter 2 with a comparison study in which we compare our method with an alternative,
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commonly used pathways method based on univariate SNP statistics, using real pathways
and genotype data. We show that our method demonstrates high sensitivity and specificity
for the detection of important pathways, showing the greatest relative gains in performance
where marginal SNP effect sizes are small.
In identifying pathways associated with a quantitative trait, a natural follow-up ques-
tion is to ask which SNPs and/or genes are driving pathway selection? One way to answer
this question is by conducting a two-stage analysis, in which we search for important SNPs
in pathways identified in an initial pathway-mapping step. Such an approach is taken by
Eleftherohorinou et al. (2009), who use the lasso to identify SNPs in previously identified
significant pathways. We adopt a two-step approach to SNP and gene ranking in the method
and application study that we describe in Chapter 3. However, since the assumption here is
that few SNPs in a pathway are contributing to any putative pathway signal, a potentially
more elegant approach is to perform simultaneous, pathway and SNP selection in a single
model. An existing sparse regression model, the sparse group lasso (SGL) (Simon et al.,
2012), generates the required ‘dual-level’ sparsity, although it has yet to be applied to path-
way and SNP selection. In Chapter 4, we develop an SGL-based sparse selection method,
which we call ‘Pathways Sparse Group Lasso With Adaptive Weights’ (P-SGLAW), and
examine whether ‘pathways-driven SNP selection’, that is the incorporation of informa-
tion on the interaction of SNPs within gene pathways into a variable selection model, can
boost the power to detect SNPs associated with a quantitative trait. In simulation stud-
ies we show that where causal variants are enriched in a particular pathway, our proposed
method can aid the identification of SNPs, compared with simple lasso selection that dis-
regards pathways information. We conclude Chapter 4 with an application study in which
we investigate pathways, SNPs and genes associated with levels of HDL-cholesterol in two
Asian cohorts.
1.3 Imaging genetics
In the emerging field of neuroimaging genetics, scans of the living brain obtained using
PET, MRI or other imaging modalities, are used to extract phenotypes in genetic associ-
ation studies (Glahn, Thompson, and Blangero, 2007). The rationale here is that the use
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of heritable imaging signatures of disease, known as endophenotypes, may increase the
power to detect causal variants, when compared for example with case-control phenotypes,
since gene effects are expected to be more penetrant at the imaging level, rather than at the
diagnostic level (Meyer-Lindenberg and Weinberger, 2006; Hibar et al., 2011a). In some re-
spects this use of quantitative endophenotypes in imaging genetics follows similar trends in
the wider field of complex trait genetics, where the search for quantitative trait loci (QTL)
influencing quantitative traits is gaining momentum as a potentially more powerful way to
study the underlying causes of complex disease (Plomin, Haworth, and Davis, 2009).
To date, neuroimaging genetic studies have been used to study genetic mechanisms un-
derpinning a wide range of psychiatric and neurodegenerative disease including depression,
schizophrenia and Alzheimer’s disease, and have also been used to study genetic effects on
cognition in healthy populations (see Bigos and Weinberger (2010) for a review). Aside
from identifying genetic factors influencing brain structure and function, the endopheno-
type approach can also enable the mapping of genetic effects across the brain, potentially
highlighting specific brain regions where genetic effects may be concentrated (Thompson,
Martin, and Wright, 2010).
Neuroimaging genetic analysis involves the search for genomic variants, for example
SNPs or copy number variations, associated with quantitative measures derived from brain
scans (Figure 1.5). Typical neuroimaging-derived quantitative measures include those de-
scribing the distribution of tissue types such as grey or white matter in the brain, variations
in the size of anatomical structures such as cortical volume, or measures of brain connectiv-
ity (Thompson, Martin, and Wright, 2010). The search for significant associations however
presents a particular statistical challenge, due to the very high dimensionality of both geno-
type and imaging data (Poline et al., 2010). For example, an imaging genetic study may in-
volve a search for causal genetic associations between upwards of 500,000 SNPs and more
than 100,000 voxels1. The simplest approach is one of ‘mass univariate linear modelling’
(MULM), in which each genetic predictor is tested for association against each voxel-wise
phenotype (see Figure 1.6, left). However, this approach has a number of drawbacks.
1Strictly speaking, the word voxel describes a single 3D picture element in a neuroimaging scan. We use
the term interchangeably to describe any voxel-wise quantity (phenotype) derived from such an image. For
example a scalar quantity measuring grey matter intensity or change in brain volume at a single voxel.
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Figure 1.5: Imaging genetic analysis. Neuroimages, for example from MRI scans (top left), are
used to derive quantitative measures describing features in the brain such as grey matter volume
(bottom right). These are compared with measures of genomic variation, such as variations in SNP
minor allele dosage (bottom right), obtained from candidate gene or genome-wide scans (top right).
Firstly, the potentially huge number of hypotheses tested under a MULM framework re-
quires the application of a very large multiple testing correction, leading to a corresponding
loss of power. Many imaging genetic studies reduce the scale of this problem by decreasing
the number of tested hypotheses. This can be achieved for example by narrowing the search
to a set of candidate genes (Hariri et al., 2002); focusing on specific ‘regions of interest’
(ROIs) obtained by parcelling the brain into different anatomical areas (Joyner et al., 2009);
or modelling single imaging measures, derived for example by taking an average intensity
value across a specific ROI (Potkin et al., 2009b). Each of these strategies involves either
additional assumptions about putative associations, or the discarding of potentially infor-
mative data. In contrast, a ‘hypothesis-free’ approach was taken by Stein et al. (2010b),
who conducted the first brain-wide, genome-wide imaging genetics study in an investi-
gation of SNPs associated with changes in brain structure in patients with Alzheimer’s
Disease. To reduce the potentially huge amount of tested hypotheses (1010 voxel x SNP
comparisons), only the most significant SNP at each voxel was assessed, combined with
Introduction 19
an adjustment to the multiple testing threshold to account for dependencies between SNPs.
This latter adjustment follows from the fact that correlation between SNPs arising from the
LD structure present in genotype data means that voxel x SNP tests are not strictly inde-
pendent. The effective number of tests is therefore reduced, so that a Bonferroni-corrected
threshold is likely to be over conservative. In the genetic domain, such adjustments are well
established (Johnson et al., 2010). Similar adjustments accounting for voxel-voxel depen-
dencies arising from spatial correlations in the imaging domain have also been developed
(Worsley, 2003), and these are discussed further in Chapter 6.
Aside from the multiple testing problem, a second potential drawback of the MULM
approach is that by treating both gene variants and voxel-wise phenotypes as independent,
the inherent structure in both is ignored. With genotypes, this structure may manifest as
complex patterns of LD, or from functional associations of SNPs in genes and pathways,
as discussed previously. With phenotypes, structure may arise from correlations between
brain regions sharing structural and/or functional features, and there is evidence that many
such features are under strong genetic influence (Peper et al., 2007; Chiang et al., 2009).
As with the case of genotypes discussed previously (Section 1.1), the fact that multiple
phenotypes may be influenced by many of the same genetic factors means that their joint
modelling can be expected to boost power (Hibar et al., 2011a; Vounou et al., 2011).
Most multilocus approaches in imaging genetics involve either the modelling of a sin-
gle summary phenotypic measure, or the performing of multiple independent multilocus
tests of association against multiple phenotypes. For example, Bralten et al. (2011) used a
multilocus, gene-based test of association to investigate the influence of the SORL1 gene
on hippocampal volume. Multiple linear regression models for the joint modelling of SNPs
have also been employed. Problems of multicollinearity with genome-wide SNP data mean
that this is often combined with some form of dimensionality reduction on the SNP data,
for example using PCA to obtain orthogonal sets of predictors (Hibar et al., 2011b). This
approach has the potential disadvantage of making the results of any such analysis diffi-
cult to interpret or replicate, since any genetic factors identified then consist of principal
components summarising the effect of multiple predictors. As discussed previously, sparse
regression techniques offer an alternative solution. Penalised regression models applied to
genotype estimation for the modelling of imaging-derived univariate phenotypes include
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the use of ridge regression (Kohannim et al., 2011), the lasso (Kohannim et al., 2012a) and
the elastic net (Kohannim et al., 2012b), with the first reporting a boost in power compared
to a univariate analysis in which each SNP is considered separately.
A number of methods that are able to jointly consider genotypes and multivariate phe-
notypes in a single multivariate model have been proposed. For example, multivariate
latent variable models such as canonical correlation analysis (CCA), parallel independent
component analysis (pICA) and partial least squares (PLS) have been used in an attempt
to identify latent factors that capture some of the relationship between genetic and phe-
notypic domains. CCA and pICA attempt to identify orthogonal (CCA) or independent
(pICA) latent factors – specifically linear combinations of variables from each domain –
that maximise the correlation between imaging and genetic data. Similarly, PLS identi-
fies orthogonal latent factors that maximise between-domain covariance. These methods
have been applied to the analysis of imaging genetic data (Hardoon et al., 2009; Calhoun,
Liu, and Adali, 2009; Liu et al., 2009; Jagannathan et al., 2010). Studies so far conducted
have used relatively small pools of SNPs and voxels, and concerns have been raised that
the power to identify latent factors may be substantially reduced with genome-wide data
(Hibar et al., 2011a). In addition, as with PCA, these latent variable models identify linear
combinations of predictors (SNPs or voxels), making it hard to assess the importance of in-
dividual predictors or compare results across studies (Hibar et al., 2011a; Vounou, Nichols,
and Montana, 2010).
Recently, variations on some of these multivariate latent variable models have been
introduced that enforce sparse selection of variables within latent factors. These mod-
els, such as sparse CCA (Parkhomenko, Tritchler, and Beyene, 2009; Witten, Tibshirani,
and Hastie, 2009; Chen and Liu, 2011) and sparse PLS (Chun and Kele, 2010) have re-
cently been compared in an imaging genetic context (Le Flochcor et al., 2012). A closely
related model, sparse reduced-rank regression (sRRR) (Vounou, Nichols, and Montana,
2010) builds on a previous technique in multivariate regression known as reduced-rank re-
gression (Izenman, 2008), and identifies latent factors linking genotype and phenotype pre-
dictors by constraining the rank of the matrix of estimated regression coefficients. sRRR
imposes an additional regularisation penalty on the resulting coefficient estimates, for ex-
ample using a lasso penalty, that enforces sparse solutions. In extensive simulations using
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realistic imaging and genotypic data, sRRR demonstrated increased power to detect true
genotype-phenotype associations, compared with a MULM approach (Vounou, Nichols,
and Montana, 2010).
In Chapter 3, we describe a method that extends the P-GLAW method for pathways se-
lection described in Chapter 2 to accommodate a multivariate quantitative phenotype. Our
proposed ‘Pathways sparse Reduced-Rank Regression’ (PsRRR) model builds on the sRRR
model, but performs pathway selection through the imposition of a group lasso penalty on
genotype coefficients. We demonstrate proof of principle of the efficacy of our proposed
method in simulation studies, and conclude Chapter 3 with an investigation of pathways
associated with longitudinal structural change in Alzheimer’s disease, using a multivariate
imaging phenotype.
1.3.1 Cluster size inference
Despite recent interest in multivariate methods, MULM remains the most common ap-
proach to imaging genetics analysis. MULM techniques are also used widely for the map-
ping of human brain function, for example in analysing fMRI to identify areas of height-
ened activation during task-related activities (Ashburner et al., 2006). The primary output
of a MULM analysis is then a list of test statistics, describing the extent of association be-
tween each SNP or task at each voxel. These are often displayed as a statistical map (see
Figure 1.6, middle and right).
The structural and functional architecture of the brain means that association signals
may often extend across neighbouring voxels to form clusters of heightened activation. For
this reason, statistical tests based on contiguous regions of heightened activation have been
developed. These can offer increased power over voxel-wise tests, where for example ac-
tivation at each voxel in a cluster does not on its own achieve statistical significance, but
inference based on cluster-wise activation does (Poline et al., 1997). Cluster size inference
works by first thresholding the statistical image at a particular significance level, and then
comparing the size of any resulting super-threshold clusters with that expected by chance
using random field theory (RFT) (Friston et al., 1996). Since the number of clusters is
typically much smaller than the number of voxels, this method has the advantage of requir-
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Figure 1.6: MULM in imaging genetic analysis. Left: Association between activation at a single
voxel (at location [8, -12, -4]) and minor allele count at a single SNP (RS9681213). Middle and
right: Statistical maps (t-images) mapping the significance of the slope at each voxel across the
brain. Sagittal (sideways) and coronal (front - on) sections are displayed.
ing a less stringent multiple testing correction, although this comes at the cost of reduced
localising power.
With voxel-wise tests, the very large number of tests performed raises concerns about
the adequate control of false positives (Meyer-Lindenberg et al., 2008). These concerns
apply equally to cluster-size inference. In particular, the use of RFT to estimate the distri-
bution of cluster sizes under the null rests on a number of assumptions, and these need to be
verified empirically (Hayasaka and Nichols, 2003). In Chapter 6, we investigate the control
of false positives using cluster size inference in an imaging genetics context, and find that
a number of conditions with regard to cluster forming thresholds and image smoothness
need to be met, if adequate control of type-I errors is to be guaranteed.
1.4 Mathematical notation and nomenclature
Throughout this thesis we use the terms predictor, genotype, genetic variant and SNP (sin-
gle nucleotide polymorphism) interchangeably. Likewise for the terms quantitative trait,
response and phenotype, and the terms pathway and group.
We assume all observations of genotypes and phenotypes are from a random sample of
N unrelated individuals, drawn from the same population. Matrices are denoted by bold
capital letters, and vectors by bold lower case. We additionally adopt the following notation
for observed genotypes and phenotypes, and for gene pathways:
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Genotypes
We assume that minor allele counts at P SNPs, x1, . . . , xP , are recorded for N subjects
and denote by xij ∈ {0, 1, 2}, the observed minor allele count for SNP j on individual i.
These observed minor allele counts are arranged in an (N × P ) SNP genotype matrix, X.
We denote by xj = (x1j, . . . , xNj)′, the column vector of minor allele counts correspond-
ing to SNP j, so that X = (x1, . . . ,xP ), and by xi. = (xi1, . . . , xiN) the vector of minor
allele counts corresponding to the ith row of X.
Phenotypes
We assume N observations of a Q-dimensional multivariate quantitative trait or phe-
notype, y1, . . . , yQ. The observed values for phenotype q are arranged in an (N × 1)
column vector, yq, and the Q phenotypes are arranged in an (N × Q) phenotype matrix
Y = (y1, . . . ,yQ). In the case that Q = 1, we drop the subscript and denote the vector of
observations for the corresponding univariate phenotype y by y.
Pathways
We frequently assume that SNPs may be mapped to L groups or gene pathways, Gl ⊂
{1, . . . , P}, l = 1, . . . , L, using prior information extracted from a pathways database.
We denote by Pl, the number of SNPs in group Gl. Groups are sometimes assumed to be
disjoint, so that Gl ∩ Gl′ = ∅ for any l 6= l′. We state clearly where this is or is not the case.
For simplicity, in the text (but not in equations) we occasionally refer to ‘pathway l’, by
which we mean the pathway indexed by l, that is Gl.
For convenience, we index the SNPs in group Gl by l1, . . . , lPl , while noting that each
index has a unique one-to-one mapping to the original set of SNP indices, so that lz ∈
{1, . . . , P} for z = 1, . . . , Pl. We denote by Xl = (xl1 , . . . ,xlPl ) the (N × Pl) matrix of
minor allele counts corresponding to SNPs in pathway Gl.
Throughout the text, we denote the cardinality, or number of elements in a set S, by
|S|. Finally we denote the `q norm of a p-dimensional vector v as ||v||q = (
∑p
j=1 |vj|q)
1
q ,
although we occasionally denote the `1 norm as |v| for simplicity.
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1.5 Abbreviations
BCGD block coordinate gradient descent
CGD coordinate gradient descent
FDR false discovery rate
(f)MRI (functional) magnetic resonance imaging
FWER family-wise error rate
FWHM full-width at half-maximum
GL group lasso
GWAS genome-wide association study/studies
LD linkage disequilibrium
MAF minor allele frequency
MC Monte Carlo
MLR multiple linear regression
MULM mass univariate linear modelling
OLS ordinary least squares
PCA principal component analysis
PET positron emission tomography
P-GLAW pathways group lasso with adaptive weights
PGAS pathways gene association study/studies
P-SGLAW pathways sparse group lasso with adaptive weights
PsRRR pathways sparse reduced-rank regression
QTL quantitative trait locus/loci
QTT quantitative trait test
ROI region of interest
RFT random field theory
SGL sparse group lasso
SGL-CGD sparse group lasso - coordinate gradient descent
SNP single nucleotide polymorphism
sRRR sparse reduced-rank regression
VBM voxel-based morphometry
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Chapter 2
Identifying pathways associated with a
univariate quantitative trait: ‘Pathways
Group Lasso with Adaptive Weights’
We now turn to the problem of developing a multiple regression model for the identification
of biological pathways associated with a quantitative trait. As outlined in Section 1.2, our
assumption is that where causal SNPs are enriched in a pathway, an approach that includes
all SNPs in a single, sparse multiple regression model will have increased power, compared
to a more conventional approach in which SNPs are considered one at a time. To this end,
we use a modified version of a sparse regression model known as the group lasso (GL) with
SNPs grouped into pathways. We believe this is the first method able to jointly model the
genome-wide, group-wise association of gene variants with a quantitative trait.
We face a number of challenges in applying GL to SNP and pathway data for the iden-
tification of implicated pathways. These include the fact that pathways overlap, since many
SNPs map to multiple pathways; the problem of selection bias, that is the tendency of the
model to select pathways having specific statistical properties irrespective of their asso-
ciation with the phenotype; and the problem of assessing pathway importance in a finite
sample. In addition, the potentially very large size of SNP datasets makes the develop-
ment of strategies for computationally efficient model estimation a necessity. In following
sections we outline our approach to tackling each of these challenges.
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The chapter is arranged as follows. We begin in Section 2.1, with a review of the most
common penalised regression models used in gene mapping – ridge regression and the lasso
and variations thereof. In Section 2.2 we describe the group lasso model, and explain its
relevance to the selection of pathways in PGAS. We also describe our strategy for dealing
with the fact that pathways overlap. In Section 2.3, we describe an estimation algorithm
for the GL with overlaps, along with a number of strategies we employ to speed up the
estimation process for the large datasets in PGAS. In Section 2.4 we outline our approach
to reducing potential bias in pathway selection using an adaptive weight tuning procedure,
and in Section 2.5 we explain a method for ranking pathways in order of importance, using
a subsampling procedure that exploits finite sample variability.
In Section 2.6, we evaluate our method, which we call ‘Pathways Group Lasso with
Adaptive Weights’ (P-GLAW) in a simulation study, using real genetic and pathway data
with quantitative phenotypes simulated under an additive genetic model. We feel the use
of real genotype and pathway data is crucial, so as to capture the distributions of gene size
and number within a pathway, together with the complex SNP LD patterns and overlaps
between pathways, all of which may have a significant effect on pathway ranking perfor-
mance. We consider a range of scenarios with different causal SNP distributions and effect
sizes, and compare our method with a popular, existing PGAS method based on combining
multiple, univariate SNP-phenotype association statistics. To our knowledge, this is the
first such power study comparing multivariate and univariate approaches using real SNP
and pathway data. We conclude the chapter with a discussion in Section 2.7.
2.1 Penalised regression approaches in gene mapping
We return here to the problem, introduced in section 1.1, of estimating P SNP regression
coefficients associated with a univariate, quantitative trait in a multiple linear regression
model. In what follows, we assume that the response vector, y is mean-centred, so that∑N
i=1 yi = 0. We additionally assume that the observed SNP allele count vectors are mean-
centred and of unit length, so that
∑N
i=1 xij = 0 and
∑N
i=1 x
2
ij = 1 for j = 1, . . . , P .
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The standard, multiple linear regression model is given by
y = Xβ + ,
where the errors, i, i = 1, . . . , N are assumed to be independent and identically dis-
tributed, with variance σ2. When the design matrix, X, is of full rank, an unbiased es-
timate for the regression coefficient vector, β is obtained by minimising the residual sum
of squares ||y −Xβ||22 to give
βˆOLS = (X′X)−1X′y (2.1)
with variance
Var(βˆOLS) = σ2(X′X)−1.
Two problems immediately arise in the context of gene mapping. Firstly, multicollinear-
ity due to LD between SNP predictors can make the inverse (X′X)−1 very sensitive to small
changes in the data. This makes the resulting estimates for individual SNP coefficients
unreliable, undermining the original goal of identifying predictors with functional signif-
icance (Malo, Libiger, and Schork, 2008). Secondly, in gene mapping we are frequently
faced with the situation where there are more predictors than subjects. In this case X is
rank deficient, X′X is not invertible, and no unique estimates for β exist.
One possible solution is to take a model selection approach, in which we attempt to
pick a subset of SNPs that best predicts the response. This strategy is used in a number of
stepwise variable selection methods in which subsets of predictors are successively either
included or excluded from the model, depending on their effect on the model’s goodness of
fit. The discrete nature of these approaches however makes them unreliable, since at each
step the model is optimised for a subset of predictors only. More exhaustive model selec-
tion methods such as all subsets regression also suffer from bias, and are computationally
feasible only for relatively small numbers of predictors (Hesterberg et al., 2008).
In contrast, continuous shrinkage or penalised regression methods have been shown
to provide more reliable coefficient estimates than the discrete methods described above
(Hastie, Tibshirani, and Friedman, 2008). These methods work by adding some form of
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regularisation to the estimation of β. This typically involves the imposition of a constraint
or penalty on β, so that
βˆ = arg min
β
||y −Xβ||22 subject to P (β) < c (2.2)
where the penalty function P (β) is some function of the regression coefficients, and c > 0.
An equivalent expression is
βˆ = arg min
β
{
||y −Xβ||22 + λP (β)
}
(2.3)
with λ > 0, where λ is a tunable parameter controlling the amount of regularisation or
penalisation to be applied. Note there is a one-to-one correspondence between c and λ
(Hastie, Tibshirani, and Friedman, 2008).
A common choice for P (β) is a function of the `γ-norm of the coefficient vectors,
P (β) = ||β||γγ =
P∑
j=1
|βj|γ (2.4)
where γ > 0. Depending on the choice of γ, the resulting estimates for the SNP coefficients
exhibit some potentially useful properties. Moreover, with γ ≥ 1, the penalty (2.4) has the
attractive property of being convex (strictly convex when γ > 1), and as we shall see, this
makes the resulting convex optimisation problem (2.3) amenable to efficient solutions.
We now consider the two paradigm cases in penalised regression, with γ = 1 and γ = 2.
2.1.1 Ridge regression
The case with γ = 2 is known as ridge regression (Hoerl and Kennard, 1970). The ridge
estimator (2.2) for β then satisfies
βˆridge = arg min
β
||y −Xβ||22 subject to
P∑
j=1
β2j < c (2.5)
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To better understand some of the properties of the ridge estimator, we begin by consider-
ing the simple case of two predictors. The optimisation (2.5) then has a simple geometric
interpretation, illustrated in Fig. 2.1. In the figure, dashed lines represent lines of increas-
ing sum of squared residual error, ||y − Xβ||22 as βˆ moves away from its optimum value
βˆOLS = arg minβ ||y −Xβ||22. The ridge penalty ensures that βˆridge is constrained to lie
within the region bounded by the blue circle, β21 + β
2
2 = c. Estimates for βˆ
ridge
1 and βˆ
ridge
2
satisfying (2.5) then correspond to the blue point in Fig. 2.1. The effect of the ridge penalty
is thus to shrink coefficient estimates, compared to their OLS values, with the amount
of shrinkage increasing with decreasing c (or equivalently increasing λ). This shrinkage
property can be very useful in the case of correlated predictors. For example, where two
predictors are highly correlated, OLS estimation can result in large variations in estimated
coefficients, where a large positive coefficient for one predictor is cancelled by a simi-
larly large negative coefficient for the other. Such variations are constrained by the ridge
penalty, which exhibits a ‘grouping effect’ that ensures correlated predictors have similar
coefficients, potentially making results easier to interpret. This shrinkage property can also
lead to superior prediction accuracy through a bias-variance trade off (Hastie, Tibshirani,
and Friedman, 2008; Malo, Libiger, and Schork, 2008).
An equivalent form for the ridge optimisation (2.5) is
βˆridge = arg min
β
{
||y −Xβ||22 + λ
P∑
j=1
β2j
}
with solution
βˆridge = (X′X + λI)−1X′y (2.6)
where I is the (P × P ) identity matrix. By comparing (2.6) with (2.1), we see how ridge
regression enables the estimation of coefficients in the P > N case, where X is rank defi-
cient, since the addition of a positive constant to the diagonal of X′X renders the problem
non-singular, even when X′X is not of full rank (Hastie, Tibshirani, and Friedman, 2008).
Several recent studies have exploited properties of the ridge estimator highlighted above
in the identification of important SNPs in GWAS, including in an imaging genetics context
(Sun et al., 2009; Kohannim et al., 2011).
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β1
β2
βˆOLS
γ = 1
γ = 2
(c,−c)(−c,−c)
(−c, c)
Figure 2.1: Coefficient estimation with two predictors, β1 and β2. Dashed lines represent contours
of constant sum of squared residual error, ||y − Xβ||22. With ridge regression, the constraint is
β21 + β
2
2 < c (blue circle) and the estimated coefficients βˆ
ridge correspond to the blue dot. With
lasso regression, the constraint is |β1|+ |β2| < c (red diamond) and the estimated coefficients βˆlasso
correspond to the red dot.
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2.1.2 Variable selection with the lasso
The case with γ = 1 is known as lasso regression (Tibshirani, 1996). The lasso estimator
for β satisfies
βˆlasso = arg min
β
||y −Xβ||22 subject to
P∑
j=1
|βj| < c. (2.7)
Once again considering the simple case with two predictors illustrated in Fig. 2.1, with the
lasso β is constrained to lie within the region bounded by the red diamond, |β1|+ |β2| = c.
Estimates for βˆlasso1 and βˆ
lasso
2 then correspond to the red point in Fig. 2.1. We see that
as c approaches zero (or equivalently λ moves away from zero), the contours of the OLS
estimation are increasingly likely to intersect the red diamond at one of the axes, meaning
that one of the coefficients, β1 or β2 is set to zero. The lasso thus performs a form of
variable or model selection, in the sense that a single variable is ‘selected’ by the model.
This example readily extends to the P > 2 case, with the lasso producing sparse es-
timates for βˆlasso, in the sense that multiple predictors have their coefficients, βˆlassoj , set
to zero. The degree of sparsity is controlled by c or λ, such that an increasing number of
predictors have zero coefficients as c is reduced, or equivalently λ is increased. We can
then think of the lasso as selecting a subset of predictors, Sˆ = {j : βj 6= 0, j = 1, . . . , P}.
In high-dimensional, large P settings typical encountered in GWAS and gene expres-
sion analysis, variable selection methods using penalised regression are attractive for a
number of reasons. Firstly, a parsimonious model that selects a small number of impor-
tant predictors is easier to interpret. In any case, in SNP mapping, we expect only a small
set, S ⊂ {1, . . . , P}, of all predictors to be truly associated with the phenotype, so that
the assumptions underlying sparse models such as the lasso are likely to hold. Secondly,
as with ridge regression, the shrinkage property can improve a model’s capacity to pre-
dict outcomes with new data, reducing variance at the expense of slightly increased bias
(Hastie, Tibshirani, and Friedman, 2008). Finally, in contrast to the discrete subset selec-
tion methods described previously, penalised regression models such as the lasso perform
continuous variable selection, and thus tend to select the set of true predictors with greater
reliability (Hesterberg et al., 2008).
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An important issue with all penalised regression models is the need to choose a value
for the regularisation parameter, λ. For sparse regression models such as the lasso this
determines the number of variables selected by the model. A common strategy is to use
K-fold cross validation to choose a λ value that minimises the prediction error between
training and test datasets. One drawback of this approach is that it focuses on optimising
the size of the set, Sˆ , of selected variables that minimises the cross validated prediction
error. Since the variables in Sˆ will vary across each fold of the cross validation, this proce-
dure may not be a good means of establishing the importance of a unique set of variables
(Vounou et al., 2011). Other approaches include the use of information-theoretic metrics
such as the Akaike or Bayesian information criteria (AIC and BIC), that trade model good-
ness of fit against model complexity (degrees of freedom) (Zou, Hastie, and Tibshirani,
2007). Data resampling or bootstrapping techniques have also been demonstrated to im-
prove model consistency, in the sense that the true model support is selected with a high
probability (Bach, 2008a; Meinshausen and Bu¨hlmann, 2010). We expand on this latter
approach in following sections.
We now turn to the problem of estimating coefficients with lasso penalised regression.
An equivalent form for the lasso optimisation (2.7) is
βˆlasso = arg min
β
{1
2
||y −Xβ||22 + λ
P∑
j=1
|βj|.
}
(2.8)
We first consider the solution for a single predictor, j. The lasso estimator then minimises
fj(βj) =
1
2
N∑
i=1
(yi − xijβj)2 + λ|βj|
=
1
2
N∑
i=1
y2i − βj
N∑
i=1
(xijyi) +
1
2
β2j + λ|βj| (2.9)
(since
∑N
i=1 x
2
ij = 1). Differentiating with respect to βj , and noting from (2.1), that the
unconstrained OLS estimate for a single predictor, j, βˆOLSj =
∑
i xijyi, we see that (2.9) is
minimised when
βˆj = βˆ
OLS
j − λ
d|βˆj|
dβj
.
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When βˆj 6= 0, this has solutions βˆj = βˆOLSj − λsign(βˆj) 1. When βˆj = 0, the derivative
d|βˆj|/dβj is not defined. We instead form the subgradient or subdifferential, d|βˆj |dβj ∈ [−1, 1]
(Bertsekas, 1999), so that λ ≥ |βˆOLSj |. More concisely, the effect of the lasso can then be
summarised as follows:
βˆlassoj = S(βˆ
OLS
j , λ), j = 1, . . . , P
where
S(βˆOLSj , λ) =

βˆOLSj − λ if βˆOLSj > 0 and |βˆOLSj | > λ
βˆOLSj + λ if βˆ
OLS
j < 0 and |βˆOLSj | > λ
0 if |βˆOLSj | ≤ λ
(2.10)
Here we see clearly that the effect of the lasso is to shrink larger OLS coefficients towards
zero. OLS coefficients below a size threshold determined by λ are set to zero. For this
reason the lasso is often described as performing ‘soft thresholding’ of OLS estimates, and
S(βˆOLSj , λ) is known as the soft thresholding operator.
For multiple, uncorrelated predictors, that is where X′X = IP , lasso estimates for each
predictor are obtained by applying the above soft thresholding procedure to each predictor
in turn, so that
βˆlassoj = S(βˆ
OLS
j , λ), j = 1, . . . , P.
Where this is not the case, that is where predictors are correlated, we can instead solve
the lasso estimation (2.7) by taking the partial derivatives with respect to each βj , that is by
minimising
f(βj) =
1
2
N∑
i=1
(yi −
∑
k 6=j
xikβˆk − xijβj)2 + λ
∑
k 6=j
|βˆk|+ λ|βj| (2.11)
with respect to βj , where βˆk, (k 6= j) are the current coefficient estimates for all predictors
other than j. However, estimates for β cannot then be obtained directly, since each βj
depends on all other estimates βˆk, k 6= j. A number of estimation algorithms to solve the
1sign(z) has the value +1 when z > 0 and −1 when z < 0.
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lasso in the non-orthogonal case have been proposed (Tibshirani, 1996; Efron et al., 2004).
The method of coordinate descent (Friedman et al., 2007) is particularly attractive due to
its simplicity and speed.
Coordinate descent algorithms (and related methods such as gradient descent (Kim and
Kim, 2004)) offer a means of solving convex optimisation problems in which the estimation
is solved for each predictor in turn, while keeping current estimates for all other coefficients
fixed at their current values, in an iterative fashion (Tseng, 1988). Thus by comparing (2.11)
with the single predictor case (2.9), we see that the coordinate wise update for βj is the same
as the lasso estimation for a single predictor, but with the OLS estimate, βˆj
OLS
replaced
with the ‘partial residual’
∑N
i=1 xij(yi −
∑
k 6=j xikβˆk), so that
βˆlassoj ← S
( N∑
i=1
xij(yi −
∑
k 6=j
xikβˆk), λ
)
.
It is convenient to express the partial residual in terms of the current full residual, rˆ =∑
i(yi −
∑P
k=1 xikβˆk), so that,
N∑
i=1
xij(yi −
∑
k 6=j
xikβˆk) =
N∑
i=1
xij(rˆi + xijβˆj)
=
N∑
i=1
(xij rˆi) + βˆj. (2.12)
A final expression for the coordinate-wise lasso update for predictor j is then given by
βˆlassoj ← S
( N∑
i=1
(xij rˆi) + βˆj, λ
)
.
Coordinate descent then proceeds by initialising βˆ (e.g. using βˆ = 0), and updating each
component j = 1, . . . , P, 1, . . . , P, . . . until some convergence criterion is met.
Lasso regression has been used for the identification of genetic predictors associated
with both quantitative and dichotomous (case-control) traits (Shi et al., 2011; Wu et al.,
2009). For the latter, Wu et al., 2009 use a log-likelihood loss function L(β) derived from
a logistic regression model with a lasso penalty to analyse two-way and higher-order SNP-
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SNP interactions in a genome-wide dataset. For subject i, disease status is labelled as
yi = 1 for cases and yi = 0 for controls, and estimates for β are then obtained by solving
βˆlasso = arg min
β
{
L(β) + λ
P∑
j=1
|βj|
}
where
L(β) = −
N∑
i=1
yi log pii + (1− yi) log(1− pii) (2.13)
and pii = Pr (yi=1) is given by
ex
′
i.β
1 + ex
′
i.β
.
The choice of λ is driven by the desired number of SNPs to be identified. SNP-SNP
and higher order interactions are analysed only for those SNPs previously selected by the
model. Hoggart et al. (2008) propose a similar method for SNP selection in a Bayesian
context. They use a Laplace or double exponential prior that performs model selection in a
manner similar to the lasso.
In contrast to ridge regression, the lasso is not strictly convex. This means that where
for example two identical predictors are included in the model, the lasso does not give a
unique solution, whereas the ridge penalty ensures that identical predictors have identical
coefficients. In practice, where predictors, or groups of predictors are highly correlated, the
lasso tends to select one predictor at random, rather than grouping coefficients together, as
with ridge regression (Zou and Hastie, 2005). This is an example of inconsistency in model
selection, meaning that the lasso may not asymptotically select the true model (Zhao and
Yu, 2006). To improve consistency, Zou (2006) propose the adaptive lasso, a two-step pro-
cedure in which the regularisation parameter, λ, is allowed to vary, with λj, (j = 1, . . . , P ),
depending on OLS estimates for each variable. Bootstrap or resampling techniques that
attempt to recover the true model by considering multiple subsamples of the data have
also been found to improve consistency (Chatterjee and Lahiri, 2011; Meinshausen and
Bu¨hlmann, 2010), and we apply this approach in methods that we develop below, and in
following chapters.
In gene mapping, where for example multiple SNPs in tight LD might tag a causal
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variant, the tendency of the lasso to select one of multiple correlated predictors may not be
desirable (Cho et al., 2009a). One solution proposed by Zou and Hastie (2005) is the elastic
net, which combines lasso and ridge penalties in a single model, enabling the selection of
groups of correlated variables, for example groups of SNPs in strong LD. This model has
been used in a number of recent gene mapping studies (Cho et al., 2009a; Do et al., 2011;
Guzzetta, Jurman, and Furlanello, 2010). A drawback of this approach is its incorporation
of an extra regularisation parameter, potentially requiring more computationally intensive
methods for the tuning of parameters.
Other interesting extensions of the lasso include the fused lasso (Tibshirani et al., 2005)
which penalises differences between adjacent, ordered predictors, and the graphical lasso
which estimates undirected graphs for continuous data by applying a lasso penalty to the
inverse covariance matrix (Friedman, Hastie, and Tibshirani, 2008).
2.2 The group lasso for pathway selection
We now turn to the description of a penalised regression model able to identify gene path-
ways associated with a univariate quantitative trait, y. We initially consider the situation
where SNPs are partitioned into L mutually exclusive pathways, or groups. Each group Gl,
for l = 1, . . . , L, is a subset of {1, 2, . . . , P} of cardinality Pl, such that Gl ∩ Gl′ = ∅ for
any l 6= l′. We denote by G = {1, . . . , P}, the set of all SNP indices. For convenience, we
denote the indices of SNPs in Gl by l1, l2, . . . , lPl .
In general, where P is large, we expect only a small proportion of SNPs to be causal, in
the sense that they influence the phenotype. We further assume that this set S ⊂ {1, . . . , P}
of causal SNPs will tend to be enriched within functional groups, or gene pathways. This
latter assumption is illustrated schematically in Fig. 2.2, where causal SNPs (marked in
grey) tend to accumulate within a small number of causal pathways, while the majority of
pathways contain no causal SNPs. A model generating such a sparsity pattern is said to be
group-sparse, in that SNPs affecting y are to be found in a set C ⊂ {1, . . . , L} of causal
gene pathways (groups), with |C|  L, where |C| denotes the cardinality of C.
We assume that y can be optimally predicted, in the least squares sense, by a linear
combination of allele counts corresponding to SNPs in S. If we denote the parameter
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Figure 2.2: Group-sparse distribution of causal SNPs. The set S ⊂ {1, . . . , P} of causal SNPs
influencing the phenotype are represented by boxes that are shaded grey. Causal SNPs are assumed
to occur within a set C of causal pathways. Here C = {2, 3}. Note that the particular distribution
of causal SNPs may vary for each individual, i = 1, . . . , N . The group sparsity assumption is that
|C|  L.
vector corresponding to SNPs in pathway Gl by βl = (βl1 , . . . , βlPl ), then under the group
sparsity assumption, one or more elements of each βl for l ∈ C are expected to be non-
zero. Conversely, the regression coefficients associated with SNPs belonging to C ′ (where
C ′ = {1, . . . , L} \ C) will be zero, that is βl = 0 for all l ∈ C ′. For example, for a single
causal pathway Gl with causal SNPs {la, lb} in S, the sparsity pattern might look like
β = {(0, . . . , 0)︸ ︷︷ ︸
G1
, . . . , (0, . . . , βla , 0 . . . , βlb , 0, . . . , 0)︸ ︷︷ ︸
Gl
, . . . , (0, . . . , 0)︸ ︷︷ ︸
GL
}.
A penalised regression model enforcing group sparsity is the group lasso (GL) (Yuan
and Lin, 2006). This imposes a constraint on the `2 norm of the group or pathway coefficient
vectors, so that the penalty function (2.4) is given by
P (β) =
L∑
l=1
wl||βl||2 (2.14)
where wl is a pathway weighting factor that allows the constraint to vary between groups.
The corresponding group lasso estimator is then given by
βˆGL = arg min
β
{1
2
||y −Xβ||22 + λ
L∑
l=1
wl||βl||2
}
. (2.15)
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The group lasso can be thought of as imposing an intermediate or ‘hybrid’ `1/`2 penalty.
Sparsity at the pathway level is encouraged through the imposition of an `1 lasso penalty
on ||βl||2, which ensures that SNPs belonging to pathways not selected by the model have
zero regression coefficients. For selected pathways, i.e. those with βˆl 6= 0, SNP coefficients
tend to shrink, through the imposition of a ridge-type penalty on ||βl||2. All SNPs within
selected pathways are retained by the model, that is βˆj 6= 0, for j = l1, . . . , lPl . The degree
of group sparsity is controlled by the regularisation parameter, λ, such that the number
of pathways selected by the model increases with decreasing λ. For a given λ, the group
sparsity pattern is determined both by the data (y and X), and by the distribution of pathway
weights, w = (w1, . . . , wl), such that an increase in wl means that pathway l is less likely
to be selected, whereas a decrease in wl will have the opposite effect. The GL optimisation
problem (2.15) is convex, and as with the lasso can be solved using group or block-wise
coordinate descent methods (see Section 2.3.1). Meier et al. (2008) describe a variation
of the GL model described above for a binary response (applicable for example to case-
control data) that utilises a logistic loss function (2.13) in place of the least squares loss in
(2.15).
The GL with its group sparsity property falls into a wider class of models imposing
structured sparsity, using prior information on the relationship between variables (Jenatton
and Bach, 2011). This extra information can be encoded in the form of group mappings,
as with GL, or for example as graphs or trees describing hierarchical relationships that
can be used to drive variable selection (Zhao, Rocha, and Yu, 2009; Huang, Zhang, and
Metaxas, 2011; Jenatton and Bach, 2011; Kim and Xing, 2012). Alongside the use of func-
tional information, such as the grouping of SNPs and genes into gene pathways considered
here, other choices for driving structured sparsity include the use of spatial information
and connectivity maps in neuroimaging applications (Jenatton et al., 2011; Kong et al.,
2010). A further example of hierarchical selection is described by Bien, Taylor, and Tib-
shirani (2012), who use a hierarchical, sparse interaction model in which interacting pairs
of variables are selected only if both variables are marginally important.
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2.2.1 The problem of overlapping pathways
The group lasso in its original formulation rests on the assumption that groups are disjoint.
Problems arise however in the situation where pathways overlap, that is where one or more
SNPs map to more than one pathway, so that Gl ∩ Gl′ 6= ∅ for some l 6= l′. This situation
is commonplace when mapping SNPs to pathways (see Fig. 1.4). Firstly, where groups
overlap, the penalty term (2.14) is no longer separable into groups, and convergence using
coordinate descent is no longer guaranteed (Tseng and Yun, 2009). Secondly, if we wish
to be able to select pathways independently, GL is unable to do this. We illustrate this last
point using a simple example in Fig. 2.3 A, where we consider three pathways, G1,G2 and
G3, two of which overlap. As a consequence of this, pathway parameter vectors β1 and β2
also overlap, since they have a number of SNPs in common (shaded dark grey). If a shared
SNP is selected (i.e. it has a non-zero coefficient), then both pathways to which it belongs
(G1 and G2) are also selected, since their corresponding pathway parameter vectors have
non-zero `2 norms. The GL regression model thus does not meet our requirements, since in
order to be able to rank pathways in order of importance, we wish to be able to distinguish
overlapping pathways and select them independently. Conversely, where shared SNPs have
zero coefficients, for example in the case that G1 is not selected in the model, then these
SNPs will have zero coefficients in each and every pathway to which they belong (here G1
and G2). Hence SNPs retained in the model are necessarily drawn from the complement of
a union of (unselected) pathways. We instead require retained SNPs to be drawn from a
union of (selected) pathways, so that a SNP driving selection in one pathway may still have
a zero coefficient in another.
A number of strategies to deal with the problem of overlapping groups have been pro-
posed (Mosci et al., 2010; Liu and Ye, 2010). One method, motivated by the analysis
of gene expression data, is to duplicate SNP predictors in X, so that SNPs belonging to
more than one pathway can enter the model separately (see Fig. 2.3 B) (Jacob, Obozinski,
and Vert, 2009; Obozinski, Jacob, and Vert, 2011). The process works as follows. An ex-
panded design matrix is formed from the column-wise concatenation of the L, (N × Pl)
sub-matrices, XGl , where XGl = {xij : i = 1, . . . , N, j ∈ Gl}, to form the expanded design
matrix X∗ = [XG1 ,XG2 , . . . ,XGL ] of size (N × P ∗), where P ∗ =
∑
l Pl. The correspond-
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Figure 2.3: The problem of overlapping pathways, with three pathways, G1,G2 and G3, two of which
overlap. A: Standard formulation. Pathway parameter vectors β1 and β2 overlap, since they have
SNPs in common (shaded dark grey). Where an overlapping SNP has a non-zero coefficient, only
G3, can be selected independently. B: Formulation with duplicated SNPs. An expanded parameter
vector, β∗, is created by duplicating overlapping SNPs (dotted line). SNPs in β∗1 and β∗2 now enter
the model separately, so that pathways can be selected independently.
ing P ∗ × 1 parameter vector, β∗, is formed by joining the L, (Pl × 1) pathway parameter
vectors, β∗l , so that β
∗ = [β∗1
′,β∗2
′, . . . ,β∗L
′]′. Pathway mappings with SNP indices in the
expanded variable space are reflected in updated groups G∗1 , . . . ,G∗L. The GL estimator
(2.15), adapted to account for overlapping groups, is then given by
βˆGL∗ = arg min
β
{1
2
||y −X∗β∗||22 + λ
L∑
l=1
wl||β∗l ||2
}
.
With this overlap expansion, the model is then able to perform pathway selection in the
way that we require, and the corresponding optimisation problem is amenable to solution
using block coordinate descent (see Section 2.3.1). In the following sections we assume
that both β and X have been expanded using the method described here, but we omit the ∗
superscript for clarity. For this reason, when referring to the group lasso with overlapping
groups we generally reference the estimator (2.15), but make it clear that the necessary
variable expansion has been performed.
P-GLAW 41
In the case of non-overlapping groups, the consistency properties of the group lasso
have been investigated for a range of different scenarios for N,L and P (Bach, 2008b; Wei
and Huang, 2010; Huang and Zhang, 2010). As with the lasso, while the GL model is often
able to accurately recover true, underlying group sparsity in the data, variations such as
the adaptive group lasso (Wang and Leng, 2008; Wei and Huang, 2010), that allow λ to
vary between groups have been advocated to improve model consistency. In the case of
overlapping groups, Percival (2012) has recently investigated the theoretical properties of
the GL using the variable expansion strategy described above. They found that the GL’s
ability to recover group-wise sparse signals depends to some extent on the complexity of
the overlap structure. For this reason, we consider it important to evaluate the performance
of our method with real data, and we do this using simulations over a range of scenarios in
Section 2.6.
2.3 Group lasso estimation algorithm
When the penalty in the optimisation (2.15) is block-separable, that is the groups indexed
by 1, . . . , L are disjoint, the resulting convex optimisation problem is amenable to solution
using block coordinate descent (BCD) (Friedman et al., 2007). The BCD algorithm of-
fers an efficient strategy for solving convex optimisation problems with grouped variables,
that guarantees convergence provided that the block-separability criterion is met (Tseng
and Yun, 2009). As with the lasso and coordinate descent (2.11), BCD works by breaking
down the optimisation into a series of single variable problems, solving the optimisation
for each variable (here SNP) in turn, while holding all the others fixed, until a suitable
minimum based on some stopping criterion is reached. Where variables are grouped, as in
GL, estimates are obtained for each pathway parameter vector, βl in turn, while holding
constant the current estimates for all other pathway parameter vectors, βˆm, (m 6= l), and
then cycling through each pathway until convergence.
Yuan and Lin (2006) derive a method for solving GL under the assumption that the
group design matrices, XGl are orthogonal, that is X
′
GlXGl = I. This assumption does
not hold in our case, so in the next section we derive a solution for GL in the case of
non-orthogonal groups. We additionally find that GL estimation using BCD can be slow,
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particularly for the large datasets common to PGAS, and so in the following sections pro-
pose a number of strategies for speeding up parameter estimation.
Apart from the BCD algorithm that we describe here, alternative estimation methods
for GL include ‘global’ and ‘group-wise’ descent algorithms in which β or βl is updated
in a single step, respectively (Yuan and Lin, 2006; Meier et al., 2008; Kim and Kim, 2006;
Roth and Fischer, 2008). Each method varies in terms of its underlying assumptions and
computational burden, with the latter depending on the dimensions of the datasets being
considered (Foygel and Drton, 2010).
2.3.1 Block coordinate descent for non-orthogonal groups
We assume that the penalty in (2.15) is block-separable, so that in our context, the SNP
duplication strategy described in Section 2.2.1 has been applied. BCD then proceeds as
follows. We begin by considering a single pathway l. We collect the observed, standardised
minor allele counts for SNP j in the column vector xj = (x1j, x2j, . . . , xNj)′. From (2.15),
an estimate βˆl, for a single block l is then obtained by minimising
f(βl) =
1
2
||rˆl −
lPl∑
j=l1
xjβj||22 + λwl||βl||2 (2.16)
with respect to βl, where rˆl = y −
∑
m6=l Xmβˆm. The vector rˆl is the ‘partial residual’
vector for pathway l, based on the current estimates, βˆm,m 6= l, of the other pathway
parameter vectors.
Estimates for each βj are then obtained by taking partial derivatives with respect to βj ,
that is by setting
∂f(βl)
∂βj
= 0 for j = l1, . . . , lPl . (2.17)
Ignoring the penalty term, the partial derivative with respect to βj is
∂
∂βj
1
2
||rˆl −
∑
j
xjβj||22 = −x′j(rˆl −
∑
j
xjβj).
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We denote the partial derivative of the penalty term, by
sj =
∂
∂βj
||βl||2
so that (2.17) can be written as
−x′j(rˆl −
∑
j
xjβj) + λwlsj = 0 j = l1, . . . , lPl . (2.18)
We first consider the case where βl = 0, that is βj = 0, for j = l1, . . . , lPl . In this
case ||βl||2 is not differentiable. We instead form the Pl sub-differentials, sj ∈ [−1, 1]
(Bertsekas, 1999), so that ∑
j
s2j ≤ 1. (2.19)
The system of equations (2.18) can then be written
sj =
1
λwl
x′j rˆl j = l1, . . . , lPl
and using (2.19), we see that βl = 0 when
∑
j
s2j =
1
λ2w2l
∑
j
(x′j rˆl)
2 ≤ 1. (2.20)
Note that for all groups to have an equal chance of being selected by the model, that is for
(2.20) to be unbiased with respect to group size, a weight, wl =
√
Pl, as proposed by Yuan
and Lin (2006), can be applied.
Finally, since ∑
j
(x′j rˆl)
2 = ||X′lrˆl||22
we can rewrite (2.20) as
(
∑
j
s2j)
1
2 =
1
λwl
||X′lrˆl||2 ≤ 1,
so that if βl = 0
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||X′lrˆl||2 ≤ λwl. (2.21)
When βl 6= 0, the objective function (2.16) can be minimised numerically using co-
ordinate descent within group l, as a series of one-dimensional estimations over βj, j =
l1, . . . , lPl , l1, . . . , lPl , . . ., until convergence of βl. At each step, the one-dimensional opti-
misation for βj is given by
βˆj = arg min
βj
{1
2
||rˆl −
∑
k∈Gl,k 6=j
Xkβˆk − xjβj||22 + λwl
( ∑
k∈Gl,k 6=j
βˆk
2
+ β2j
) 1
2
}
. (2.22)
Once group l has converged, the estimation proceeds for each group, l = 1, . . . , L, 1, . . . , L,
. . . until global convergence of β. Friedman, Hastie, and Tibshirani (2010) suggest a
golden section search over βj , combined with parabolic interpolation for the 1d optimi-
sation (2.22). The number of such estimations depends on L and P ∗. This can make the
GL optimisation prohibitively slow, particularly for the large P typically found in PGAS.
For this reason, we next describe three strategies for speeding up the estimation.
2.3.2 Taylor approximation of penalty
One means of speeding up the estimation for βj is to use a linear or quadratic approxima-
tion of the GL `2 penalty (Zou and Li, 2008; Fan and Li, 2001), enabling the replacement
of the multi-step numerical optimisation over βj with a one-step calculation. Breheny and
Huang (2009) propose the use of a Taylor approximation for a range of different estima-
tion problems with grouped variables and we adopt this approach for our GL estimation
problem.
For convenience, we rewrite the 1d optimisation (2.22) as
f(βl|βˆk, k 6= j) = 1
2
||rˆ + xjβˆj − xjβj||22 + λwlΓ(βl|βˆk), (2.23)
where rˆ = y −∑l Xlβˆl is the total residual, using the current estimates of all SNP coeffi-
cients; and Γ(βl|βˆk) = (c+ β2j )
1
2 , with c =
∑
k 6=j βˆ
2
k .
We now consider the first order Taylor expansion of Γ(βl|βˆk) as a function of x = β2j ,
P-GLAW 45
about the point a = βˆ2j ,
Γ(x) ' Γ(a) + Γ′(a)(x− a).
Now
Γ(x) = (c+ x)
1
2
and Γ′(a) =
1
2(c+ a)
1
2
so that
Γ(x) ' (c+ a) 12 + x− a
2(c+ a)
1
2
Substituting a = βˆ2j , and noting that (c + a)
1
2 = ||βˆl||2, where βˆl denotes the current
estimate of βl, this gives
Γ(β2j ) ' βˆl +
β2j − βˆ2j
2||βˆl||2
Substituting this expression in (2.23), we have
f(βl|βˆk, k 6= j) = 1
2
||rˆ + xjβˆj − xjβj||22 + λwl
[
βˆl +
β2j − βˆ2j
2||βˆl||2
]
Differentiating with respect to βj gives
∂f(βl)
∂βj
∣∣∣∣
βˆk,k 6=j
= −x′j(rˆ + xjβˆj − xjβj) + λwl
βj
||βˆl||2
= −x′j rˆ− βˆj + βj + λwl
βj
||βˆl||2
since
∑
i x
2
ij = x
′
jxj = 1. Rearranging terms and setting the partial derivative equal to
zero, we see that the minimum is achieved when
βj =
x′j rˆ + βˆj
1 + λ′
where λ′ =
λwl
||βˆl||2
(2.24)
Where the current estimate ||βˆl||2 = 0, that is when group l first enters the estimation, we
set ||βˆl||2 to be a small positive quantity, enabling βj in (2.24) to be estimated.
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BCD proceeds by obtaining estimates for each βj, j = l1, . . . , lPl , 1, . . . , lPl , . . . until
convergence within the block, and for each pathway, l = 1, . . . , L, 1, . . . , L, . . . in turn,
until a stopping criterion indicating a global minimum of (2.15) has been satisfied. The
estimation process is summarised in Box 2.1.
Box 2.1 GL estimation algorithm using BCD
1. initialise βˆ ← 0
block coordinate descent
2. repeat
3. for pathway l = 1, 2, . . . , L
4. rˆl ← y −
∑
m6=l Xmβˆm
5. if ||X′lrˆl||2 ≤ λwl
6. βˆl ← 0
7. else
8. coordinate descent within block
9. repeat
10. for j = l1, . . . , lPl
11. estimate βj using (2.24)
12. until βl converges
13. βˆl ← βl
14. until βˆ converges
15. βˆGL ← βˆ
2.3.3 Use of pathway ‘active set’
Sparse model estimation with large datasets can be fast, because for example the lasso
soft-thresholding operator, (2.10), or the GL group selection criterion (2.21), sets most
coefficients to zero, so reducing the need for subsequent coefficient estimation through co-
ordinate descent. However, for GL with multiple, large overlapping groups, the need for
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the repeated calculation of (2.21) to establish whether or not a particular group can enter
the estimation carries a substantial computational burden. This problem motivates another
strategy providing substantial gains in computational efficiency for a range of sparse regres-
sion problems. This active set strategy relies on the pre-selection of a subset of ‘potentially
active’ predictors, or groups of predictors that are likely to be selected by the model at a
given λ (Tibshirani et al., 2010; Roth and Fischer, 2008). The optimisation can then be run
over this reduced set of variables, with a subsequent check to ensure that no other predic-
tors should have been included in the first place. The active set procedure offers potentially
dramatic speed up in execution times, particularly for very large datasets such as those
found in PGAS, due to the reduced number of computations that need to be performed. In
addition there are substantial savings in the amount of working memory required to store
data during processing, which can also lead to big reductions in computation times with
large datasets where memory is constrained.
For the GL, we begin by considering the inequality (2.21). For groups to enter the
model we require
||X′lrˆl||2 > λwl l = 1, . . . , L (2.25)
so that, at the first iteration, with β initialised to zero, a group Gl enters the model if
||X′ly||2 > λwl l = 1, . . . , L. (2.26)
We define the ‘active set’ A of potentially active groups that satisfy (2.26) as
A = {m ∈ G : ||X′my||2 > λwm}
and additionally define
λmax = min
λ
: ||X′ly||2 ≤ λwl l = 1, . . . , L (2.27)
as the smallest λ value for which the active set is empty. Note that provided λ is close to
λmax, then |A|  L.
Once one or more groups enter the model, not all βl will be zero, so that the inequality
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(2.25) then determines which groups may enter or leave the model during block coordinate
descent. The active set procedure rests on the observation that in practice, the final set of
groups selected by the model rarely includes any groups not in A (Tibshirani et al., 2010).
We can therefore perform the full estimation on A, followed by a check of the inequality
(2.25), to see if any additional groups not inA can enter the model. If there are no additional
groups, then we have the full solution. If not, then we run the full estimation again, with
the additional groups satisfying (2.25) added to A. A summary of the active set algorithm
is given in Box 2.2.
Box 2.2 Active set algorithm for a single λ value
1. Form the active set, A = {m ∈ G : ||X′my||2 > λwm}
2. Initialise β ← 0
3. Solve the GL estimation at λ, using only the groups in A:
βˆ = min
β
1
2
||y −
∑
m∈A
Xmβm||22 + λ
∑
m∈A
wm||βm||2
4. Compute the revised active set on the full dataset:
A+ = {z ∈ G : ||X′z rˆz||2 > λwz}
5. if A+/A = ∅
6. βˆGL ← βˆ
7. STOP
8. else
9. A ← A+
10. goto 2.
2.3.4 Efficient computation of block residuals
A further, large computational burden results from the repeated calculation of the residuals
rl and r in (2.21) and (2.24). The computational overhead for these calculations is substan-
tial, both because of the size of the expanded design matrix (N = 743 and P ∗ = 66, 085 in
the simulation study described in section 2.6, substantially larger for genome wide data),
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and because of the iterative nature of the BCD algorithm, meaning that a very large number
of calculations are performed. We therefore achieve one further substantial gain in compu-
tational efficiency by noting that since the blocks are separable, during BCD only the single
block residual, hl = y − Xlβl, changes between iterations j = 1, . . . , lPl , 1, . . . , lPl , . . .
within block l, and between iterations l = 1, . . . , L, 1, . . . , L, . . . across blocks. We there-
fore only need update hl at each iteration, with r and rl updated using computationally
inexpensive matrix subtractions and additions.
2.4 Selection bias and pathway weighting
PGAS methods derived from univariate SNP statistics are subject to various biasing factors
that can influence pathway ranking under the null, where no SNPs influence the phenotypic
trait, y. These factors vary from method to method, but may include the number and size
of genes in a pathway, as well as LD between SNPs and genes. Such biasing factors are
generally corrected through the use of permutation procedures. For example, the ‘GenGen’
method (Wang et al., 2009b), measures the degree to which pathways are enriched with
high ranking genes, and is subject to potential bias due to variation in the number of SNPs
mapped to a gene, and to differences in LD between SNPs mapped to different genes.
The bias correction procedure begins by forming multiple datasets through permutation
of phenotype labels. For each permuted dataset, gene scores are generated from univariate
SNP statistics, and a pathway enrichment score is calculated. A normalised (bias-corrected)
pathway enrichment score is then derived by comparing the distribution of pathway scores
under the null with the score obtained from the unpermuted data.
Regression-based methods are similarly prone to bias, and once again the use of permu-
tation has been proposed to correct for this, along with dimensionality reduction to extract
non-redundant information. For example, with the GRASS method (Chen et al., 2010),
genetic information within each gene is first summarised as ‘eigenSNPs’, obtained through
PCA. The biasing effect of gene size is once again accounted for through the generation of
a null distribution, formed by permuting phenotype labels.
With the GL under the null, pathway selection will be influenced by pathway size
(i.e. the number of SNPs within a pathway), since the accumulation of spurious associ-
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ations in larger pathways will give rise to larger ||βl||2 in (2.15). In addition, variation in
dependencies between SNPs within pathways, and to a lesser extent between pathways will
give rise to corresponding variations in ||βl||2 where spurious associations arise in regions
of high LD.
One way to correct for biases arising from variations in the statistical properties of dif-
ferent pathways or groups is through the use of appropriate group weightsw = (w1, . . . , wL),
enabling the group penalty (2.14) to vary between groups. For example, as noted by Yuan
and Lin (2006), one possible choice for the pathway weighting would be
wl =
√
Pl (2.28)
which ensures that groups of different size are penalised equally, and so have an equal
chance of being selected by the model, other things being equal (see (2.20)). In principle,
we could follow this strategy and attempt to account for other, additional factors that may
also bias pathway selection. However, there are a number of problems with this approach.
Consider for example the biasing effect of dependencies between SNPs within a pathway.
Where causal SNPs tag, or reside within large blocks with strong LD, the pathway signal
will be amplified, increasing the chance that such pathways will be selected by the model,
compared with other pathways where LD is low. This biasing effect will further depend on
the distribution of LD within the pathway, which will in turn depend on other factors such
as the number and size of pathway genes. The precise form of any additional term(s) that
should be added to (2.28) to account for this bias is thus unclear. Even if we were able to
identify a list of potential biasing factors, and formulate bias-correcting weight adjustments
for each, we are still faced with the problem that there may be other, unknown factors
that contribute to the bias. We therefore adopt a ‘hypothesis-free’ approach to adjusting
pathway weights, which makes no assumptions about those factors which might influence
pathway selection.
Consider pathway selection under the GL model (2.15), with λ tuned to select M path-
ways. We begin with the case M = 1. When there is no selection bias, and assuming no
genetic association, a pathway Gl should be randomly selected by the model according to a
uniform distribution, namely with probability Πl = 1/L, for l = 1, . . . , L. However, when
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biasing factors are present this is generally not the case, and the empirical probability distri-
bution describing pathway selection, Π∗(w) will not be uniform. Here the dependence on
the weight vector w has been made explicit, since with λ tuned to select a single pathway,
and for given y and X, w alone determines the frequency distribution. A measure of dis-
tance between these two distributions can be obtained by computing their Kullback-Leibler
(KL) divergence
D =
∑
l
Π∗l (w) log
Π∗l (w)
Πl
(2.29)
where Π∗l (w) is the empirical probability for the selection of pathway Gl under the assump-
tion of no genetic associations. When GL pathway selection is unbiased, we expect this
distance to be approximately zero. Our strategy consists in adaptively adjustingw in order
to minimise D.
Our adaptive weighting procedure is an iterative one, whereby at each iteration τ we
first update the previous weight vectorw(τ−1), and then re-estimate Π∗(w(τ)) by fitting the
GL model Z times, each with a random permutation of the response in order to create Z
null data sets2. Π∗l (w
(τ)) is then the frequency at which pathway Gl is selected across the
Z null data sets at iteration τ . The algorithm is initialised at iteration τ = 0 by using an
initial weight vector w(0), for instance the standard size weighting (2.28). This procedure
is then repeated until D reaches some suitably small value.
From (2.29), a reduction in D can be obtained by reducing the magnitude of the dif-
ference, dl = Π∗l (w) − Πl, for all l. As each |dl| approaches zero, the ratio, Π∗l (w)/Πl,
approaches one, so that the contribution of pathway Gl toD is decreased. With this in mind,
at each iteration, we adjust pathway weights according to the following formula,
w
(τ)
l = w
(τ−1)
l
[
1− sign(dl)(η − 1)L2d2l
]
0 < η < 1 (2.30)
where the parameter η controls the maximum amount by which each wl can be reduced
in a single iteration, in the case that pathway Gl is selected with zero frequency. The
weighting update equation has the following desirable properties. When 0 ≤ Π∗l < Πl,
2Alternatively, in a simulation study where the null distribution of the response is known (as in section
2.6), the Z models can be fitted after sampling a response from that null distribution.
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i.e. − 1
L
≤ dl < 0, wl is decreased, up to a maximum factor η when Π∗l = 0, increasing the
chance that group l is selected. When Π∗l > Πl, i.e. dl > 0, wl is increased, decreasing the
chance that group l is selected. Finally, when Π∗l = Πl, i.e. dl = 0, wl is unchanged. The
square in the weight adjustment factor ensures that large values of |dl| result in relatively
large adjustments to wl.
The estimation of Π∗ when M > 1, that is where more than one pathway is selected
by the model, is computationally infeasible even for a small value of M , since we would
need to estimate the empirical joint probability distribution that M pathways are selected.
However, we expect that many of the factors biasing pathway selection when M = 1
will similarly affect this joint probability distribution. Under this assumption, we estimate
the optimal weight vector w only in the M = 1 case. Simulation studies (see section
2.6.3) indicate that this data-driven adaptive waiting scheme is able to substantially increase
power and specificity compared with the standard weighting (2.28), even when M > 1,
indicating that this assumption holds in practice.
Note that under the null, where more than one pathway is selected by the model, we
don’t expect pathway selection probabilities to be uniform, since the presence of overlap-
ping SNPs means that pathways are not independent.
Finally, we note that despite the need for multiple MC simulations over multiple itera-
tions, our proposed bias-adjusted weighting strategy is fast, since it relies on fitting the GL
model with λ tuned to select a single pathway only, ensuring that the active set (Section
2.3.3) is very small, and model estimation time for each of the Z model fits is minimal.
2.5 Pathway ranking
With most variable selection methods, a choice for the regularisation parameter, λ, must
be made, since this determines the number of variables selected by the model. Common
strategies include the use of cross validation to choose a λ value that minimises the pre-
diction error between training and test datasets (Hastie, Tibshirani, and Friedman, 2008).
One drawback of this approach is that it focuses on optimising the size of the set, Cˆ, of
selected pathways (more generally, selected variables) that minimises the cross validated
prediction error. Since the variables in Cˆ will vary across each fold of the cross validation,
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this procedure is not in general a good means of establishing the importance of a unique
set of variables, and can give rise to the selection of too many variables (Vounou et al.,
2011; Meinshausen and Bu¨hlmann, 2010). For the lasso, alternative approaches, based on
data subsampling or bootstrapping have been shown to improve model consistency, in the
sense that the correct model is selected with a high probability (Bach, 2008a; Meinshausen
and Bu¨hlmann, 2010; Chatterjee and Lahiri, 2011). These methods work by recording se-
lected variables across multiple subsamples of the data, and forming the final set of selected
variables either as the intersection of variables selected at each model fit, or by assessing
variable selection frequencies. Examples of the use of such approaches can be found in
a number of recent gene mapping studies involving model selection using either the lasso
or elastic net (Cho et al., 2010; Eleftherohorinou et al., 2011; Motyer et al., 2011; Vounou
et al., 2011). Motivated by these ideas, we adopt a resampling strategy in which we calcu-
late pathway selection frequencies by repeatedly fitting the model over B subsamples of
the data, at a fixed value for λ. Each random subsample of size N/2 is drawn with replace-
ment. Our motivation here is to exploit knowledge of finite sample variability obtained by
subsampling, to achieve better estimates of pathway importance. With this approach, which
in some respects resembles the ‘pointwise stability selection’ strategy of Meinshausen and
Bu¨hlmann (2010), selection frequencies provide a direct measure of confidence in the se-
lected pathways in a finite sample.
This resampling strategy also allows us to rank pathways in order of their strength
of association with the phenotype, so that we expect pathways in C will achieve a high
ranking, whereas those in C ′ will be ranked low. The presentation of results as ranked lists
of pathways or SNPs is common in genetic association mapping, and this approach has
the added advantage of allowing us to make direct comparisons with alternative pathway
methods that use p-values as a ranking criterion (see Section 2.6.3).
We denote the set of selected pathways at subsample b by
Cˆ(b) = {l : βˆ(b)l 6= 0} b = 1, . . . , B
where βˆ(b)l is the estimated SNP coefficient vector for pathway l at subsample b. The
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selection probability for pathway l measured across all B subsamples is then
pipathl =
1
B
B∑
b=1
I
(b)
l l = 1, . . . , L
where the indicator function, I(b)l = 1 if l ∈ Cˆ(b), and 0 otherwise. Pathways are ranked in
order of their selection probabilities, pipathl1 ≥, . . . ,≥ pipathlL .
Computation time increases rapidly with M , the number of selected pathways, so that
with the number, |C|, of causal pathways unknown, the choice ofM is driven by the number
of causal pathways we expect to identify within computational constraints. For the simu-
lation study described in Section 2.6, we use B = 100 subsamples, and at each subsample
we perform a line search over λ, to ensure that M ≥ Mmin pathways are selected. This
procedure is described in Box 2.3. We note that since typically M  L, some pipathl may
be zero. Such pathways are classified as unranked.
Box 2.3 Line search procedure for tuning λ to select M ≥Mmin pathways
1. λmax ← minλ : ||XTl y||2 ≤ λwl, l = 1, . . . , L (2.27)
2. M ← 0; c← 0.8†
3. while M < Mmin
4. λ← cλmax
5. A ← {m ∈ G : ||XTmy||2 > λwm}
6. if |A| ≥M ‡min
7. obtain βˆGL(λ,A), as described in box 2.2 (starting at step 2.)
8. M ← |{l ∈ G : ||βˆl|| > 0}|
† The value of c is chosen for computational convenience. A value close to 1 ensures as few
pathways are selected by the model as possible, thus speeding up the estimation. However, a value
too close to 1 means that the decrease in λ at each iteration is small, meaning that many iterations
may have to be performed before M reaches the desired range.
‡ This step is introduced for computational efficiency, since during BCD, the number of selected
groups rarely decreases
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2.5.1 Ranking performance measures
In this section we describe 3 separate ranking performance measures that we use to eval-
uate the performance of our method in a simulation study described in Section 2.6. One
complicating factor is the issue of overlapping pathways, making the effective number of
causal pathways, |C|, dependent on the degree to which SNPs in S overlap multiple path-
ways. In addition, with any method based on variable selection, the possibility that causal
pathways are unranked, i.e. they are not selected by the model, must be taken into account.
Consider the situation where the set S of causal SNPs, with cardinality |S| > 1, is
known. We may choose to define C in its most restricted sense as the set of pathways that
contain all members of S, or alternatively C might include all pathways containing one or
more SNPs belonging to S. In either case |C| will depend on the degree to which SNPs in
S overlap multiple pathways. This in turn depends on the particular distribution of causal
SNPs with respect to overlapping genes. The need to accommodate this variability in |C|
in part motivates our formulation of the ranking measures described below.
We propose three separate ranking measures that capture different aspects of ranking
performance, and focus on the top 100 ranked pathways only. We do this firstly because in
any method attention is inevitably focused on the highest ranking pathways (or alternatively
those with the highest statistical significance in a hypothesis testing framework). Also,
since in a simulation study we compare the performance of our variable selection method
which identifies a limited number of pathways against an alternative method that scores all
pathways, some suitable cutoff in rank must be chosen.
We denote the set of ranked causal pathways by Cˆ∗ = {k ∈ C : pipathk > 0}3, and their
rankings by rk1 , rk2 , . . ., ranked in order of their respective selection frequencies, pi
path
k1
>
pipathk2 >, . . .. We further denote by Cˆ∗100 = {k ∈ Cˆ∗ : rk ≤ 100}, cardinality |Cˆ∗100|, the set
of causal pathways falling in the top 100 ranks. Our three proposed ranking measures are
as follows:
1. Highest causal pathway rank, rk1 , that is the single highest rank achieved by any
pathway in Cˆ∗100. This lies in the range 1 ≤ rk1 ≤ 100, and is only defined for
3The ∗ superscript is used to distinguish Cˆ∗, from Cˆ, the set of all ranked pathways.
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|Cˆ∗100| ≥ 1.
2. Ranking power, p100, defined as
p100 =
|Cˆ∗100|
|C| (2.31)
with 0 ≤ p100 ≤ 1. p100 = 0 when no causal pathways are ranked in the top
100 (Cˆ∗100 = ∅), and p100 = 1 when all causal pathways are ranked in the top 100
(Cˆ∗100 = C)4.
3. Power-adjusted, normalised, weighted ranking score, R. This takes account of the
actual rankings, rk1 , . . . as well as the ranking power, p100. We begin by defining a
normalised, weighted ranking score,
R∗ =
∑
k∈Cˆ∗100 r
1
2
k∑|Cˆ∗100|
k=1 k
1
2
Here the square root places greater emphasis on highly-ranked causal pathways.
The denominator is a normalising factor which represents the minimum possible
weighted ranking score, with rk1 = 1, rk2 = 2 . . ., ensuring that R
∗ attains its min-
imum value of 1 when the pathways in Cˆ∗100 are optimally ranked. Higher values of
R∗ indicate suboptimal ranking. R∗ takes no account of the possibility that not all
causal pathways are ranked, i.e. Cˆ∗100 6= C. To do this we form the adjusted measure
R =
R∗/p100 if p100 > 0R0 if p100 = 0 (2.32)
R thus attains a minimum value of 1 when all causal pathways are optimally ranked,
and the value R0 when no causal pathways are ranked.
4We assume that |C| ≤ 100, which is always true in the simulation study described in Section 2.6
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2.6 P-GLAW Simulation Study
We assess the power of our proposed P-GLAW method in a simulation study using real
genotype and pathway data, with simulated, quantitative phenotypes generated under an
additive genetic model from SNPs within a single, randomly selected causal pathway. The
presence of overlapping SNPs means that the actual number of causal pathways is then
typically greater than one. We additionally compare our method’s performance with an
alternative, univariate-based method commonly used in gene set analysis. Computation
times for both methods increase with P , and because of this, and the large number of
scenarios and simulations tested, we restrict this analysis to SNPs on a single chromosome.
2.6.1 Genotype and pathways data
We use genotypes obtained from the Alzheimer’s Disease Neuroimaging Initiative, ADNI
(www.loni.ucla.edu/ADNI), derived from the Illumina Human 610-Quad BeadChip. Sub-
jects comprise a mix of healthy controls, those diagnosed as having mild cognitive im-
pairment, and those with AD. After removing variants with a call rate < 95%, minor al-
lele frequency (MAF) < 0.1, and significant deviation from Hardy-Weinberg equilibrium
(p < 5.7×10−7), 448, 294 SNPs remain. In this study we use genotype data fromN = 743
subjects, and consider only SNPs from chromosome 1 (33, 850 SNPs).
Popular databases used for the mapping of genes to biological pathways include the
Kyoto Encyclopedia of Genes and Genomes (KEGG, www.genome.jp/kegg/pathway.html)
and BioCarta (www.biocarta.com/genes/index.asp). For this study we use data on ‘canon-
ical pathways’ from the Molecular Signals Database (MSigDB, www.broadinstitute.org/
gsea/msigdb/index.jsp), which is a commonly-used, curated collection of pathways ob-
tained from multiple sources. At the time of writing this comprised 880 pathways mapped
to 6, 804 genes. 2, 382 human gene locations on chromosome 1, corresponding to assembly
GRCh36 are obtained using Ensembl’s biomart API (www.biomart.org). ADNI-genotyped
SNPs on chromosome 1 are then mapped to annotated genes within 10kb (20, 399 SNPs
mapped to 2, 096 genes), and these remaining genes and SNPs are then mapped to path-
ways using MSigDB (8, 102 SNPs mapped to 778 pathways). Thus we see that the majority
of chromosome 1 SNPs fail to map to any pathway, but that the majority of annotated path-
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ways map to at least 1 SNP on this chromosome. Finally, small (< 10 SNPs) and identical
pathways are removed. After all pre-processing we are left with a total of P = 8, 078 SNPs
mapped to 551 pathways (max: 1, 059; min: 10; mean: 120 ± 142 SNPs per pathway).
All SNP to pathway mapping and filtering was performed using bespoke code written in
Python. The mapping and filtering process is illustrated in Fig. 2.4.
More than 80% of SNPs are observed to overlap more than 1 pathway, with around
20% overlapping 10 or more pathways and 2% overlapping 60 or more (see Fig. 2.5).
After variable expansion to account for overlapping pathways (see Section 2.2.1), we have
P ∗ = 66, 085 SNPs.
Pathways:	  	  
880	  Pathways	  
containing	  6,804	  
dis5nct	  genes	  
20,399	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  Chr1	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P	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  to	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P*	  =	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Figure 2.4: SNP to pathway mapping.
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Figure 2.5: Frequency distribution of ADNI SNPs by number of pathways they map to. SNPs are
mapped to genes within 10kbp. The data set consists of 8, 078 SNPs and 551 pathways.
2.6.2 Simulation framework
We begin by adjusting the pathway weight vector, w, using the bias-adjusted adaptive
weighting procedure described in Section 2.4. We use 10 iterations (i.e. τ = 1, . . . , 10),
and calculate the empirical, null pathway selection distribution Π∗, using Z = 40, 000
simulations, each with response vector y sampled from a standard normal distribution,
N (0, 1), since many quantitative traits are expected to be normally distributed.
For the simulation of a SNP-dependent response, we begin by drawing |S| SNPs from a
single, randomly selected causal pathway, Gφ, according to some specified distribution (see
below), and then form the set C, of causal pathways that contain all the members of S. We
thus chose to define C in its most restricted sense, rather than for example including path-
ways that contain one or more SNPs in S5. Note that the number, |C| of causal pathways
will vary according to the particular pattern of overlaps corresponding to genes mapping to
SNPs in S.
For each MC simulation we generate a univariate quantitative phenotype,
yi =
∑
k∈S
ζkxik +  i = 1, . . . , N
5It would also be interesting to consider the more general case. However, here we have a particular interest
in identifying small, distributed signals, that are typically missed in SNP-wise GWAS.
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where ζk is the allelic effect per minor allele due to causal SNP k. Setting wk = ζkxk, we
define the effect size of SNP k as δk = E(wk)/E(y) for k ∈ S , and set  ∼ N (1, σ2 ) so
that δk = 0 when ζ = 0. We also record the average SNP effect size as a proportion of
total phenotypic variance, ESk = Var(wk)/Var(y), and the mean proportionate change in
response per minor allele, E(ζk). For our simulations we control δk, and set ζk accordingly,
so that effect size is independent of SNP MAF, whereas ζk and ESk are MAF-dependent.
The power and specificity of any PGAS method is likely to depend on a range of fac-
tors including the number and distribution of causal SNPs, and the size of their phenotypic
effect (Wang, Li, and Hakonarson, 2010; Fridley and Biernacka, 2011). We therefore as-
sess the performance of our method across 6 different scenarios in which we vary each of
these factors. Furthermore, we test each scenario over 500 MC simulations to account for
variation in causal SNP MAFs, gene size and number within pathways, and LD patterns
within and between causal pathways. The list of scenarios tested is presented in Table 2.1.
scenario |S| δk distribution description
(a) 10 0.005 random from Gφ |S| large; δk large; random distribn
(b) 3 0.005 random from Gφ |S| small; δk large; random distribn
(c) 3 0.005 random from single gene in Gφ |S| small; δk large; single gene
(d) 10 0.001 random from Gφ |S| large; δk small; random distribn
(e) 3 0.001 random from Gφ |S| small; δk small; random distribn
(f) 3 0.001 random from single gene in Gφ |S| small; δk small; single gene
Table 2.1: Scenarios tested in simulation study. For scenarios (c) and (f), in the rare event that a
gene has less than 3 SNPs, all SNPs within the gene are selected.
First, we consider scenarios where the number of causal SNPs is small (|S| = 3) or
large (|S| = 10).
Secondly, we consider two different SNP effect sizes. We choose values for σ2 and δk
to mimic effect sizes obtained in recent association studies, focusing particularly on the
smallest reported effect sizes. Park et al. (2010) review GWAS for a number of quantitative
traits (height, Crohn’s disease and breast, prostate and colorectal cancers) and report values
for ESk ranging from 0.02 to 0.0004. Cho et al. (2009b) report values for ζk for 8 quantita-
tive traits in a large GWAS ranging from 1.6 to 0.006. A recent neuroimaging genetic study
measuring genetic effects on a variety of traits related to brain structure reports significant
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values for ζk of around 0.07 (Joyner et al., 2009). We set σ = 0.2, and test δk = 0.005
and 0.001, which gives values for ESk = 0.001 and 0.00004 and E(ζk) = 0.01 and 0.002
respectively.
Finally, we also vary the distribution of causal SNPs with respect to genes and asso-
ciated LD blocks, since we expect this to affect performance in our regression model (see
Section 2.4). The particular distribution of causal SNPs is also expected to the affect the
sensitivity of other pathways methods, for example where pathway scores are derived in a
two-step process that begins with the calculation of gene association scores (Wang, Li, and
Bucan, 2007). The distributions of |C|, the number of causal pathways for each scenario
described in Table 2.1, are shown in Fig. 2.6.
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Figure 2.6: Distributions of |C| across 500 MC simulations for each of the 6 scenarios described
in Table 2.1. Causal pathways are defined as those containing all SNPs in S. Where SNPs are
distributed within a single gene (scenarios (c) and (f)), the number of causal pathways tends to
be larger, since a single gene can map to multiple pathways. Where causal SNPs are distributed
randomly across Gφ (scenarios (a), (b), (d), and (e)), this number tends to be smaller, particularly
where the number of causal SNPs is large (scenarios (a) and (d)).
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P ∗ = 4k, L = 126 P ∗ = 66k, L = 551 P ∗ = 647k, L = 879
sample size BCD BCD+ BCD BCD+ BCD BCD+
371 (N/2) 7.93 0.17 421 1.35 5490 16
743 (N) 16.9 0.27 511 2.5 6430 30.0
Table 2.2: GL estimation times in seconds, with M = 10. Table shows the time taken for the
full estimation with a nullN ∼ (0, 1) response, and with varying number of SNPs in the regression
model (P ∗), and sample size (N ). ‘BCD’ - estimation using block coordinate descent only. ‘BCD+’
- estimation using BCD with active set, Taylor approximation of the group penalty and efficient
computation of block residuals. Genotype and pathway data as described in section 2.6.1. P ∗ =
4k : 5, 000 SNPs from chromosome 1 mapped to 126 pathways. P ∗ = 66k : all 33, 850 genotyped
SNPs from chromosome 1 mapped to 551 pathways. P ∗ = 647k : 448, 294 genome-wide SNPs
mapped to 879 pathways. All computations performed using multi-threading on a single machine
with 8 3.2 GHz processors and 64GB RAM.
2.6.3 Results
We begin with an investigation of the effect of our proposed methods for speeding up
the GL estimation algorithm (see Sections 2.3.2, 2.3.3 and 2.3.4). We first note that GL
estimation times will depend on the sample size (N) and the number of SNPs (P ), which
will in turn affect the number of mapped pathways (L) and the number of SNPs in the
regression model after expansion to account for overlaps (P ∗). Estimation times will further
depend on the number of groups selected (M), and the amount of signal present, since these
affect convergence times. For illustrative purposes, in Table 2.2 we compare execution
times using our accelerated methods, with ‘standard’ block coordinate descent (described in
Section 2.3.1), for a single model fit with a null response, and forM = 10. Estimation times
are seen to be substantially reduced across a range of values for N and P , dramatically so
for larger datasets.
We next illustrate the application of the bias-correcting strategy described in Section
2.4. The pathway weight vector, w, is adjusted over 10 iterations, each with Z = 40, 000
MC simulations with the response vector y sampled from N (0, 1). Fig. 2.7 (c) shows how
the weight adjustment factor w(τ)/w(τ−1), (see (2.30)), varies with dl across all pathways
at a single iteration. Fig. 2.7 (a) and (b) show the observed, empirical distribution, Π∗,
using the standard size weighting (2.28), and the adapted weights (2.30) after 10 iterations,
respectively. The corresponding KL divergence measure, D (see (2.29)), is observed to
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Figure 2.7: Application of bias-adjusted weighting procedure to the data used in the simulation
study. Z = 40, 000, with a different null response, y ∼ N (0, 1), at each MC simulation. η = 0.98.
(a) Empirical pathway selection frequency distribution, Π∗, with standard, pathway size weighting,
wl =
√
Pl. D = 2.24. Dotted horizontal line shows the expected distribution, Πl = 1/L '
0.002. (b) Π∗ with bias-adjusted weights after 10 iterations. D = 0.12. (c) Variation of weighting
adjustment factor w(τ)/w(τ−1) with dl at a single iteration, with η = 0.98. Each point represents
the adjustment to a single wl, l = 1, . . . , L. (d) Decrease in K-L divergence, D, over 10 iterations.
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reduce steadily over the 10 iterations (Fig. 2.7 (d)), illustrating how the proposed weight
adjustment procedure reduces pathway selection bias.
Next, we compare performance using the bias-adjusted weights with that obtained us-
ing the standard size weighting wl =
√
Pl. We find the adjusted weighting scheme offers a
considerable improvement in ranking performance for all ranking measures, and illustrate
this in Fig. 2.8 for a single scenario (scenario (a)) using the ranking performance measures
described in section 2.5.1. Fig. 2.8 (a) shows the first ranking measure (rk1) as a ROC curve,
in which we show the proportion of simulations with rk1 ≤ z, for ranks z = 1, 2, . . . , 100.
We plot z on the horizontal axis as a false positive rate (FPR), so that FPR = (z − 1)/L.
At a FPR of 0.05, we see that the adapted weighting scheme shows a more than 2 fold
increase in power (from 0.29 to 0.62) over the standard pathway size weighting (2.28),
indicating 62% of MC simulations have rk1 ≤ 28, compared with 29% for the standard
size weighting. The distribution of p100 across 500 MC simulations is illustrated as a box-
plot in Fig. 2.8 (b). Here we see that the adapted weighting scheme offers a clear and
substantial improvement in GL’s capacity to rank a high proportion of causal pathways in
the top 100 (p = 2.03 × 10−50 that the two population p100 CDFs are equal using a two-
sample Kolmogorov-Smirnov (KS) test). GL with the standard weighting scheme performs
particularly poorly with 55% of simulations failing to rank any causal pathway in any sim-
ulation, compared with 18% for the adapted weighting scheme. Finally, Fig. 2.8 (c) shows
the distribution of the R ranking measure across 500 simulations under the two weighting
schemes. Once again we see that the adaptive weighting scheme demonstrates improved
ranking performance over the standard size weighting scheme, with the distribution of R
scores skewed towards lower values for the former, indicating that causal pathways tend to
be ranked higher.
For the remainder of this section, we describe results obtained using the bias-adjusted
pathway weighting scheme described above. We assess P-GLAW ranking performance
across the full range of scenarios described in Table 2.1, and compare these with pathway
rankings obtained using the ‘GenGen’ (GG) method proposed by Wang, Li, and Bucan
(2007). GG is a widely-used, GSEA-type PGAS method that measures pathway enrich-
ment using genes scores derived from univariate SNP statistics. Studies using GG include
searches for implicated pathways in Crohn’s disease (Wang et al., 2009b), autism spectrum
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Figure 2.8: Ranking performance using adapted weights, compared with standard pathway size
weighting, wl =
√
Pl. Ranking measures are described in Section 2.5.1. Results for a single
scenario (scenario (a)) are illustrated, corresponding to |S| = 10 and δk = 0.005, with causal
SNPs selected at random from a single randomly selected pathway. All measures over 500 MC
simulations. (a) ROC curves illustrating power to identify at least one causal pathway in the top 100.
(b) Distribution of ranking power, p100, across 500 simulations. This is the proportion |Cˆ|∗100|/|C| of
causal pathways that are ranked in the top 100. Notches indicate 95% confidence intervals for the
true median. (c) Distribution of the power-adjusted, normalised, weighted ranking score, R, across
500 simulations, with R0 = 100. The final ‘50+’ column includes simulations for which no causal
pathway was ranked in the top 100.
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disorders (Wang et al., 2009a), breast cancer (Menashe et al., 2010) and Alzheimer’s dis-
ease (Lambert et al., 2010). GG begins by scoring each SNP according to its association
with the phenotype. SNPs are then mapped to genes within a specified distance, and each
gene is scored according to its most significant mapped SNP. The enrichment of highly-
ranked genes in a given pathway is then compared with those across all pathways, to obtain
a pathway enrichment score. For GenGen we use identical source data (genotypes, pheno-
types, SNP to gene, and gene to pathway mappings), and rank pathways by their normalised
enrichment score, NES(l) (see A.1), determined from 1,000 permutations (the GG default
settings). MC simulations for P-GLAW and GG are performed in parallel across 50 (P-
GLAW) and 500 (GG) processors respectively, on a high-performance computing cluster.
As described above for the comparison of alternative weighting schemes, results for the
comparison study are presented in the form of rk1 ROC curves (Fig. 2.9), p100 boxplots
(Fig. 2.10) and R bar graphs (Fig. 2.11). Selected ranking measures are presented in nu-
merical form in Tables 2.3 and 2.4.
scen. ROC power, FPR = 0.05 median p100 propn. p100 = 0 KS 2 sample test
P-GLAW GG ratio P-GLAW GG ratio P-GLAW GG ratio p100 cdfs the same
(a) 0.62 0.35 1.76 0.60 0.60 1.00 0.18 0.26 0.70 p = 0.0082
(b) 0.61 0.33 1.84 0.33 0.11 3.00 0.21 0.45 0.46 p = 9.6× 10−25
(c) 0.81 0.54 1.49 0.35 0.20 1.73 0.06 0.23 0.25 p = 2.5× 10−25
(d) 0.44 0.18 2.37 0.33 0.00 ∞ 0.30 0.62 0.48 p = 7.7× 10−27
(e) 0.59 0.27 2.18 0.33 0.01 37.33 0.23 0.50 0.46 p = 9.2× 10−28
(f) 0.79 0.45 1.74 0.31 0.14 2.31 0.06 0.31 0.20 p = 3× 10−38
Table 2.3: Selected ranking performance measures for P-GLAW and GG for the 6 scenarios de-
scribed in Table 2.1. ROC power, FPR = 0.05: proportion of 500 MC simulations with rk1 ≤ 28
corresponding to a FPR of 0.05. median p100: median of p100 distribution across 500 MC simula-
tions. Proportion with p100 = 0: proportion of 500 MC simulations with no causal pathway in the
top 100 ranks. KS 2 sample test: two-sample Kolmogorov-Smirnov test of the hypothesis that the
P-GLAW and GG p100 population cdfs are the same.
Beginning with the ROC curves illustrating the rk1 ranking measure (Fig. 2.9 and ‘ROC
power’ column in Table 2.3), P-GLAW consistently demonstrates increased power and
specificity across all of the top 100 ranks illustrated. The relative gain in power for P-
GLAW is greater at the smallest effect size for each equivalent scenario, (a) vs. (d), (b)
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vs. (e), and (c) vs. (f). At the smaller effect size, where causal SNPs are distributed ran-
domly within causal pathways, power increases where the number of causal SNPs is fewer
((d) vs. (e)). Finally, maximum power is achieved for both methods where causal SNPs are
located within a single gene ((c) and (f)).
Turning to the distributions of the p100 ranking measure (Fig. 2.10, and ‘median p100’
column in Table 2.3), P-GLAW again outperforms GG across all scenarios. For example,
the null hypothesis that the two population cdfs are equal is rejected at the α = 0.05 level
(Table 2.3, final column), as is the null hypothesis that the two sample medians are the same
(see Fig. 2.10, notches indicate 95% confidence intervals for median), except for scenario
(a) where median p100 is not significantly different for the two methods. Excluding sce-
nario (a) where both methods perform relatively well, P-GLAW median p100 is consistent
across each scenario, and is maintained from the larger to the smaller effect size. This is
in marked contrast to GG, where this measure shows a large decrease at the smaller effect
size, although the decrease is less marked when causal SNPs are located within a single
gene. A similar pattern persists for both P-GLAW and GG if we consider the proportion of
simulations with p100 = 0, i.e. where no causal pathways are found in the top 100 ranks,
except for P-GLAW in the case where causal SNPs are located in a single gene, where this
measure is particularly low (Table 2.3, 4th column).
The final series of plots (Fig. 2.11), illustrate the distributions of the power-adjusted,
normalised, weighted ranking score R (2.32). These distributions once again follow the
trends in ranking performance highlighted above, but they offer a more nuanced view, in
the sense that while this measure takes power into account, it is also sensitive to the actual
causal pathway rankings. Here we see that P-GLAW distributions are skewed towards
lowerR values compared with GG, indicating that causal pathways tend to be ranked higher
with P-GLAW. This is borne out if we focus on the proportion of simulations with R <
10 (Table 2.4, ‘R < 10’). Here we see once again that proportionate gains in ranking
performance for P-GLAW over GG are largest for the smallest effect size ((a)-(c) vs. (d)-
(f)). This table also gives results for the proportion of simulations showing near optimal
ranking of causal pathways (R < 3), although the very small frequencies suggest that little
can be inferred from these.
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Figure 2.9: ROC curves illustrating proportion of simulations with rk1 ≤ z, for ranks z =
1, 2, . . . , 100. Power is average across 500 simulations. False positive rate = (z − 1)/L. Sce-
narios corresponding to the higher SNP effect size (δk = 0.005) are presented in the left-hand
column, with the equivalent scenarios at the lower effect size (δk = 0.001) on the right.
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Figure 2.10: Box plots of distribution of ranking power, p100, across 500 simulations. This is the
proportion, |Cˆ|∗100/|C|, of causal pathways that fall in the top 100 ranks. Notches indicate 95%
confidence intervals for the true median.
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Figure 2.11: Distribution of the power-adjusted, normalised, weighted ranking score, R, across 500
simulations. The final ‘50+’ column includes simulations for which no causal pathway was ranked
in the top 100, i.e. Cˆ∗100 = ∅ with R0 = 100 (see (2.32)).
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scenario proportion R < 10 proportion R < 3
P-GLAW GG ratio P-GLAW GG ratio
(a) 0.68 0.46 1.47 0.13 0.09 1.38
(b) 0.50 0.24 2.11 0.03 0.03 0.93
(c) 0.55 0.33 1.68 0.01 0.07 0.18
(d) 0.44 0.20 2.22 0.03 0.02 2.00
(e) 0.46 0.20 2.33 0.02 0.03 0.69
(f) 0.45 0.23 1.96 0.01 0.04 0.30
Table 2.4: Proportion of 500 simulations with R < 10 and R < 3 for the 6 scenarios described in
Table 2.1.
2.7 Discussion
We have described a penalised regression-based strategy (P-GLAW) that exploits func-
tional structure within genotypes to identify biological pathways associated with a con-
tinuous trait. We use the group lasso, with all mapped SNPs and pathways in a single
regression model, and use a novel combination of methods including bias-adjusted group
weights, a subsampling scheme to rank pathways, and a number of adjustments to the es-
timation algorithm designed to accelerate model estimation and make the analysis of large
scale datasets computationally feasible. An important feature of our method is its ability to
accommodate the presence of overlapping pathways. On the assumption that causal SNPs
are enriched within a biological pathway, we find in a simulation study that our proposed
method shows relative gains in both power and specificity across a range of scenarios, com-
pared with an alternative pathways method (GG), based on univariate SNP statistics, that
we use as a benchmark. We believe this is the first such study evaluating the performance
of a GL-based method for pathway selection using real SNP and pathway data across a
range of realistic scenarios.
One key motivation for a pathways-based approach is the desire to harness the joint
effects of those SNPs or genes with relatively small effect size, that typically fail to achieve
genome-wide significance in GWAS (Baranzini et al., 2009). We hypothesise that the ad-
vantages inherent in a multivariate approach to modelling SNP effects will increase power
to detect these, and in our simulation study we therefore focus on scenarios with causal
SNPs that exhibit effect sizes at or below the limits of those found in recent GWAS. To
evaluate the performance of each method considered here, we devise three separate rank-
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ing metrics, each of which measures a different aspect of ranking performance.
One factor affecting power is the ‘genetic architecture’ of the disease in question, that is
the number and distribution of SNP effects across causal pathways (Wang, Li, and Hakonar-
son, 2010). For example, causal SNPs may be distributed across many genes in a pathway,
or restricted to a single gene. Since PGAS methods vary in the way that they combine the
effects of individual SNPs, the specific genetic architecture is expected to impact power for
different methods in different ways (Wang et al., 2009b; Holmans et al., 2009). GG uses
genes scores corresponding to the most significant SNP associated with a gene to establish
pathway significance. This has the advantage of reducing redundant information arising
from SNPs in LD with a causal SNP within a single gene, but may lead to reduced power
where causal variants reside in distinct LD blocks within a gene (Wang, Li, and Bucan,
2007).
An important, related factor that we find has received little attention is the issue of
overlapping pathways, and the consequent effect on PGAS performance. Aside from the
issue of how to handle overlapping predictors in our regression model, the precise distri-
bution of causal SNPs with respect to genes that overlap multiple pathways will affect the
number of pathways that are considered to be ‘causal’, and we expect this to affect ranking
performance for different methods in different ways. Most existing PGAS methods con-
sider pathways individually. In certain circumstances this approach may be advantageous,
for example where the goal is to identify as many pathways harbouring potentially causal
genes as possible. However, a potential disadvantage of this approach is that it can fail to
distinguish between pathways having a similar effect (Skarman et al., 2012), and it has been
suggested that overlapping genes may render permutation-based procedures for the control
of false positives less reliable (Wang, Li, and Bucan, 2007). One proposed solution is to
reduce or down-weight the contribution of overlapping genes (Tarca et al., 2012), although
this seems hard to justify on biological grounds. We instead force all pathways to compete
in a single regression model, with the motivation that this will tend to distinguish impor-
tant pathways from overlapping pathways with a smaller association signal. Ultimately the
choice of PGAS model will depend on the goals of the analysis.
To explore some of these issues we investigate a variety of different genetic architec-
tures, in which we vary both the number and distribution of causal SNPs within causal
P-GLAW 73
pathways. In general, we find that P-GLAW performance is reasonably consistent across
the range of causal SNP distributions and effect sizes considered. Additionally, our method
is generally able to outperform the benchmark (GG). GG performance at the smaller effect
size is particularly weak, so that P-GLAW shows the largest gains in relative performance
here.
An insight into some of those factors affecting ranking performance for the two meth-
ods considered here is afforded by considering some of the ranking measures in more detail.
Starting with the highest ranking causal pathway measure (rk1), as expected we find that
this decreases for each scenario at the smaller effect size. However, at the smaller effect
size this measure is observed to increase for both methods as the number of causal SNPs
is decreased, markedly so when the reduced number of causal SNPs are concentrated in a
single gene. Since the effect size for each causal SNP is held constant, this seems counterin-
tuitive, since the pathway signal is reduced when there are fewer causal SNPs. In addition,
for the reasons described above, for GG this signal may be further reduced where causal
SNPs reside within a single gene. The explanation is likely to be that the effective number
of causal pathways tends to increase as the number of causal SNPs is reduced, increasing
the probability that a single causal pathway is ranked high (see Fig. 2.6). The number of
causal pathways is at its largest when causal SNPs are concentrated in a single gene. This
once again highlights the importance of considering the distribution of overlaps when inter-
preting PGAS results, and in particular the presence of so-called ‘hub genes’, that have the
potential to dis-regulate large numbers of pathways (Kim, Wuchty, and Przytycka, 2011).
Where the pathway signal is strongest (scenario (a)), both methods tend to rank a high
proportion of causal pathways in the top 100 (high p100), although the proportion of MC
simulations in which GG fails to rank any causal pathways (that is the proportion of simu-
lations with p100 = 0) is relatively high. On this measure of ranking power and in marked
contrast to P-GLAW, GG performs relatively poorly across all other scenarios, particularly
at the smaller effect size. This would seem to confirm our intuition that a multivariate
method that retains all SNPs in a pathway may be more sensitive to smaller SNP effects.
Finally, we note that P-GLAW is generally relatively insensitive to variation in the number
and distribution of SNPs within causal pathways, as might be expected from the smoothing
properties of the GL `2 penalty, which ensures that all SNPs within a selected pathway are
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retained in the model (Zhou et al., 2010).
The need to account for factors such as variation in LD, gene and pathway size is a
feature common to all PGAS methods. A range of approaches, often used in combination,
have been proposed to correct for these biasing factors, including the use of gene scores that
summarise SNP statistics (Holmans et al., 2009), and permutation of phenotypes (Wang et
al., 2009b). Dimensionality reduction techniques have also been advocated for the control
of redundant information (Chen et al., 2010; Zhu and Li, 2011; Ballard, Cho, and Zhao,
2010). For P-GLAW, we propose a method that adjusts the distribution of pathway weights
according to the observed bias in pathway selection frequencies across multiple MC sim-
ulations under the null. We find in a simulation study that our proposed bias correction
method does substantially increase power and specificity, indicating that pathway selection
bias is decreased. One potential disadvantage of our approach is that it takes no account
of the variation in biasing factors across a pathway. It would be interesting to compare
the relative merits of our approach against alternative bias-reduction methods, for exam-
ple the use of PCA for within-pathway dimensionality reduction. However, we consider
the retention of all SNPs in the regression model to be a potentially attractive feature of
our approach, as it affords the possibility of the simultaneous identification of causal SNPs
driving pathway selection, a feature that we explore in Chapter 4.
In situations where predictors, or groups of predictors are correlated, both the lasso
and group lasso can demonstrate problems with consistency, that is they may be unable to
identify the true set of causal predictors or groups, even for large sample sizes (Zhao and
Yu, 2006; Wei and Huang, 2010). A range of strategies for improving model consistency
have been proposed (Bach, 2008b; Wang et al., 2010; Wei and Huang, 2010), and for the
lasso, the use of bootstrap or other subsampling techniques has been advocated (Chatterjee
and Lahiri, 2011). For the lasso, a subsampling approach has been shown to offer a number
of advantages including reduced sensitivity to the choice of λ, and much improved control
of false positives (compared to alternative methods such as cross-validation), although this
may come at the cost of a small reduction in power (Meinshausen and Bu¨hlmann, 2010).
We adopt a subsampling approach for the ranking of pathways and demonstrate promising
group selection performance with the real dataset considered here.
We pay considerable attention to the need to develop fast algorithms for solving the
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GL, a problem that is particularly acute when using regression models with GWAS data.
Using a combination of techniques, we develop a GL estimation algorithm that can quickly
solve the GL using whole genome data. However, the very large number of simulations
and scenarios considered in our simulation study, and the relatively slow performance of
the benchmark method mean that we restrict the analysis to mapped SNPs from a single
chromosome.
We note that phenotypes in our simulation study are generated under an additive lin-
ear model for allelic effects, so that phenotypic effects increase linearly with minor allele
dosage. This assumption of additive linear SNP effects is built into both the P-GLAW and
GG models, in the former through the SNP allele codings in the genotype design matrix,
and in the latter through the particular model used to generate the univariate SNP scores.
For both methods alternative models, for example capturing dominant or recessive effects,
can easily be accommodated.
Further discussion is reserved for Chapter 5, where we highlight issues arising from a
comparison of the P-GLAW method with others discussed in following chapters.
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Chapter 3
Identifying pathways associated with a
multivariate quantitative trait:
‘Pathways Sparse Reduced-rank
Regression’
We now turn to the problem of identifying gene pathways associated with a multivariate
quantitative trait (MQT). We do this by incorporating the group sparsity constraint on geno-
type coefficients used in our previous P-GLAW model, into a multivariate sparse reduced-
rank regression model, previously developed for the identification of SNPs (Vounou, Nichols,
and Montana, 2010). As with P-GLAW, our proposed ‘Pathways Sparse Reduced-Rank Re-
gression’ (PsRRR) method includes all SNPs in a single model, and accounts for potential
biasing factors such as dependencies between phenotypes and SNPs using an adaptive,
weight-tuning procedure.
A primary motivation for extending the previous model to the case of a multivariate
response is our interest in analysing high-dimensional neuroimaging genetic datasets, al-
though we note that the model and algorithms we describe here can be applied to any type
of MQT. In neuroimaging genetics, the use of high-dimensional endophenotypes offers a
potentially more power approach to identifying gene variants influencing brain structure
and function, and can enable the voxel-wise mapping of genetic effects across the brain
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(see Section 1.3). Previous work has demonstrated that a sparse reduced-rank regression
(sRRR) approach that exploits the multivariate nature of the phenotype can be more power-
ful than a mass-univariate linear modelling approach in which each phenotype is regressed
against each SNP (Vounou, Nichols, and Montana, 2010).
In the following section we describe the PsRRR model in detail, before outlining an
algorithm for coefficient estimation in Section 3.2. In Section 3.3 we explain how our
previous subsampling strategy is used for pathway ranking with PsRRR, and introduce a
method for additionally ranking SNPs and genes that may be driving pathway selection.
We describe two simulation studies demonstrating the efficacy of our proposed method for
both pathway and voxel selection in Section 3.4. In Section 3.5 we describe an application
study, in which we identify a number of gene pathways associated with voxelwise structural
change in subjects with Alzheimer’s Disease. We conclude with a discussion in Section 3.6.
3.1 The pathways sparse reduced-rank regression model
We consider the problem of identifying gene pathways associated with an MQT or pheno-
type, y1, . . . , yQ. The observed values for phenotype q, measured for N unrelated individ-
uals, are arranged in an (N × 1), mean-centred response vector yq, and the Q phenotypes
are arranged in an (N × Q) response matrix Y = (y1, . . . ,yQ). Notation for genotypes
and pathways is as described in the previous chapter.
If we denote by C = (C1, . . . ,CQ), a (P × Q) matrix of regression coefficients, then
we can model the multivariate response using a multivariate, multiple linear regression
(MMLR) model, as
Y = XC + E (3.1)
where E is an (N×Q) matrix of error terms, with zero mean, possibly correlated columns.
A least squares estimate for C may be obtained by generalising the multiple least squares
optimisation to include a multivariate response, that is by minimising the residual sum of
squares
MMMLR = Tr{(Y −XC)(Y −XC)′}. (3.2)
Where N > P and the design matrix X is of full rank, the least squares estimates are given
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by Cˆ = (X′X)−1X′Y. Note that the (P × 1) column vectors Cˆ1, . . . , CˆQ of Cˆ are then
just the least squares estimates of the regression of each yq on X, that is
Cˆq = arg min
Cq
||yq −XCq||22 q = 1, . . . , Q. (3.3)
As was noted in the previous case with a univariate response (Section 2.1), multi-
collinearity and/or rank deficiency in the genotype matrix X make the direct application
of this model to the case of high-dimensional genomic datasets problematic. Furthermore,
since the estimation (3.3) is equivalent to performing Q independent regressions, it takes
no account of the multivariate nature of Y. Ideally, we would like to exploit this in our
estimation procedure to boost power (Breiman and Friedman, 1997; Vounou, Nichols, and
Montana, 2010).
These limitations are addressed in reduced-rank regression (RRR) (Izenman, 2008), by
restricting the rank of the coefficient matrix C. Specifically we impose the constraint that
C has rank r < min(P,Q), and rewrite C as C = BA, where A and B both have (full)
rank r. The reduced rank form of (3.1) is then given by
Y = XBA + E (3.4)
where B and A are (P × r) and (r × Q) matrices of regression coefficients respectively
relating to genotypes and phenotypes (Fig. 3.1).
Y! X!
B!
!" #"
$%&'()*$&+" ,&'()*$&+"
-&./0&.1-2'3"
$%&'()*$&"
0(&405&')+"
N x Q! N x P!
P x r!
E!
&--(-+"
N x Q!
A!
r x Q!
-&./0&.1-2'3"
,&'()*$&"
0(&405&')+"
Figure 3.1: Reduced-rank regression model.
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This model has an interesting interpretation as exposing r hidden or latent factors,
which capture the major part of the relationship between Y and X. If we denote by B(k),
the kth column of B, then we see that the products XB(k), k = 1, . . . , r, represent r linear
combinations of the P predictor variables. Similarly, the r row vectors, A(k), k = 1, . . . , r,
represent the transformation of each of these back to the dimensions of Y, so that they
can predict the response. The linear combinations XB(k) and YA′(k) thus represent a re-
duced set of r (latent) factors that capture the relationship between response and predictors,
reduced in the sense that this set has dimensionality r < min(P,Q) (see Figure 3.2).
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Figure 3.2: Reduced-rank regression latent factors.
We now consider the rank-1 RRR model which captures the first, main set of genotype
and phenotype latent factors describing the association between X and Y. With r = 1, we
rewrite (3.4) as
Y = Xba + E (3.5)
where b and a are (P×1) and (1×Q) coefficient vectors respectively relating to genotypes
and phenotypes. Least squares estimates for b and a are then obtained by minimising the
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rank-1 equivalent of (3.2),
MRR1R = Tr{(Y −Xba)Γ(Y −Xba)′} (3.6)
where Γ is a given (q× q) positive definite matrix of weights. The choice of Γ reflects how
we deal with correlation between the responses y1, . . . ,yq in the least squares optimisation.
Such correlations can be exploited by setting Γ to be the inverse of the estimated covari-
ance of the responses. In the context of imaging genetics for example, where a voxel-wise
multivariate response may be derived from structural MRI, spatial correlations between
phenotypes are expected in part to reflect common genetic variation. However, the calcula-
tion of Y′Y is computationally very intensive, and is in any case likely to be inaccurate for
small sample sizes, so we instead use the simplifying approximation Γ = Iq, effectively
assuming the responses to be uncorrelated (Vounou, Nichols, and Montana, 2010; Vounou
et al., 2011).
In sparse reduced-rank regression (sRRR), Vounou, Nichols, and Montana (2010) ex-
tend the RRR model by imposing a regularisation penalty on b and/or a, to obtain sparse
estimates for genotype and/or phenotype coefficient vectors respectively. In our proposed
‘Pathways Sparse Reduced-Rank Regression’ (PsRRR) model, we obtain group-sparse es-
timates for b by imposing an additional group lasso penalty on (3.6). As before, we do this
under the assumption that only a small proportion of SNPs will be ‘causal’, in the sense
that they exhibit phenotypic effects, and further assume that causal SNPs will tend to be
enriched within functional groups, or gene pathways.
As with the previous P-GLAW model, we assume that all P SNPs may be mapped to
L groups, Gl ⊂ {1, . . . , P}, l = 1, . . . , L, and further assume that groups are disjoint or
non-overlapping, so that in the case of overlapping pathways, a suitable expansion of the
genotype matrix X and coefficient vector b has been performed (Section 2.2.1). We denote
the rank-1 vector of SNP regression coefficients by b = (b1, . . . , bP ), and the corresponding
vector of coefficients for SNPs mapping to Gl by bl = (bl1 , bl2 , . . . , bPl).
Group-sparse solutions to the rank-1 RRR model (3.5) are then obtained by minimising
PsRRR 81
the penalised least squares problem
MPsRR1R`2 =
1
2
Tr{(Y −Xba)(Y −Xba)′}+ λ
L∑
l=1
wl||bl||2 (3.7)
with respect to b and a. This corresponds to the OLS optimisation (3.6), but with an
additional group-wise penalty on the `2-norm of the pathway coefficient vectors ||bl||2, l =
1, . . . , L; a regularisation parameter λ; and an additional group weighting parameter ωl
that can vary from group to group. As with the GL penalty in the previous P-GLAW model
(Section 2.2), depending on the value of λ, this penalty has the effect of setting multiple
pathway SNP coefficient vectors, bl = 0, l ⊂ {1, . . . , L}, thereby enforcing group sparsity.
Pathways with non-zero coefficient vectors then form the set Cˆ of selected pathways, so that
Cˆ(λ) = {l : bˆl 6= 0}.
Finally, if we assume that only a small proportion of phenotypes (or voxels), Q, will
be affected by SNPs residing in causal pathways, then we can additionally perform voxel
selection, by imposing an additional sparsity constraint on the phenotype coefficient vector.
For example, with an `1 lasso-type constraint on a, the minimisation (3.7) becomes
MPsRR1R`1,`2 =
1
2
Tr{(Y −Xba)(Y −Xba)′}+ λ1
L∑
l=1
wl||bl||2 + λ2||a||1. (3.8)
Note that the additional penalty entails an extra regularisation parameter, λ2. The set Qˆ of
selected voxels is then given by
Qˆ(λ1, λ2) = {q : aˆq 6= 0}
where aˆq are the estimated coefficients of the rank-1 phenotype coefficient vector a, re-
spectively mapping to phenotype, q = 1, . . . , Q.
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3.2 Model estimation
We now describe an efficient algorithm for estimating genotype and phenotype coefficients
by minimising the group-sparse, rank-1 penalised least squares problem (3.7). Expanding
(3.7), and noting that the first term YY′ does not depend on b or a, solutions satisfy
bˆ, aˆ = arg min
b,a
{1
2
(−2aY′Xb + aa′b′X′Xb) + λ
L∑
l=1
wl||bl||2
}
. (3.9)
This optimisation is bi-convex in a and b, in the sense that it is convex in a for fixed b
and vice versa (Gorski, Pfeuffer, and Klamroth, 2007). This makes it amenable to solution
using coordinate descent (Friedman et al., 2007), and a global solution can then be obtained
by iteratively estimating one coefficient vector (b or a), while holding the other fixed at its
current value, until convergence (Chen and Chan, 2012).
Thus, for fixed b = bˆ, and with the additional constraint that bˆ′bˆ = 1, we estimate aˆ
as
aˆ = arg min
a
{1
2
(−2aY′Xbˆ + aa′bˆ′X′Xbˆ) + λ
L∑
l=1
wl||bˆl||2
}
.
Differentiating and setting to zero gives
aˆ =
bˆ′X′Y
bˆ′X′Xbˆ
.
Similarly, for fixed a = aˆ, and with the additional constraint that aˆaˆ′ = 1, we have
bˆ = arg min
b
{1
2
(−2aˆY′Xb + b′X′Xb) + λ
L∑
l=1
wl||bl||2
}
. (3.10)
This is precisely the standard group lasso optimisation (2.15), but with the univariate re-
sponse vector, y, replaced by its rank-1 equivalent, Yaˆ′. (3.10) can thus be solved using
block coordinate descent (BCD) as described in Box 2.1. The equivalent BCD estimation
algorithm with multivariate Y is presented in Box 3.1.
As with the effect of the GL penalty in the previous P-GLAW model, as λ increases,
fewer groups (or pathways) are selected by the model (Box 3.1, step 5), while for selected
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Box 3.1 Ω(aˆ,Y,X, λ): Rank-1 PsRRR estimation of b using BCD
1. b← bˆ (initialise to current estimate)
block coordinate descent
2. repeat
3. for l = 1, 2, . . . , L
4. rl ← Yaˆ′ −
∑
k 6=l Xkbk
5. if ||X′lrl||2 ≤ λwl
6. bl ← 0
7. else
coordinate descent within block
8. repeat
9. for j = l1, . . . , lPl
10. r← Yaˆ′ −Xb
11. bj ← X
′
jr+bj
1+
λwl
||bl||2
12. until bl converges
13. until b converges
14. Ω← b
pathways with bl 6= 0, estimated SNP coefficients, bj, j = l1, . . . , lPl , tend to shrink to-
wards zero (Box 3.1, step 11).
The full PsRRR estimation algorithm is presented in Box 3.2. The addition of a pheno-
type vector sparsity constraint (3.8) is easily accommodated by adding a coordinate descent
procedure to the estimation of a in Box 3.2 step 5, as described in Section 2.1.2.
As with P-GLAW, before proceeding with the full model estimation, we apply an initial
weight tuning step, to account for factors that may bias pathway selection. To do this we
follow the adaptive weighting strategy described previously (see Section 2.4), but with R
PsRRR estimations performed over multiple permutations of the rows of the phenotype
matrix, Y.
Estimates for b and a respectively represent the first (rank 1) latent factors that are ex-
pected to capture the strongest signal of association between gene pathways and the pheno-
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Box 3.2 Rank-1 PsRRR full estimation algorithm using coordinate descent
1. initialise:
a0 ← 1/||1||2; b0 ← 1/||1||2
λ← cλmax
where λmax = minλ{λ : ||XTl Ya′0||2 = λwl, l = 1, . . . , L}
and 0 < c < 1
2. repeat:
3. b← Ω(a0,Y,X, λ) (from Box 3.1)
4. b← b/||b||2 (normalise)
5. a← b′X′Y
b′X′Xb
6. a← a/||a||2 (normalise)
7. b0 ← b; a0 ← a
8. until b and a converge
type. In principle, it is possible to capture further latent factors of diminishing importance,
by iteratively repeating the procedure described above, after regressing out the effects of
previous factors (Vounou, Nichols, and Montana, 2010). With PsRRR however, the estima-
tion of further ranks is complicated by the fact that pathways overlap, by the typically large
number of SNPs in selected pathways, and by the need to recalibrate the group weights at
each step. For this reason we consider only the first latent factor in the application study
described in Section 3.5.
3.3 Pathway, gene and SNP ranking
3.3.1 Pathway ranking
As with P-GLAW, we use a resampling strategy to rank pathways by repeatedly fitting the
model over B subsamples, each of size N/2, drawn without replacement, at a fixed value
for λ. We denote the set of selected pathways at subsample b by
Cˆ(b) = {l : bˆ(b)l 6= 0} b = 1, . . . , B.
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The selection probability for pathway l measured across all B subsamples is then
pipathl =
1
B
B∑
b=1
I
(b)
l l = 1, . . . , L
where the indicator function, I(b)l = 1 if l ∈ Cˆ(b), and 0 otherwise. Pathways are ranked in
order of their selection probabilities, pipathl1 ≥, . . . ,≥ pipathlL .
3.3.2 SNP and gene ranking
The PsRRR model is designed to identify important pathways which may contain multiple
genetic markers with varying effect sizes. However, it is still interesting to establish which
SNPs and genes are most predictive of the response amongst those mapped to the set Cˆ(b) of
selected pathways at subsample b. Note that these are not necessarily the SNPs and genes
that are driving the selection of any particular pathway in the PsRRR model.
To do this, we perform a second level of variable selection using sRRR with a lasso
penalty (Vounou et al., 2011). In the unexpanded variable space, we first form the reduced
(N × Z(b)) matrix XCˆ(b) , with columns {xj : j ∈
⋃
l∈Cˆ(b) Gl} corresponding to all SNPs in
pathways selected at subsample b. Sparse estimates for the corresponding SNP coefficient
vector, β, and rank-1 phenotype vector α then satisfy the equivalent of (3.9) with a lasso
penalty, namely
βˆ, αˆ = arg min
β,α
{1
2
(−2αY′XCˆ(b)β +αα′β′X′Cˆ(b)XCˆ(b)β) + λ||β||1
}
.
We denote the set of SNPs selected at sample b by Sˆ(b), and further denote the set of selected
genes to which the SNPs in Sˆ(b) are mapped by φˆ(b) ⊂ Φ, where Φ = {1, . . . , G} is the
set of gene indices corresponding to all G mapped genes. Using the same strategy as for
pathway ranking, we obtain an expression for the selection probability of SNP j across B
subsamples as
piSNPj =
1
B
B∑
b=1
I
(b)
j
where the indicator function, I(b)j = 1 if j ∈ Sˆ(b), and 0 otherwise. A similar expression
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for the selection probability for gene g is
pigeneg =
1
B
B∑
b=1
J (b)g
where the indicator function, J (b)g = 1 if g ∈ φˆ(b), and 0 otherwise. SNPs and genes are
then ranked in order of their respective selection frequencies.
3.4 Simulation studies
In this section we describe two simulation studies to demonstrate proof of principle of the
efficacy of our proposed PsRRR model and estimation algorithm. In the first study we con-
firm the intuition that the power to detect causal pathways will depend on both SNP effect
size, and the proportion of affected phenotypes for a multivariate trait. In a second simula-
tion study, we focus on the convergence of the phenotype coefficient vector in PsRRR. To
illustrate this we impose an additional lasso penalty on a (3.8), so that pathway and voxel
selection are performed simultaneously. We then explore the relationship between pathway
and voxel selection power, while again varying genetic effect size and the proportion of
affected phenotypes.
3.4.1 Data simulation
We simulate P = 5000 genetic markers for N = 400 individuals. Marker frequencies for
each SNP are sampled independently from a multinomial distribution following a Hardy
Weinberg equilibrium frequency distribution, so that for SNP j with minor allele frequency
mj , p(xij=0) = m
2
j ; p(xij=1) = 2mj(1−mj) and p(xij=2) = m2j . SNP minor allele frequen-
cies are sampled from a uniform distribution U(0.1, 0.5).
SNPs are distributed equally between 50 non-overlapping pathways, each containing
100 SNPs. Since pathways are non-overlapping, of equal size, and SNP genotypes are
independent, there factors cannot bias pathway selection. While some pathway selection
bias may still be present due to variation in {mj}, we make the simplifying assumption that
this will be negligible, and use a uniform pathway weighting vector w = 1.
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A baseline multivariate phenotype, yq, q = 1, . . . , 1000 is sampled from the multivari-
ate normal distribution M(µ,Σ), with mean vector µ = (µ1, . . . , µ1000) sampled from
N (10, 1) and Σ = I1000. To generate SNP effects, we first select a single pathway, Gl, at
random. From this pathway we randomly select 5 SNPs to from the set S ⊂ Gl of causal
SNPs affecting one or more phenotypes. At each MC simulation we generate a genetic
effect in a fixed proportion, ρ, of all phenotypes, and denote the set of affected phenotypes
by Q ⊂ {1, . . . , Q}, so that |Q| = 1000ρ. Affected phenotype q is then adjusted so that
y∗q = yq + wq
where
wq = δq
∑
k∈S
ζkxk.
Here δq controls the overall additive genetic effect on phenotype yq due to all casual SNPs
in S, and ζk determines the contribution from causal SNP k, with
∑
k∈S ζk = 1. In our
simulations we maintain a constant overall genetic effect size,
γ = E(wq)/E(yq)
across all affected phenotypes, so that γ represents the proportionate increase in the mean
value of yq due to all genetic effects. We also set ζk = 1/5, for k ∈ S, so that the
contribution from each causal SNP allele is equal. This enables us to determine δq for a
given γ as
δq =
5γE(yq)
2
∑
k∈S mk
.
Note that for constant γ, the proportionate effect on the mean value of yq due to SNP k is
MAF dependent, and is given by 2δqmk/E(yq).
Finally, we denote the mean signal to noise ratio by
SNR =
1
Q
∑
q∈Q
Var(wq)
Var(yq)
. (3.11)
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3.4.2 PsRRR Simulation study 1: Pathway selection
In the first simulation study, we investigate how the ability of PsRRR to correctly identify a
single causal pathway depends on both the overall genetic effect size, γ, and the proportion
of affected phenotypes, ρ. We use the estimation procedure described in Section 3.2, with
a sparsity constraint imposed on the genotype coefficient vector, b, only. Each scenario
(γ/ρ combination) is tested over 500 MC simulations. For each simulation we randomly
select 5 causal SNPs from a single causal pathway, and generate a multivariate phenotype
according to the simulation procedure described in the preceding section. We consider a
range of values for both γ and ρ, and present the corresponding values for the observed
mean signal to noise ratio (3.11) across 500 MC simulations in Table 3.1. SNR is observed
to increase both with increasing γ and with increasing ρ.
ρ
0.1 0.2 0.3 0.4 0.5
0.001 2.31× 10−06 4.51× 10−06 7.05× 10−06 9.30× 10−06 1.14× 10−05
0.003 2.07× 10−05 4.10× 10−05 6.31× 10−05 8.31× 10−05 1.04× 10−04
γ 0.005 5.79× 10−05 1.15× 10−04 1.69× 10−04 2.32× 10−04 2.93× 10−04
0.007 1.11× 10−04 2.23× 10−04 3.42× 10−04 4.62× 10−04 5.73× 10−04
0.009 1.86× 10−04 3.79× 10−04 5.64× 10−04 7.58× 10−04 9.55× 10−04
Table 3.1: Empirical phenotypic SNR values (3.11) corresponding to the range of overall genetic
effect size (γ) and proportion of affected phenotypes (ρ) used in Simulation study 1. Each figure is
average SNR across 500 MC simulations.
At each simulation, the regularisation parameter, λ is tuned so that a single pathway
is selected by the model. Results are shown in Fig. 3.3. It is clear that power increases
both with increasing genetic effect size on each affected phenotype, and also as the number
of affected phenotypes as a proportion of all phenotypes increases. Comparison with the
empirical mean signal to noise ratios presented in Table 3.1 shows that the power to detect
a causal pathway closely follows SNR.
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Figure 3.3: Simulation study 1. Effect on power of varying overall genetic effects size, γ and
the proportion of affected phenotypes ρ. Each scenario (ρ/γ combination) is tested over 500 MC
simulations. Q = 1000 for all scenarios. The regularisation parameter, λ, is tuned so that a single
pathway is selected at each simulation. Power for each scenario is then defined as the proportion of
all 500 simulations in which the correct causal pathway is selected.
3.4.3 PsRRR Simulation study 2: Simultaneous pathway
and voxel selection
In the second simulation study we perform simultaneous pathway and voxel selection by
imposing an additional lasso constraint on the phenotype coefficient vector (3.8). The
simulation and model estimation procedures are as described for the previous simulation
study, except that for each MC simulation, sparse estimates for the phenotype coefficient
vector are estimated using the coordinate descent procedure described in Section 2.1.2.
This replaces the non-sparse a update, described in Box 3.2 step 5. Once again, the group-
sparsity (pathway) regularisation parameter λ1 is tuned so that a single pathway is selected
at each MC simulation. We additionally set the lasso (phenotype) regularisation parameter
λ2 = 0.3λ
SNP
max (see (3.8)), where λ
SNP
max is the smallest value for λ2 at which no SNPs are
selected (i.e. the equivalent of (2.27)). This results in an average of 240 voxels selected at
each simulation.
For each scenario, the number of affected phenotypes, |Q| = ρQ varies, as does the
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number of selected voxels, |Qˆ|, across MC simulations. For this reason we concentrate on
selection precision, or the number of correctly selected voxels as a proportion of |Qˆ|. At
MC simulation z, this is given by
Vz(γ, ρ) =
|Qˆz ∩Qz|
|Qˆz|
,
where |Qˆz| and |Qz| are respectively the number of selected voxels and the number of
affected voxels at simulation z. We then report the average value of this quantity across all
500 MC simulations,
V (γ, ρ) =
1
500
500∑
z=1
Vz(γ, ρ), (3.12)
so that V = 1 when there is maximum precision (no false positives), and V = 0 when the
precision is zero, that is all selected voxels are false positives.
SNR values for the range of scenarios explored in this simulation study are presented
in Table 3.2, and results are presented in Figure 3.4.
ρ
0.1 0.2 0.3 0.4 0.5
γ
0.0025 1.46× 10−05 2.97× 10−05 4.41× 10−05 5.79× 10−05 7.17× 10−05
0.005 5.85× 10−05 1.17× 10−04 1.78× 10−04 2.36× 10−04 2.93× 10−04
0.01 2.34× 10−04 4.71× 10−04 7.08× 10−04 9.42× 10−04 1.17× 10−03
0.02 9.26× 10−04 1.88× 10−03 2.73× 10−03 3.78× 10−03 4.66× 10−03
Table 3.2: Empirical phenotypic SNR values for Simulation study 2.
The left hand plot in Figure 3.4 shows variation in pathway selection power, which is
the proportion of simulations in which the correct causal pathway is selected. The right
hand plot shows voxel selection precision, V (γ, ρ). Note that by chance, the expected
precision is just ρ, the proportion |Qz|/Q of causal phenotypes. This expected value is
indicated by the dashed line.
Pathway selection power (Figure 3.4, left-hand plot) is broadly in line with that ob-
served in Simulation study 1, where there was no voxel selection. Note however that the
range of effect sizes explored in this simulation study stretches beyond those used in the
previous study, to include larger pathway effects. This is because voxel selection per-
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Figure 3.4: Simulation study 2. Left hand: proportion of 500 MC simulations in which the true
causal pathway is selected. Right hand: Voxel selection performance. This is the proportion of
selected voxels that are ‘affected’, i.e. that exhibit genetic effects, averaged over 500 MC simulations
(see (3.12)). The dashed line represents the value of this measure expected by chance.
formance lags behind pathway selection performance, in the sense that pathway selection
power is observed to be high, even when voxel selection performance is relatively poor. For
example with γ = 0.005 (green lines in Figure 3.4), pathway selection power is relatively
high where ρ ≥ 0.4, and yet the proportion of correctly selected voxels, V , is no greater
than that expected by chance.
With real data, relative pathway and voxel selection performance is expected to depend
on numerous factors including, for example, the number of voxels, SNPs and pathways,
and the extent of correlations between voxels and between SNPs. Both the preceding simu-
lation studies are presented primarily as a proof of principle of the efficacy of our proposed
algorithm, as well as providing a simple illustration that pathway selection power will de-
pend on maximising the signal to noise ratio in the phenotype. In the context of identifying
pathways in an imaging genetics study, this entails selecting an imaging phenotype that is
likely to maximise the phenotypic signal to noise ratio of the genetic effects under investi-
gation.
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3.5 PsRRR Application study:
Identification of gene pathways implicated in Alzheimer’s disease
using longitudinal imaging phenotypes
A growing list of genetic variants has now been associated with greater susceptibility to
develop early and late-onset Alzheimer’s disease (AD), with the APOE4 allele consis-
tently identified as having the largest effect (for an up to date list see www.alzgene.org).
SNP association studies have been augmented by numerous studies considering differen-
tial gene expression across various brain regions, again focusing on differences between
cases and controls (Zou et al., 2010). Recently, case-control susceptibility studies have
been augmented by studies using neuroimaging phenotypes. The rationale here is that the
use of heritable imaging signatures (endophenotypes) of disease may increase the power
to detect causal variants, since gene effects are expected to be more penetrant at this level
(see Section 1.3). This approach has been used to identify genes associated with a range
of AD-associated imaging phenotypes including measures of hippocampal volume (Stein
et al., 2012), cortical thickness (Burggren et al., 2008) and longitudinal changes in brain
structure (Vounou et al., 2011).
AD is a moderate to highly heritable condition, yet as with many common heritable dis-
eases, association studies have to date identified gene variants explaining only a relatively
modest amount of known AD heritability (Braskie, Ringman, and Thompson, 2011). We
therefore perform a pathways analysis in the hope that we can reveal aspects of the disease’s
genetic architecture that may not be amenable to standard methods. A longer term goal is
that studies such as these will lead to a deeper understanding of the underlying mechanisms
by which gene mutations impact disease etiology, potentially playing an important role in
the translation of basic AD biology into therapy and patient care (Sleegers et al., 2010).
At least two recent studies have performed pathways analyses using dichotomous (case-
control) phenotypes (Lambert et al., 2009; Jones et al., 2010). In the following sections we
describe what we believe to be the first AD pathways study using a multivariate imaging en-
dophenotype. Specifically, we apply the PsRRR method described earlier in this chapter to
a pathways analysis of the ADNI cohort (www.loni.ucla.edu/ADNI), comparing genome-
wide SNP data with voxel-wise tensor-based morphometry (TBM) maps describing longi-
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tudinal structural changes that are characteristic of AD. As in our previous P-GLAW simu-
lation study (Section 2.6), we map SNPs to pathways from the KEGG pathways database,
a curated collection of functional gene pathways representing current knowledge of molec-
ular interaction and reaction networks (http://www.genome.jp/kegg/pathway.html). Our
method is however able to accommodate alternative sources of information for the group-
ing of SNPs and genes, for example using gene ontology (GO) terms, or information from
protein interaction networks (Wu, Feng, and Stein, 2010; Jensen and Bork, 2010).
In this study we use a high-dimensional phenotype describing structural change relative
to baseline over three time points in subjects with AD, and in healthy controls. From this
we extract an imaging endophenotype that is highly characteristic of AD in our sample by
using a stringent statistical threshold to exclude voxels that do not discriminate between
AD and CN. Our main objective here is not to build a robust statistical classifier for AD,
but instead to produce a quantitative phenotype having maximal sample variability between
AD and CN for the subsequent gene mapping stage of our analysis.
The study is presented as follows. We begin in section 3.5.1 with a description of the
voxel-wise TBM maps used in the analysis, and in section 3.5.2 we outline how we use
these maps to generate an imaging signature characteristic of structural change in AD, that
is able to discriminate between AD patients and controls in our sample. In section 3.5.3 we
describe the genotype data used in the study, together with quality control procedures, and
in section 3.5.4 we explain how this genotype data is mapped to gene pathways. We discuss
our strategies for addressing the significant computational challenge of fitting a regression-
based model with such high dimensional datasets in section 3.5.5. Pathway, SNP and gene
ranking results are presented in section 3.5.6, and we conclude with a discussion in section
3.6.
3.5.1 Imaging data
Image pre-processing was carried out by Xue Hua and Paul Thompson from the Laboratory
of Neuro Imaging, Department of Neurology at the UCLA School of Medicine, USA.
Longitudinal brain MRI scans (1.5 Tesla) were downloaded from the ADNI public
database (http://www.loni.ucla.edu/ADNI/Data/). Serial brain MRI scans (N = 1446; see
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Table 3.3) were analysed from 200 probable AD patients and 232 healthy elderly controls
(CN). AD and CN subjects were scanned at screening and followed up at 6, 12, and 24
months. Additional scans for CN subjects at 36 and 48 months are not included in this
study. All subjects were scanned with a standardised 1.5T MP-RAGE protocol developed
for ADNI (Jack et al., 2008). The typical acquisition parameters were repetition time (TR)
of 2400 ms, minimum full echo time (TE), inversion time (TI) of 1000 ms, flip angle of 8◦,
24 cm field of view, 192×192×166 acquisition matrix in the x−, y−, and z− dimensions,
yielding a voxel size of 1.25×1.25×1.2 mm3, later reconstructed to 1 mm isotropic voxels.
Image correction steps included gradwarp (Jovicich et al., 2006), B1-correction (Jack et al.,
2008), N3 bias field correction (Sled, Zijdenbos, and Evans, 1998), and phantom-based ge-
ometrical scaling (Gunter et al., 2006).
Linear registration (9-parameter) was used to align the longitudinal scan series of each
subject, and then the mutually aligned time-series was registered to the International Con-
sortium for Brain Mapping template (ICBM-53) (Mazziotta et al., 2001). Brain masks that
excluded skull, other non-brain tissues, and the image background were generated automat-
ically using a parameter-less robust brain extraction tool (ROBEX) (Iglesias et al., 2011).
Individual Jacobian maps representing voxelwise structural brain change were created
by warping the skull-stripped, globally registered and scaled follow-up scan to match the
corresponding screening scan. We used a non-linear, inverse consistent, elastic intensity-
based registration algorithm (Leow et al., 2005), which optimises a joint cost function based
on mutual information (MI) and the elastic energy of the deformation. Colour-coded maps
of the Jacobian determinants were created to illustrate regions of ventricular/CSF expansion
(i.e., with det J(r) > 1), or brain tissue loss (i.e., with det J(r) < 1) (Frackowiak et al.,
2003; Chung et al., 2001; Freeborough and Fox, 1998; Riddle et al., 2004; Thompson
et al., 2000; Toga, 1999) over time. These longitudinal maps of tissue change were also
spatially normalised across subjects by non-linearly aligning all individual Jacobian maps
to an average group template known as the minimal deformation target (MDT), for regional
comparisons and group statistical analyses.
The study was conducted according to the Good Clinical Practice guidelines, the Dec-
laration of Helsinki and U.S. 21 CFR Part 50-Protection of Human Subjects, and Part 56-
Institutional Review Boards. Written informed consent was obtained from all participants
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before experimental procedures, including cognitive tests, were performed.
Table 3.3: Available scans at 6, 12 and 24 months for the ADNI-1 dataset (downloaded on February
28, 2011)
Screening 6Mo 12Mo 24Mo
AD 200 165 144 111
CN 232 214 202 178
Total 432 379 346 289
At screening:
Group age (years) N male N female
AD 75.7±7.7 103 97
CN 76.0±5.0 120 112
3.5.2 Phenotype extraction
Phenotype extraction was carried out by Eva Janousova, at the time visiting Imperial Col-
lege from the Institute of Biostatistics and Analyses, Masaryk University, Brno in the Czech
Republic.
For the study, we include 253 individuals (99 AD, 154 CN) with longitudinal maps at
all three time points (6, 12 and 24 months), who have also been genotyped by ADNI.
To maximise the power to detect causal pathways, we seek a phenotype which is highly
representative of those structural changes in the brain that are characteristic of AD. One
way to do this is to use prior knowledge on regions of interest (ROI) to extract a univariate
quantitative measure as a disease signature (Potkin et al., 2009b). We instead use a voxel-
wise, data-driven approach to produce a multivariate disease signature that may present a
stronger signal for the detection of genetic effects (Vounou et al., 2011).
A previous imaging genetic study on the same ADNI cohort measured structural change
relative to baseline at a single time point only. In that study an AD-specific phenotype was
produced using a sparse linear classifier to select a subset of voxels that minimised the
CN/AD classification error (Vounou et al., 2011). In the present study where we incor-
porate two additional timepoints, we instead begin by fitting a linear regression with an
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intercept term, where the dependent variable is the voxel value (change relative to baseline
at screening), and the independent variable is time. The regression coefficient for the slope
thus gives a summary measure of tissue change over time at each voxel. To obtain a phe-
notype that is maximally discriminative between CN and AD in our sample, we remove
all voxels where the difference in the slopes is not significantly different from zero, by
performing an analysis of variance (ANOVA), with sex and age as covariates. Finally we
select the most discriminative voxels whose ANOVA p-values exceed a level of 0.05, with
a Bonferroni correction for multiple testing. Once again, the use of an ultra-conservative
significance threshold ensures that our phenotypic disease signature is maximally discrim-
inative between CN and AD in our sample. The final set of phenotypes used in the study
then corresponds to the voxel-wise slope coefficients for all 253 subjects at the selected
voxels, corrected for sex and age (see Section 3.5.6).
3.5.3 Genotype data
ADNI Genotypes for the 253 subjects in the present study were extracted from imputed
genotype data used in two previous studies (Vounou et al., 2011; Stein et al., 2010a). ADNI
genotyping is performed using the Human610-Quad Bead-Chip, which includes 620,901
SNPs and copy number variations (see Saykin et al. (2010) for details). SNPs defining the
APOE4 variant are not included in the original genotyping chip, but have been genotyped
separately by ADNI. These were added to the final genotype dataset. Subjects were unre-
lated, and all of European ancestry, and had previously passed screening for evidence of
population stratification using the procedure described in Stein et al. (2010a). 78,874 non-
autosomal SNPs are excluded from the study, as are SNPs with a genotyping rate < 95%
(42,680 SNPs excluded), a Hardy-Weinberg equilibrium p-value < 5 × 10−7 (873 SNPs
excluded), and a minor allele frequency < 0.1 (64,204 SNPs excluded). 434,271 SNPs
remained after all SNP filtering steps described above.
3.5.4 SNP to pathway mapping
For our AD pathways study, we proceed as follows. A list of 21,004 human gene chromo-
somal locations, corresponding to human genome assembly GRCH36 was obtained using
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Ensembl’s BioMart API (www.biomart.org). SNPs were then mapped to any gene within
10k base pairs. This resulted in 211,106 SNPs being mapped to 18,405 genes. While the
majority of known genes did map to at least one SNP in our study, approximately half of the
SNPs passing QC were not located within 10kbp of a known gene. For pathway mapping,
we used the KEGG canonical pathway gene sets obtained from from the Molecular Signa-
tures Database v3.0 (http://www.broadinstitute.org/gsea/msigdb/index.jsp), which contains
186 gene sets, mapping to a total of 5,267 distinct genes, with many genes mapping to more
than one pathway. Note that only around 25% of all known genes map to a pathway in this
dataset. We map all SNPs within 10kbp of one or more of the 5,267 pathway-mapped
genes to the pathway(s) concerned. Finally, we exclude the largest pathway, by number of
mapped SNPs, (‘Pathways in Cancer’) that is highly redundant, in that it contains multiple
other pathways as subsets. This results in 66,162 SNPs mapped to 4,425 genes and 185
pathways (see Fig. 3.5).
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Figure 3.5: Mapping SNPs to pathways
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The distribution of pathway sizes in terms of the number of SNPs that they map to is
illustrated in Fig. 3.6 (left). Pathway sizes range from 57 to 5,111 SNPs (mean 949). The
distribution of overlapping SNPs, that is the number of pathways to which each SNP is
mapped, is illustrated in Fig. 3.6 (right). This ranges from 1 to 45 pathways (mean 2.65).
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Figure 3.6: Left: Pathway sizes. Distribution of KEGG pathways, by the number of ADNI SNPs
that they map to. Right: SNP overlaps. Distribution of ADNI SNPs, by the number of pathways
that they map to. SNPs map to multiple pathways either because they map to a gene that belongs
to more than one pathway, or because they map to more than one gene belonging to more than one
pathway.
Note that following the above procedure, some genes previously implicated in AD
imaging genetic studies do not map to any pathways, and thus are not included in the anal-
ysis. For example, in this study, 12 out of 30 genes highlighted in the review by Braskie,
Ringman, and Thompson (2011) are mapped to pathways. The remaining 18 genes are
excluded because they do not feature in any KEGG pathway. Also note that since SNPs are
mapped to all genes within a range of 10kbp, AD implicated SNPs may map to more than
one gene, and its corresponding pathway(s). This is the case for example with a number
of SNPs mapping to the APOE and TOMM40 genes. This information is summarised in
Table 3.4.
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Table 3.4: AD genes included in this study. 12 out of 30 genes previously linked to AD imaging
endophenotypes (Braskie, Ringman, and Thompson, 2011) that are included in this study are listed
in the left hand column. These are genes that (a) map to a KEGG pathway and (b) have a genotyped
SNP within 10kbp. The right hand column shows neighbouring genes that map to one or more SNPs
mapping to the respective AD implicated gene.
Implicated gene Mapped genes in study
TOMM40 TOMM40 APOE PVRL2
ACE ACE
EPHA4 EPHA4
CCR2 CCR2 CCR5
APOE TOMM40 APOE PVRL2
FAS FAS
CHRNB2 ADAR CHRNB2
EFNA5 EFNA5
LDLR LDLR
CR1 CR1 CR2
GRIN2B GRIN2B
IL8 IL8
3.5.5 Computational Issues
All computer code for the analysis was written in the open source Python programming
language, using Numpy and SciPy modules which are optimised for efficient operation
with large matrices. Execution of the PsRRR estimation algorithm nonetheless presents
a considerable computational burden, both in terms of processor time and memory use.
We therefore implement the full range of strategies designed to increase computational ef-
ficiency for the GL described earlier, namely a Taylor approximation of the group lasso
penalty (Section 2.3.2), efficient computation of block residuals (2.3.4), and the use of a
pathway active set (2.3.3). The latter in particular leads to substantial gains in computa-
tional efficiency and a large reduction in memory requirements, resulting from the very
much reduced size of X in Ω(a,Y,X, λ) (Box 3.1).
The need to fit a large number of PsRRR models over multiple subsamples of the data
for pathway ranking presents another major drain on computational resources. However,
the fact that model estimations for each subsample are entirely independent presents an
opportunity for performing multiple model fits in parallel. We implement such a strategy
using a computer cluster, in which a single client node distributes subsamples across mul-
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tiple CPU cores (see Figure 3.7). Parallel computations and client-server communication
are implemented in Parallel Python (http://www.parallelpython.com/). All high-bandwidth
processor and memory intensive operations are carried out on the server nodes. Only low-
bandwidth instructions and results pass between client and servers. The computational
framework is highly scalable, so that the user can specify the number of server nodes and
CPUs, with the software determining how model estimations are distributed between these.
The resulting reduction in computation time due to parallelisation is considerable. For ex-
ample, in the AD study described here, total execution time (excluding weight tuning) with
B = 1000 subsamples was 61
2
hours, whereas total execution time if each job were run
serially would be approximately 101
2
days.
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Figure 3.7: Parallel computing framework for PsRRR estimation. Coefficient estimation for mul-
tiple data subsamples is carried out by CPUs (‘workers’) distributed across a computing cluster.
Computing jobs are distributed by a single python process residing on the server node. All workers
reside on one of 8 client nodes. High-bandwidth, data intensive operations are carried out within
each client node. Only low-bandwidth instructions and results pipes pass between server and client.
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3.5.6 Results
AD associated phenotypes
An imaging signature characteristic of AD was created using the procedure described in
section 3.5.2. As described previously, we begin by computing a linear least-squares fit
of the longitudinal structural change across 3 time points at each voxel. An illustration
of average slope coefficients, and their variation between subjects, is shown in Fig. 3.8.
Increased expansion of ventricular volumes is clear in all subjects, but this increase is most
marked in AD patients, where ventricular volumes expand by an average 1.2% per year
(white regions in left hand part of Fig. 3.8). AD patients also show the most variation in
structural change over time.
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Figure 3.8: Sample mean (left) and standard deviation (right) of slope coefficients for the 2 subject
groups. Slope coefficients represent a linear approximation of change in brain volume over time.
Scales represent 10× percentage change in voxel volume per year, so that for example a slope
coefficient of 12 (white areas in left hand plot) is equivalent to an average yearly increase in voxel
volume of 1.2%.
A statistical image showing the corresponding ANOVA p-values, a measure of the ex-
tent to which each voxel is able to discriminate between ADs and CNs, is shown in the top
row of Fig. 3.9. From the Q∗ = 2, 153, 231 voxels in this image, we extract a final set of
Q = 148, 023 voxels whose p-values exceed a Bonferroni-corrected threshold of 0.05/Q∗.
This final set of voxels that are most discriminative between ADs and CNs, are highlighted
in yellow in the bottom row of Fig. 3.9. These Q voxels constitute the phenotype for each
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Figure 3.9: Imaging signature characteristic of AD. Top: Statistical image showing p-values
(− log10 scale) obtained from an ANOVA on the linear structural change over 3 time points,
corrected for age and sex, to discriminate between AD and CN subjects. Bottom: The final
set of Q = 148, 023 selected voxels with p-values exceeding a Bonferroni-corrected threshold
αB = 0.05/2153231, (− log10 αB = 7.6) are highlighted in yellow.
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subject used in the study. We provide a further indication of the discriminatory power of the
selected voxels by visualising the Euclidean distances between subjects using the selected
voxels in a 3D multi-dimensional scaling plot in Fig. 3.10. The relatively small overlap
between CD and AD subjects indicates that our chosen disease signature is indeed discrim-
inative between the two groups. As expected we also see evidence of greater variability in
the AD group, compared with CN.
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Figure 3.10: 3D multi-dimensional scaling plot illustrating the spread of imaging signatures across
ADs and CNs. Imaging signatures correspond to selected voxels only.
Pathway, SNP and gene rankings
We use the PsRRR algorithm described in section 3.1 to identify KEGG pathways associ-
ated with the AD-discriminative longitudinal phenotypes described in the preceding sec-
tion. Pathways are ranked in order of importance using the resampling strategy described
in section 3.3, with B = 1000 subsamples. Each subsample is balanced to maintain a
constant AD:CN ratio. We use λ = 0.8λmax, which results in the selection of an average
of 7 pathways at each subsample (min 1, max 15, SD = 2.3). Pathway ranking results are
presented in Table 3.5.
SNPs and genes are ranked using sRRR with a lasso penalty on the SNP coefficient
vector, as described in section 3.3. Lasso selection is performed on pathways selected at
each subsample in the pathways analysis described above, so that once again B = 1000.
The number of SNPs, Z(b), included in the lasso model at subsample b varies according to
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the number and size (in terms of the number of mapped SNPs) of selected pathways. Z(b)
ranges from a minimum of 227, to a maximum of 19,642 (mean = 8400; SD = 3000). As
with pathway ranking, we use λ = 0.8λmax, which results in the selection of an average of
11.5 SNPs at each subsample (min 1, max 56, SD = 11.7). SNP and gene ranking results
are presented in Table 3.6.
We first consider the pathway ranking results in Table 3.5. Under the null, where there
is no association between phenotypes and genotypes, and with a single pathway selected
by the model at each subsample, the expected pathway selection frequency distribution
is uniform, with, pipathl = 1/185 ≈ 0.005. With an average of 7 pathways selected at
each subsample, as is the case here, and assuming pathways are independent, the corre-
sponding pathway selection frequency distribution under the null is also uniform, with,
pipathl = 7/185 ≈ 0.038. However, where more than one pathway is selected by the model,
pathway selection probabilities will not be uniform, since the presence of overlapping SNPs
means that pathways are not independent. Instead, selection probabilities will reflect the
pattern of overlaps corresponding to the distribution of causal SNPs (or spurious associa-
tions under the null). Indeed, even when relatively few SNPs or genes are associated with
the phenotype, we can expect multiple pathways to harbour genetic effects since many
SNPs and genes overlap multiple pathways. For this reason the figure of 0.038 should be
seen only as a guide threshold to signify pathway importance, and while we report pathway
selection frequencies, pipathl , our main focus is on pathway rankings. To aid interpretation
of pathway rankings, for each pathway we list those genes in the pathway that are ranked
in the top 30 genes, selected by lasso selection (see Table 3.6).
In the final column of Table 3.5 we list genes in the top ranked pathways that have
previously been linked to AD imaging phenotypes in the review by Braskie, Ringman, and
Thompson (2011). Both the number of such genes affecting phenotypes in this study, and
the extent to which these genes may drive pathway selection are unknown. It is nevertheless
interesting to consider whether these genes are significantly enriched amongst high-ranking
pathways. To do this we calculate an average ranking for each ‘AD gene’ by taking the av-
erage rank achieved by all pathways containing the gene in question. We then derive an
AD gene enrichment score by summing average AD gene ranks across all AD genes. A
lower score thus indicates pathways containing AD genes tend to be ranked high. We com-
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Table 3.6: Top 30 SNPs and genes, respectively ranked by SNP and gene selection frequency, using
lasso sRRR. Note the APOE gene is selected at a lower frequency than the APO4 SNP, since the
allele is often selected in a pathway where it is mapped to the TOMM40 gene only.
SNP RANKING GENE RANKING
Rank SNP piSNP Mapped gene(s) Gene pigene # mapped SNPs
1 rs4788426 0.451 PRKCB PRKCB 0.451 73
2 rs11074601 0.429 PRKCB ADCY8 0.411 69
3 rs263264 0.411 ADCY8 ADCY2 0.392 106
4 rs13189711 0.392 ADCY2 HK2 0.302 28
5 rs680545 0.302 HK2 PRKCA 0.290 99
6 rs4622543 0.290 PRKCA PIK3R3 0.267 9
7 rs9896483 0.274 PRKCA MYLK 0.234 24
8 rs1052610 0.267 PIK3R3 PIK3CG 0.207 9
9 APO4 0.251 TOMM40 APOE COL5A3 0.174 14
10 rs1254403 0.234 MYLK GNAI1 0.167 22
11 rs4730205 0.207 PIK3CG ACACA 0.164 23
12 rs889130 0.174 COL5A3 G6PC 0.163 6
13 rs6973616 0.167 GNAI1 DGKA 0.160 3
14 rs9906543 0.164 ACACA CR1 0.154 21
15 rs2229611 0.163 G6PC TOMM40 0.152 6
16 rs10876862 0.160 DGKA WNT2 0.137 12
17 rs772700 0.160 DGKA DGKB 0.131 200
18 rs12734030 0.154 CR1 PLCB1 0.128 218
19 rs11117959 0.154 CR1 APOE 0.127 4
20 rs650877 0.154 CR1 RELN 0.117 160
21 rs11118131 0.154 CR1 DGKI 0.112 49
22 rs6691117 0.142 CR1 ACTN1 0.110 41
23 rs677066 0.142 CR1 ALLC 0.108 18
24 rs2239956 0.137 WNT2 XCL1 0.086 7
25 rs4719392 0.131 DGKB ITK 0.084 27
26 rs6077420 0.128 PLCB1 DNAI2 0.077 16
27 rs7777178 0.126 DGKB GNG2 0.076 31
28 rs12699607 0.122 DGKB GRK5 0.074 56
29 rs7796440 0.122 DGKB UQCRH 0.071 2
30 rs1872837 0.120 HK2 YES1 0.068 11
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pare this empirically derived score with the distribution of scores obtained by permuting
pathway rankings 100,000 times. The null distribution of this enrichment score (obtained
by permutation), and the empirically observed value are compared in Fig. 3.11. Finally, we
compute a p-value for the null hypothesis that the empirically observed enrichment score
has arisen by chance, as the proportion of enrichment scores obtained through permutation
that are lower than the observed value. This gives a value p = 0.0051, indicating that AD
genes are highly over-represented amongst top ranking pathways, compared to what would
be expected by chance.
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Figure 3.11: Measure of extent to which genes previously linked to AD are enriched in highly-
ranked pathways. The histogram shows the distribution of AD gene enrichment scores obtained
when permuting pathway rankings 100,000 times. The vertical black line indicates the observed
AD gene enrichment score using the true pathway rankings obtained in the study. From this we
derive a p-value indicating the probability that the empirical AD gene enrichment score could arise
by chance as p = 0.0051. AD-linked genes are those identified in Braskie, Ringman, and Thompson
(2011).
3.6 Discussion
We have described a method for the identification of gene pathways associated with a
multivariate quantitative trait (MQT). Here, we extended previous work modelling a uni-
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variate response (Chapter 2), where we showed that a multilocus, group-sparse modelling
approach can demonstrate increased power to detect causal pathways, when compared to
conventional approaches that begin by modelling individual SNP-phenotype associations.
We applied our method in an AD gene pathways study using imaging endophenotypes, but
our method is not restricted to the case of biological pathways or imaging phenotypes, and
can be applied to any data in which we seek to identify sparse groups of predictors affecting
a multivariate response.
To the best of our knowledge, few other multilocus methods for the identification of
biological pathways currently exist, and of those that do, none are able to accommodate a
multivariate phenotype. While a methodological study comparing the various approaches
would be interesting, as has been noted by others, a lack of benchmark datasets with val-
idated pathways makes comparison between methods difficult (Chen et al., 2010; Khatri,
Sirota, and Butte, 2012). The GRASS method (Chen et al., 2010) and the method proposed
by Zhao et al. (2011) use sparse regression techniques to measure pathway significance.
These methods are currently implemented for case-control data, and univariate phenotypes
only. Each method makes different assumptions about the distribution of important SNPs
and genes affecting the phenotype. GRASS assumes sparsity at the SNP level within each
pathway gene, and retains all genes in each pathway considered. Zhao’s method assumes
sparsity at the gene level. In contrast, our PsRRR method assumes sparsity only at the path-
way level (although we subsequently perform SNP and gene selection as a second step in
selected pathways), and considers all pathways together in a single model. As such, each
method is expected to perform differently, depending on the true distribution of causal
SNPs and genes. GRASS and Zhao’s methods also use a pre-processing dimensionality
reduction step on SNPs within each gene using PCA. While this has been shown to be
advantageous in certain circumstances (Wang and Abbott, 2008), we elect to retain orig-
inal SNP genotypes in our model, since this facilitates sparse SNP selection. A further
feature that distinguishes our method from GRASS and Zhao’s method is that we include
all pathways together in a single regression model. By doing this we hope to gain a better
measure of the relative importance of different pathways by ensuring they compete against
each other.
In any method modelling effects on an MQT, the use of a multivariate disease signature
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that is characteristic of the disease under investigation is important. This is especially so in
the case of high-dimensional imaging phenotypes, where a poorly characterised imaging
signature with low signal to noise ratio may show no advantage over a simple ROI average-
based approach (Vounou et al., 2011). In our application study we extract an AD imaging
phenotype that is highly discriminative of subjects with the disease, compared to controls,
by excluding voxels at which the fitted slopes, measuring structural change over 3 time
points, are not significantly different between the two groups. The subsequent pathway
and gene mapping stages will clearly depend on the particular choice of phenotype, so
that a different phenotype may well highlight different genetic effects. An analysis of the
sensitivity of our gene mapping procedure to the choice of phenotype is however beyond
the scope of the present study.
We use a resampling strategy to rank pathways by selection frequency across multiple
N/2 subsamples of the data. Similar strategies have been advocated for improving consis-
tency with the lasso (Bach, 2008a; Chatterjee and Lahiri, 2011), and here this strategy is
designed to provide a robust measure of the relative importance of individual pathways in
a finite sample. In some respects our approach resembles the ‘pointwise stability selection’
strategy proposed by Meinshausen and Bu¨hlmann (2010). For the latter, a theoretical bound
for determining a selection frequency threshold that controls the expected number of false
positives has been derived. However, this rests on an exchangeability assumption regarding
the selection of noise variables that does not apply here, since the variables under selection
are groups of variables (pathways) that are functionally related, and overlap in terms of the
genes that they contain.
In principle our method enables the voxel-wise mapping of pathway effects across the
brain, through the analysis of the phenotype coefficient vector a. In Section 3.4.3 we
demonstrated in a simple simulation study that our method is able to identify important
voxels, through the imposition of an additional lasso penalty on a to enforce sparse voxel
selection. Alternative sparse penalties such as those associated with the elastic net (Carroll
et al., 2009) or indeed GL may be particularly appropriate here, as they could account for
spatial or other structural features present in the imaging domain, although both would re-
quire the tuning of addition regularisation parameters. Although we do not perform voxel
selection in our AD application study, we note that this would make an interesting exten-
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sion, by highlighting specific voxels or regions associated with high ranking causal path-
ways.
Of the top-ranking pathways identified in our AD application study (see Table 3.5),
functions associated with many of the top 10 ranked pathways have been linked to aspects
of AD biology described in the literature. Beginning with the top 2 ranked pathways,
numerous studies suggest links between disruption to the insulin signalling pathway and
AD (Liu et al., 2011; Liao and Xu, 2009; Monte and Wands, 2005; Biessels and Kappelle,
2005; Steen et al., 2005), and to the role of vascular smooth muscle dysfunction in AD-
associated neurodegeneration (Zlokovic, 2011). Other functions previously associated with
AD biology among high-ranking pathways include those related to focal adhesion, gap
junctions, chemokine signalling and phosphatidylinositol signalling (Caltagarone, Jing, and
Bowser, 2007; Nakase and Naus, 2004; Xia and Hyman, 1999; Kim et al., 2003; Huber,
Egleton, and Davis, 2001; Ravetti et al., 2010). Ideally we would like to validate these
results using an independent dataset. However, at the time of writing no other datasets with
similar endophenotypes were available.
In order to better elucidate which genes may be driving pathway selection in our AD
application study, we performed a follow up analysis designed to identify SNPs and genes
in selected pathways that are separately associated with the phenotype (see Table 3.6).
These rankings are derived from lasso selection of SNPs within all selected pathways at
each subsample, irrespective of their groupings within pathways. They are therefore ex-
pected to capture larger, independent signals of association, and not necessarily all the
salient signals within a particular pathway that may be driving pathway selection. In par-
ticular, the group lasso is designed to detect distributed signals that are unlikely to coin-
cide with those captured using lasso selection. From this analysis, it is clear that the lipid
kinase genes PIK3R3/PIK3CG, and the calcium-activated, phospholipid-dependent genes
PRKCA/PRKCB play a role in driving selection of many pathways in the top 30 ranks. All
these genes have previously been linked in gene expression studies with β-amyloid plaque
formation in the AD brain (Liang et al., 2008). Aside from the previously validated AD
endophenotype-related genes TOMM40, CR1 and APOE (Shen et al., 2010; Lambert et al.,
2009; Biffi et al., 2010), other genes occurring in the top 10 ranking pathways, include
ADCY2, ACTN1, ACACA and GNAI1, all of which have been associated with AD related
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changes in hippocampal gene expression (Taguchi et al., 2005; Ravetti et al., 2010, support-
ing information). Along with APOE and TOMM40, ADCY2 was also highlighted in a pre-
vious study searching for SNPs associated with AD-associated structural change (Vounou
et al., 2011). This latter study was on the same ADNI cohort, but unlike the current study
was not pathways-driven, and used phenotypes describing structural change measured at a
single time point (relative to baseline) only.
The major AD risk and phenotype-related gene APOE, and risk allele APOE4 are
respectively ranked 19 and 9. In our study the APOE gene maps to a single pathway, the
KEGG Alzheimer’s disease pathway, and this pathway is selected in≈ 13% of subsamples.
Notably, in all subsamples in which the KEGG Alzheimer’s disease pathway is selected, the
APOE4 allele is the sole selected SNP, confirming the known large marginal effect of this
allele on AD phenotypes. The higher ranking of the APOE4 SNP, relative to the APOE
gene, reflects the fact that this SNP also maps to the TOMM40 gene, which occurs in a
number of other pathways selected by the model. This may affect the Alzheimer pathway’s
ranking, as may the fact that selection of this pathway is driven by the presence of this
single, strong APOE4 signal, and as explained above, the model is designed to identify
distributed signals across a pathway.
Our model rests on a number of assumptions, and as a consequence will fail to detect
a number of different association signals. For example, while our model implicitly ac-
commodates the fact that SNPs and genes interact within functional pathways, we do not
explicitly model interaction effects. Also, we make the simplifying assumption that voxel-
wise measures are uncorrelated. In reality, the phenotype will exhibit a complex correlation
structure which will affect the association signal. Vounou, Nichols, and Montana (2010)
have demonstrated that even under this simplifying assumption, significant gains in power
can be achieved by modelling a multivariate phenotype, compared to a mass univariate
modelling approach. Finally, our model is founded on the assumption that causal SNPs
tend to accumulate within functional pathways, and as such is not designed to identify sig-
nificant marginal effects, as evidenced for example by the failure of our model to rank the
high-risk APOE gene highly in our AD application study. For this last reason, any path-
ways analysis should be seen as being complementary to conventional GWAS approaches.
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Chapter 4
Pathways-driven SNP selection:
‘Pathways Sparse Group Lasso with
Adaptive Weights’
We now consider an extension to the previous P-GLAW model (Chapter 2) that uses path-
ways information to drive the identification of SNPs associated with a univariate quan-
titative trait. The motivation here is that the use of prior information on putative gene
interactions within pathways will increase power to identify causal SNPs, compared to al-
ternative methods that disregard such information. The GL is not well-suited to this task,
since it performs non-sparse, continuous shrinkage of SNP coefficients within a selected
pathway. These SNP coefficients are themselves an unreliable measure of SNP importance,
in part because of LD, and also because the majority of SNPs within a selected pathway are
unlikely to be associated with the phenotype under consideration. We instead seek a model
with the following properties:
• sparsity at the pathway level, so that only pathways containing multiple SNPs with
possibly small or moderate marginal effects are selected by the model, and
• sparsity at the SNP level within selected pathways, so that only those SNPs driving
pathway selection are selected by the model
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A suitable sparse regression model enforcing the required ‘dual-level’ sparsity pattern
is the sparse group lasso (SGL). SGL is a comparatively recent development in sparse mod-
elling, and in simulations has been shown to accurately recover dual-level sparsity, in com-
parison to both GL and lasso (Friedman, Hastie, and Tibshirani, 2010; Simon et al., 2012).
SGL has been used for the identification of rare variants in a case-control study by group-
ing SNPs into genes (Zhou et al., 2010); for the identification of genomic regions whose
copy number variations have an impact on RNA expression levels (Peng et al., 2010); and
to model geographical factors driving climate change (Chatterjee et al., 2011).
A schematic illustration of the two types of sparsity pattern generated by the GL and
SGL is given in Figure 4.1. As with GL, SGL can be seen as fitting into a wider class
of structured-sparsity inducing models that use prior information on relationships between
predictors to enforce different sparsity patterns (Zhao, Rocha, and Yu, 2009; Huang, Zhang,
and Metaxas, 2011; Jenatton and Bach, 2011).
G1 G2 GL
" 	   	  
G3
group	  lasso	  
" 	   	   sparse	  group	  
lasso	  
j = 1 2 3 P. . .
Figure 4.1: Sparsity patterns enforced by the group lasso and sparse group lasso. The set S ⊂
{1, . . . , P} of causal SNPs influencing the phenotype are represented by boxes that are shaded grey.
Causal SNPs are assumed to occur within a set C ⊂ {1, . . . , L} of causal pathways, G1, . . . ,GL.
Here C = {2, 3}. The group lasso enforces sparsity at the group or pathway level only, whereas the
sparse group lasso additionally enforces sparsity at the SNP level.
In passing, we note that in principle we could attempt to identify important SNPs by
conducting a two-stage analysis, in which we first identify important pathways, and then
in a second step search for SNPs within selected pathways (Eleftherohorinou et al., 2009;
Eleftherohorinou et al., 2011). This is the strategy we adopted in the AD study described
in the previous chapter, where we perform a second round of lasso selection after the ini-
tial pathway selection step. There are however a number of problems with this approach.
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Firstly, as discussed previously, highlighted SNPs are then not necessarily those that were
driving pathway selection in the first step of the analysis. Secondly, an implicit (and rea-
sonable) assumption is that only a small number of SNPs are driving pathway selection, so
that a sparse regression model that assumes this is preferable. Finally, a model imposing
dual-level sparsity is able to perform simultaneous pathway and SNP selection, and is thus
simpler to implement.
This chapter is organised as follows. In Section 4.1 we introduce the SGL model, and in
Section 4.1.1 we describe an efficient estimation algorithm, using block coordinate gradient
descent (BCGD), for the case of non-overlapping groups. In Section 4.1.2, we describe a
simulation study illustrating superior group (pathway) and variable (SNP) selection perfor-
mance in the case that the true supporting model is group-sparse. In Section 4.2 we extend
the previous model to the case of overlapping groups, using the same procedure of dupli-
cating overlapping variables as we described previously for GL. In principle, we can then
solve this model using the BCGD estimation algorithm described for the non-overlapping
case. However, we argue in Section 4.2.1 that this approach does not give us the outcome
we require. For this reason we describe a modified estimation algorithm using coordinate
gradient descent, that treats each group as independent, and in Section 4.2.2 we demon-
strate in a simulation study that this new algorithm is able to identify the correct SNPs and
pathways with improved sensitivity and specificity. In Sections 4.2.3 and 4.2.4 we explain
how the weight tuning and pathway ranking strategies previously described for our GL-
based models can be applied to SGL. We call the resulting method for pathways-driven
SNP selection ‘Pathways-Sparse Group Lasso with Adaptive Weights’ or P-SGLAW. In
Section 4.3 we apply the P-SGLAW method in a study looking at pathways, SNPs and
genes associated with high-density lipoprotein cholesterol levels in two separate cohorts of
Asian adults. We conclude this chapter with a discussion in Section 4.4.
4.1 The sparse group lasso model
We begin by considering the case of non-overlapping groups. For a univariate response
vector, y, with the SGL (Simon et al., 2012), sparse estimates for the SNP coefficient
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vector, β are given by
βˆSGL = arg min
β
{1
2
||y −Xβ||22 + (1− α)λ
L∑
l=1
wl||βl||2 + αλ||β||1
}
(4.1)
with |α| ≤ 1. Note that this is equivalent to the group lasso estimator (2.15), with the
addition of an extra `1 penalty. When α = 0, (4.1) reduces to the group lasso. With α > 0,
the additional penalty on the l1-norm of β encourages sparsity at the SNP level. α then
controls the distribution of the regularisation between groups (pathways) and SNPs, such
that as α approaches 0 from above, greater sparsity at the group level is encouraged over
sparsity at the SNP level.
4.1.1 Model estimation
For the estimation of β we proceed, as with the group lasso, by noting that the optimisation
(4.1) is convex, and (in the case of non-overlapping groups) that the penalty is block-
separable, so that we can obtain a solution using block, or group-wise coordinate descent
(Tseng and Yun, 2009). For a single group, l, the minimising function corresponding to
(4.1) is given by
f(βl) =
1
2
||y −Xβ||22 + (1− α)λwl||βl||2 + αλ||βl||1. (4.2)
An optimal solution for SNP coefficient βj is then derived from the subgradient equations
−X ′j(rˆl −
∑
k 6=j
Xkβˆk −Xjβj) + (1− α)λwlsj + αλtj = 0 j = l1, . . . , lPl , (4.3)
where as before (Section 2.3.1) βˆk, k 6= j are the current estimates for other SNP coeffi-
cients in group l, and the group partial residual, rˆl = y−
∑
m6=l Xmβˆm. Here sj and tj are
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the respective subgradients of ||βl||2 and |βj|, with
sj =

βj
||βl||2 if ||βl||2 6= 0
∈ [−1, 1] if ||βl||2 = 0
tj =
sign(βj) if βj 6= 0∈ [−1, 1] if βj = 0. (4.4)
If βl = 0, that is group l is not selected by the model, then from (4.3)
−X ′j rˆl + (1− α)λwlsj + αλtj = 0, j = l1, . . . , lPl . (4.5)
Substituting a = X′lrˆl gives
aj = (1− α)λwlsj + αλtj, j = l1, . . . , lPl
so that
s2j =
1
(1− α)2λ2w2l
(aj − αλtj)2, j = l1, . . . , lPl ,
and ∑
j
s2j =
1
(1− α)2λ2w2l
∑
j
(aj − αλtj)2.
From (4.4), when βl = 0, ||s||2 = (
∑
j s
2
j)
1
2 ≤ 1, so that
∑
j
(aj − αλtj)2 ≤ (1− α)2λ2w2l . (4.6)
Also from (4.4), one further condition when βl = 0 is that tj ∈ [−1, 1]. The values, tˆj that
minimise the left hand size of (4.6) are therefore given by
tˆj =

aj
αλ
if | aj
αλ
| ≤ 1
sign( aj
αλ
) if | aj
αλ
| > 1.
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Substituting for aj , we can then write the values for aj − αλtj that minimise the left hand
side of (4.6) as
aj − αλtj =
0 if |X ′j rˆl| ≤ αλsign(X ′j rˆl)(|X ′j rˆl| − αλ) if |X ′j rˆl| > αλ
= S(X ′j rˆl, αλ)
for j = l1, . . . , lPl , where
S(X ′j rˆl, αλ) = sign(X
′
j rˆl)(|X ′j rˆl| − αλ)+ (4.7)
is the usual lasso soft thresholding operator (2.10). Finally, we can now rewrite the condi-
tion for βˆl = 0, (4.6) as
||S(X′lrˆl, αλ)||2 ≤ (1− α)λwl, (4.8)
where the vector S(X′lrˆl, αλ) = [S(X
′
l1
rˆl, αλ), . . . , S(X
′
lP
rˆl, αλ)]. Note that with α = 0,
this reduces to the GL group selection criterion (2.21).
In the case that βl 6= 0, that is group l is selected by the model, from (4.3) and (4.4) we
see that βj = 0 when
−X ′j(rˆl −
∑
k 6=j
Xkβˆk) ≤ |αλ|. (4.9)
For completeness, we rewrite the criterion for selecting pathway l from (4.8) as
||S(X′lrˆl, αλ)||2 > (1− α)λwl (4.10)
and the criterion for selecting SNP j in selected pathway l from (4.9) as
|X ′j rˆl,j| > αλ (4.11)
where rˆl,j = rˆl −
∑
k 6=j Xkβˆk is the SNP partial residual, obtained by regressing out the
current estimated effects of all other predictors in the model, except for predictor j.
A number of methods for the estimation of βl in the case that ||βl||2 6= 0 have been
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proposed (Friedman, Hastie, and Tibshirani, 2010; Foygel and Drton, 2010; Liu and Ye,
2010; Simon et al., 2012). A complicating factor is the discontinuities in the first (and sec-
ond) derivatives of sj at ||βl||2 = 0, that is where ||βl||2 first moves away from zero, and of
tj when βj = 0. As with GL, Friedman, Hastie, and Tibshirani (2010) describe a numeri-
cal method using coordinate descent, by combining a golden search over βj with parabolic
interpolation. However we find this too computationally intensive for the large datasets
we wish to analyse. Simon et al. (2012) propose an accelerated, block gradient descent
method in which βl is iteratively updated in a single step along the line of steepest descent
of the block objective function until convergence. We instead use a block, coordinate-wise
gradient descent (BCGD) method that uses a Newton update, similar to that proposed by
Zhou et al. (2010), and we describe this below.
To update βj from its current estimate, βˆj , we note from (4.3) and (4.4) that if βˆj 6= 0,
the subgradient equation for predictor j is given by
∂j = −X ′j(rˆl −Xlβˆl) + (1− α)λwl
βˆj
||βˆl||2
+ αλ · sign(βˆj). (4.12)
We then descend along the gradient at βˆj towards the minimum using Newton’s method.
The Newton update, β∗j , is then given by
βˆ∗j = βˆj −
∂j
∂′j
,
where ∂′j = 1 +
(1− α)λwl
||βˆl||2
(
1− βˆ
2
j
||βˆl||22
) (4.13)
is the derivative of (4.12) evaluated at βˆj . The update (4.13) is repeated until convergence.
We must also deal with the case where βˆj = 0. Here we adopt a slightly different
strategy, since the partial derivative, tj of βj is not continuous. We avoid this discontinuity
by testing the ‘directional derivatives’, ∂+j and ∂
−
j , respectively representing the partial
derivatives at βj = 0 in the direction of increasing and decreasing βj . Recalling that we are
dealing with the case ||βl||2 6= 0, at βj = 0 the group penalty term in (4.12) disappears.
That is, once a group is selected by model it becomes easier for each SNP coefficient to
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move away from zero. The two directional derivatives are then given by
∂+j = −X ′j(rˆl −Xlβˆl) + αλ
∂−j = −X ′j(rˆl −Xlβˆl)− αλ.
(4.14)
Since the minimising function (4.2) is convex, there are three possible outcomes, and we
substitute for ∂j in (4.13) accordingly:
∂j ←

∂−j if ∂
−
j > 0 and ∂
+
j > 0
∂+j if ∂
−
j < 0 and ∂
+
j < 0
0 if ∂−j < 0 and ∂
+
j > 0
(4.15)
In the third case, f(βl) is increasing either side of βj = 0, so that βˆj must remain at zero.
We can then proceed with the standard Newton update (4.13).
Finally, since the Newton update may occasionally overstep the minimum (where ∂j =
0), a simple remedy proposed by Zhou et al. (2010) is to check that f(βl) is decreasing at
each iteration. If this is not the case, then the step size in (4.13) is halved. The complete
algorithm for SGL estimation using BCGD is presented in Box 4.1.
One remaining practical issue is the obtaining of a value for λmax, the smallest value of
λ at which no groups are selected by the model. We require this when setting a value for λ,
for example when using the variable ranking strategy described in Section 2.5. Noting that
rˆl = y when no groups are selected, from (4.8) we obtain the smallest value, λminl , for the
minimum value of λ at which group l is not selected as
λminl =
||S(X′ly, αλminl )||2
(1− α)wl (4.16)
We can solve this in its quadratic form by first setting an upper bound for λ at the point λ∗l ,
where the soft thresholding function S(X′lyl, αλ) = 0, that is when no SNPs are selected
by the model. We then obtain the solution by solving
||S(X′ly, αλminl )||22 − (1− α)2(λminl )2w2l = 0 0 < λminl < λ∗l (4.17)
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for λminl , where
λ∗l = max
j
|X ′jy|
α
j = l1, . . . , lPl .
Finally, we obtain a value for λmax as
λmax = max
l
λminl . (4.18)
Box 4.1 SGL estimation algorithm using BCGD
1. initialise β ← 0.
2. repeat: [pathway loop]
for pathway l = 1, 2, . . . , L:
if ||S(X′lrl, αλ)||2 ≤ (1− α)λwl
βl ← 0
else
repeat: [SNP loop]
for j = l1, . . . , lPl:
if βˆj = 0 :
Newton update β∗j ← βˆj using (4.15) and (4.13)
else:
Newton update β∗j ← βj using (4.12) and (4.13)
if f(β∗l ) > f(βl):
β∗j ←
β∗j+βj
2
βj ← β∗j
until convergence of βl [SNP loop]
until convergence of β [pathway loop]
3. βˆSGL ← β
4.1.2 SGL simulation study 1
Using a simple simulation study, we now test the hypothesis that where causal SNPs are
enriched in a given pathway, pathway-driven hierarchical SNP selection using SGL will
outperform simple lasso selection that disregards pathway information. Since we wish to
perform power calculations using a Monte Carlo framework over multiple data simulations,
we implement the following simple data simulation protocol:
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We simulate P = 2500 genetic markers for N = 400 individuals. Marker frequencies for
each SNP are sampled independently from a multinomial distribution following a Hardy
Weinberg equilibrium frequency distribution (see Section 3.4.1 for details). SNP minor
allele frequencies are sampled from a uniform distribution U [0.1, 0.5].
SNPs are distributed equally between 50 non-overlapping pathways, each containing
50 SNPs. Since pathways are of equal size, and SNP genotypes are independent, there
are no factors biasing pathway selection and we use a uniform pathway weighting vector
w = 1.
At each MC simulation, a baseline univariate phenotype, y is sampled from N (10, 1).
To generate genetic effects, we randomly select 5 SNPs from a single, randomly selected
pathway Gl, to form the set S ⊂ Gl of causal SNPs. Genetic effects are then generated as
described in Section 3.4.1, but with a univariate phenotype, so that q = 1.
To enable a fair comparison between the two methods (SGL and lasso), we ensure
that both methods select the same number of SNPs at each simulation. We do this by first
obtaining the SGL solution, SˆSGL, with λ = 0.85λmax and α = 0.8, which ensures sparsity
at both the pathway and SNP level. We then compute the lasso solution using coordinate
descent over a range of values for the lasso regularisation penalty, λ, and choose the set
Sˆ lasso(λ′) such that |Sˆ lasso(λ′)| = |SˆSGL|
where |SˆSGL| is the number of SNPs previously selected by SGL, and |Sˆ lasso(λ′)| is the
number of SNPs selected by the lasso with λ = λ′. We measure performance as the mean
power to detect all 5 causal SNPs over 500 MC simulations, and test a range of genetic
effect sizes (γ). In a follow up study, we compare the performance of the two methods in a
scenario in which pathways information is uninformative. For this we repeat the previous
simulations, but with 5 causal SNPs drawn at random from all 2500 SNPs, irrespective of
pathway membership. Results are presented in Figure 4.2.
Here we see that where causal SNPs are concentrated in a single causal pathway (Figure
4.2 - left), SGL demonstrates greater power (and equivalently specificity, since the total
number of selected SNPs is constant), compared with the lasso, above a particular effect
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Figure 4.2: SGL vs Lasso. Comparison of power to detect 5 causal SNPs. Each data point represents
mean power over 500 MC simulations. Left: Causal SNPs drawn from single causal pathway. Right:
Causal SNPs drawn at random.
size threshold (here γ ≈ 0.04). Where pathway information is not important, that is causal
SNPs are not enriched in any particular pathway (Figure 4.2 - right), SGL performs poorly.
To gain a deeper understanding of what is happening here, we also consider the power
distributions across all 500 MC simulations corresponding to each point in the plots of
Fig.4.2. These are illustrated in Figure 4.3. The top row of plots illustrates the case where
causal SNPs are drawn from a single causal pathway. Here we see that there is a marked
difference between the two distributions (SGL vs lasso). The lasso shows a smooth distri-
bution in power, with mean power increasing with effect size. In contrast, with SGL the
distribution is almost bimodal, with power typically either 0 or 1, depending on whether or
not the correct causal pathway is selected. This clearly illustrates the power of hierarchi-
cal, pathway-driven SNP selection in the case that pathways are important. As previously
found by Zhou et al. (2010) in the context of rare variants and gene selection, the joint
modelling of SNPs within groups gives rise to a relaxation of the penalty on individual
SNPs within selected groups, relative to the lasso. This can enable the detection of SNPs
with small effect size or low MAF that are missed by the lasso, which disregards pathways
information and treats all SNPs equally. Finally, where causal SNPs are not enriched in a
causal pathway (bottom row of Figure 4.3), as expected SGL performs poorly. In this case
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Figure 4.3: SGL vs Lasso. Distribution over 500 MC simulations of power to detect 5 causal SNPs.
Each plot represents the power distribution at a single data point in Figure 4.2. The power distri-
bution is discrete, since each method can identify 0, 1, 2, 3, 4 or 5 causal SNPs, with corresponding
power 0, 0.2, 0.4, 0.6, 0.8 or 1.0. Top row: Causal SNPs drawn from single causal pathway. Bottom
row: Causal SNPs drawn at random.
SGL will only select a SNP where the combined effects of constituent SNPs in a pathway
are large enough to drive pathway selection.
4.2 Pathways sparse group lasso with overlaps
Where pathways overlap, we can apply the strategy described in Section 2.2.1 of expanding
X and β, to produce a SGL estimator (4.1) for overlapping groups as
βˆSGL∗ = arg min
β
{1
2
||y −X∗β∗||22 + (1− α)λ
L∑
l=1
wl||β∗l ||2 + αλ||β∗||1
}
. (4.19)
As before, the expanded (N × P ∗) design matrix X∗ and (P ∗ × 1) coefficient vector
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β∗, (where P ∗ =
∑
l Pl), allow each SNP predictor to enter the model separately. Pathway
mappings with SNP indices in the expanded variable space are reflected in updated groups
G∗1 , . . . ,G∗L. This variable expansion procedure confers the same advantages as with the
GL case (Section 2.2.1), namely allowing overlapping pathways to be individually selected
(or not selected) by the model, and also ensuring block-separability, so enabling model
estimation through block coordinate descent. With SGL, variable expansion also allows
overlapping SNPs to be selected (or not selected) in different pathways.
4.2.1 Model estimation
In principle, once the above variable expansion procedure has been applied, the optimi-
sation can be solved using the estimation algorithm described in Box 4.1. However, for
the purpose of pathways-driven SNP selection, the application of this algorithm presents
a problem. This arises from the replication of overlapping SNP predictors in each group,
X∗l , that they occur.
Consider for example the simple situation where there are two pathways, G∗k ,G∗l , con-
taining sets of causal SNPs S∗k ⊆ G∗k and S∗l ⊆ G∗l respectively. Here the ∗ indicates that
SNP indices refer to the expanded variable space. We begin by assuming that S∗k and S∗l
contain the same SNPs, so that in the unexpanded variable space, Sk = Sl.
We then proceed with BCGD by first estimating β∗k. We assume that the correct SNPs
are selected, so that {βˆ∗j 6= 0 : j ∈ S∗k}, and βˆ∗j = 0 otherwise. For the estimation of β∗l ,
the estimated effect
∑
j∈S∗k X
∗
j βˆ
∗
j , of these overlapping causal SNPs is removed from the
regression, through its incorporation in the block residual rˆ∗l = y −
∑
j∈S∗k X
∗
j βˆ
∗
j . Since
no other causal SNPs exist in pathway G∗l , X∗′l rˆ∗l = 0, so that the criterion for pathway
selection, ||S(X∗′l rˆ∗l , αλ)||2 > (1− α)λwl (4.10) is not met. That is G∗l is not selected.
Now consider the case where additional, non-overlapping causal SNPs, possibly with
smaller effects, occur in G∗l , so that in the unexpanded variable space, Sk ⊂ Sl. In other
words, causal SNPs are partially overlapping (see Fig 4.4)1. During BCGD pathway G∗l
is then less likely to be selected by the model, than would be the case if there were no
1This is the situation for example where multiple causal genes overlap both pathways, but one or more
additional causal genes occur in Gl.
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Gl
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Figure 4.4: Two pathways with partially overlapping causal SNPs. Causal SNPs (marked in grey) in
the set Sk overlap both pathways, so that Sk = Gk ∩Gl. Additional causal SNPs, Sl ∩\Sk, (marked
in purple) occur in pathway l only.
overlapping SNPs, since once again the effects of overlapping causal SNPs, Sk ∩ Sl = Sk,
are removed. We provide an illustration of this effect in the simulation study described in
Section 4.2.2.
For pathways-driven SNP selection, we will argue that we instead require that SNPs
are selected in each and every pathway whose joint SNP effects pass a revised pathway
selection threshold
||S(X∗′l y, αλ)||2 > (1− α)λwl,
irrespective of overlaps between pathways. This is equivalent to the previous pathway se-
lection criterion (4.10), but with the additional assumption that pathways are independent,
in the sense that they do not compete in the model estimation process. We describe a revised
estimation algorithm under the assumption of pathway independence below.
We justify the strong assumption of pathway independence with the following argu-
ment. In reality, we expect that multiple pathways may simultaneously influence the phe-
notype, and we also expect that many such pathways will overlap, for example through
their containing one or more ‘hub’ genes, that overlap multiple pathways (Kim, Wuchty,
and Przytycka, 2011; Lehner et al., 2006). By considering each pathway independently,
we aim to maximise the sensitivity of our method to detect these variants and pathways.
In contrast, without the independence assumption, a competitive estimation algorithm will
tend to pick out one from each set of similar, overlapping pathways, and miss potentially
causal pathways and variants as a consequence. Again we illustrate this idea in the sim-
ulation study in Section 4.2.2. One potential concern is that by not allowing pathways to
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compete against each other, specificity (or equivalently ranking accuracy) may be reduced,
since too many pathways and SNPs may be selected. We aim to avoid this, firstly by once
again employing a resampling strategy to highlight the most important pathways and SNPs
driving pathway selection. We also describe a heuristic approach to assessing the control of
false positives by comparing empirical and null rankings in the application study in Section
4.3. We discuss the issue of specificity further in the context of results from the simulation
study in Section 4.2.2.
As an aside, note that with GL, interactions between overlapping pathways are likely
to be somewhat diminished. This is because all SNPs in a selected pathway are retained in
the model, so that block residuals rˆ∗l , l = 1, . . . , L reflect effects arising from all SNPs in a
selected pathway, rather than the effects of a small number of individual SNPs. Interactions
between pathways arising from shared SNPs will nonetheless remain, and in fact we exploit
these in our GL-based pathway selection models by allowing all pathways to compete, in
order to give a robust measure of the relative importance of different pathways. In con-
trast, with pathways-driven SNP selection, we are additionally concerned with maximising
power to identify causal SNPs, so that competition between pathways is less important.
Indeed in addition to SNP selection, it is arguably desirable to highlight all potentially im-
portant causal pathways in which the combined effect of causal SNPs is sufficient to drive
pathway selection.
In what follows we assume as usual that X and β have been expanded to account for
overlaps, but we once again drop the ∗ notation for clarity. We precede as before by solving
the block-separable optimisation (4.19) for each group or pathway in turn. However, for
overlapping pathways, the assumption of pathway independence requires that each Xl, (l =
1, . . . , L) is regressed against the full phenotype vector y rather than the partial residual,
rˆl. With this in mind, the revised subgradient equations for group l (4.3) are given by
−X ′j(y −
∑
k 6=j
Xkβˆk −Xjβj) + (1− α)λwlsj + αλtj = 0 j = l1, . . . , lPl . (4.20)
The estimation for group l then proceeds as described previously in Section 4.1.1, but
with the partial residual rˆl replaced by y, so that the group sparsity condition (4.8) for
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||βˆl||2 = 0 becomes
||S(X′ly, αλ)||2 ≤ (1− α)λwl. (4.21)
As before, where group l is selected by the model, the update for βj , with current estimate
βˆj , is derived from the partial derivative (4.12), which under the independence assumption
is given by
∂j = −X ′j(y −Xlβˆl) + (1− α)λwl
βˆj
||βˆl||2
+ αλ · sign(βˆj), (4.22)
for j = l1, . . . , lPl . The Newton update (4.13) remains the same. When βˆj = 0, the revised
directional derivatives (4.14) are given by
∂+j = −X ′j(y −Xlβˆl) + αλ
∂−j = −X ′j(y −Xlβˆl)− αλ.
(4.23)
As before the conditions for SNP sparsity within a selected group are determined by (4.15).
The value of λmax, the smallest λ value at which no group is selected by the model, is
determined in the same way as before, since this procedure (described in (4.16), (4.17) and
(4.18)) does not depend on rˆl.
Importantly, since each group is regressed independently against the phenotype vector
y, there is no block coordinate descent stage in the estimation, that is the revised algorithm
utilises only coordinate gradient descent within each selected pathway. For this reason we
use the acronym SGL-CGD for the revised algorithm, and SGL-BCGD for the previous
algorithm using block coordinate gradient descent. The new algorithm is described in Box
4.2. Note that since the block coordinate descent stage is avoided, the new algorithm has
the added benefit of being much faster than would otherwise be the case.
Finally, we note that for SNP selection we are interested only in the set Sˆ of se-
lected SNPs in the unexpanded variable space, and not the set S∗ = {j∗ : β∗j 6= 0, j∗ ∈
{1, . . . , P ∗}}. Since, under the independence assumption, the estimation of each β∗l does
not depend on the other estimates, β∗k, k 6= l, we do not need to record separate coefficient
estimates for each pathway in which a SNP is selected. Instead we need only record the set
Sˆl, l ∈ Cˆ of SNPs selected in each selected pathway. This has a useful practical implication,
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since we can avoid the need for an expansion of X or β, and simply form the complete set
of selected SNPs as
Sˆ =
⋃
l∈Cˆ
Sˆl.
Box 4.2 SGL-CGD estimation algorithm
1. initialise βˆ ← 0.
2. for pathway l = 1, 2, . . . , L:
if ||S(X′ly, αλ)||2 ≤ (1− α)λwl
βˆl ← 0
else
repeat: [CGD (SNP) loop]
for j = l1, . . . , lPl:
if βˆj = 0 :
Newton update βˆ∗∗j ← βˆj using (4.23) and (4.13)
else:
Newton update βˆ∗∗j ← βˆj using (4.22) and (4.13)
if f(β∗∗l ) > f(βl):
βˆ∗∗j ←
βˆ∗∗j +βˆj
2
βˆj ← βˆ∗∗j
until convergence
4.2.2 SGL simulation study 2
We now explore some of the issues raised in the preceding section, specifically the potential
impact on pathway and SNP selection power and specificity of treating the pathways as
independent in the SGL estimation algorithm. We do this in a simulation study in which we
simulate overlapping pathways. The simulation scheme is specifically designed to highlight
differences in pathway and SNP selection with the independence assumption (using the
SGL-CGD estimation algorithm in Box 4.2) and without it (using the standard SGL-BCGD
estimation algorithm in Box 4.1).
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Figure 4.5: SGL Simulation Study with overlapping pathways. (a): Illustration of pathway overlap
scheme. The are 30 SNPs in each pathway. Pathways Gl, (l = 1, . . . , 50) overlap each adjacent
pathway by 10 SNPs. (b): Causal SNPs from adjacent pathways, l, l+1 are randomly selected from
the region marked in purple, ensuring that SNPs in S overlap a maximum of two pathways.
SNPs with variable MAF are simulated using the same procedure described in the pre-
vious simulation study (Section 4.1.2), but this time SNPs are mapped to 50 overlapping
pathways, each containing 30 SNPs. Each pathway overlaps any adjacent (by pathway
index) pathway by 10 SNPs. This overlap scheme is illustrated in Figure 4.5 (a).
As before we consider a range of overall genetic effect sizes, γ. A total of 2000 MC
simulations are conducted for each effect size. At MC simulation z, we randomly select
two adjacent pathways, Gl,Gl+1 where l ∈ {1, . . . , 49}. From these two pathways we
randomly select 10 SNPs according to the scheme illustrated in Figure 4.5 (b). This ensures
that causal SNPs overlap a minimum of 1, and a maximum of 2 pathways, with Sz ⊂
(Gl ∩ \Gl−1) ∪ (Gl+1 ∩ \Gl+2). The true set of causal pathways, C, is then given by {l},
{l + 1} or {l, l + 1} (although simulations where |C| = 1 will be extremely rare). Genetic
effects on the phenotype are generated as described previously (Section 4.1.2).
SNP coefficients are estimated for each model, SGL-BCGD and SGL-CGD, using the
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same regularisation with λ = 0.85λmax and α = 0.85 for both.
The average number of pathways and SNPs selected by SGL-BCGD and SGL-CGD
across all 2000 MC simulations is reported in Table 4.1. As expected, for both models, the
number of selected variables (pathways or SNPs) increases with decreasing effect size, as
the number of pathways close to the selection threshold set by λmax (4.18) increases.
Table 4.1: Simulation Study 2: Mean number of pathways and SNPs selected by each model at each
effect size, γ, across 2000 MC simulations.
γ
0.02 0.04 0.06 0.08 0.1 0.12
pathways SGL-CGD 5.8 5.9 5.4 4.8 3.9 3.2
SGL-BCGD 5.8 5.9 5.4 4.8 3.9 3.2
SNPs SGL-CGD 26.6 27.0 24.8 22.2 18.5 15.3
SGL-BCGD 28.8 29.3 26.7 23.6 19.4 15.8
For each model, at MC simulation z we record the pathway and SNP selection power,
|Cˆz ∩ Cz|/|Cz| and |Sˆz ∩ Sz|/|Sz| respectively. Since the number of selected variables can
vary slightly between the two models, we also record false positive rates (FPR) for pathway
and SNP selection as |Cˆz ∩ \Cz|/|Cˆz| and |Sˆz ∩ \Sz|/|Sˆz| respectively.
The large possible variation in causal SNP distributions, causal SNP MAFs etc. make
a comparison of mean power and FPR between the two methods somewhat unsatisfactory.
For example, depending on effect size, a large number of simulations can have either very
high, or very low pathway and SNP selection power, masking subtle differences in perfor-
mance between the two methods. Since we are specifically interested in establishing the
relative performance of the two methods, we instead illustrate the number of simulations
at which one method outperforms the other across all 2000 MC simulations, and show
this in Figure 4.6. In this figure, the number of simulations in which SGL-CGD outper-
forms SGL-BCGD, i.e. where SGL-CGD power > SGL-BCGD power, or SGL-CGD FPR
< SGL-BCGD FPR, are shown in green. Conversely, the number of simulations where
SGL-BCGD outperforms SGL-CGD are shown in red.
We first consider pathway selection performance (top row of Figure 4.6). For both
methods, the same number of pathways are selected on average, across all effect sizes
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Figure 4.6: SGL-CGD vs SGL-BCGD performance, measured across 2000 MC simulations. Top
row: Pathway selection performance. (Left) green bars indicate the number of MC simulations
where SGL-CGD has greater pathway selection power than SGL-BCGD. Red bars indicate where
SGL-BCGD has greater power than SGL-CGD. (Right) green bars indicate the number of MC
simulations where SGL-CGD has a lower FPR than SGL-BCGD. Red bars indicate the opposite.
Bottom row: As above, but for SNP selection performance.
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(Table 4.1). At low effect sizes, there is no difference in performance between the two
methods for the large majority of MC simulations, and where there is a difference, the two
methods are evenly balanced. As with the previous SGL simulation study (4.1.2), this is
the region (with γ ≤ 0.04) where pathway selection fairs no better than chance. With
γ > 0.04, SGL-CGD consistently outperforms SGL-BCGD, both in terms of pathway
selection sensitivity and control of false positives (measured by FPR).
To understand why, we turn to SNP selection performance (bottom row of Figure 4.6).
At small effect sizes (γ ≤ 0.04), in the small minority of simulations where the correct
pathways are identified, SGL-BCGD tends to demonstrate greater power than SGL-CGD
(Figure 4.6 bottom left). However, this is at the expense of lower specificity (Figure 4.6
bottom right). These difference are due to the slightly larger number of SNPs selected by
SGL-BCGD (see Table 4.1), which in turn is due to the ‘screening out’ of previously se-
lected SNPs from the adjacent causal pathway during BCGD, as described at the beginning
of Section 4.2. This results in the selection of a larger number of SNPs when any two
overlapping pathways are selected by the model. In the case where two causal pathways
are selected, SNP selection power is then likely to be higher, although at the expense of a
greater number of false positives.
When pathway effects are just on the margin of detectability (γ = 0.06), SGL-CGD
is more often able to select both causal pathways, although this doesn’t translate into in-
creased SNP selection power. This is most likely because at this effect size neither model
can detect SNPs with low MAF, so that SGL-CGD is detecting the same (overlapping)
SNPs in both causal pathways. Note that once again SGL-BCGD typically has a higher
FPR than SGL-CGD, since more SNPs are selected from non-causal pathways.
As the effect size increases, the number of simulations in which SGL-CGD outperforms
SGL-BCGD for SNP selection power grows, paralleling the former method’s enhanced
pathway selection power. This is again a demonstration of the screening effect with SGL-
BCGD described previously. This means that SGL-CGD is more often able to select both
causal pathways, and to select additional causal SNPs that are missed by SGL-BCGD.
These additional SNPs are likely to be those with lower MAF, for example, that are harder
to detect with SGL-BCGD, once the effect of overlapping SNPs are screened out during
estimation using BCGD. Interestingly, as before SGL-CGD continues to exhibit lower false
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positive rates than SGL-BCGD. This suggests that, with the simulated data considered
here, the independence assumption offers better control of false positives by enabling the
selection of causal SNPs in each and every pathway to which they are mapped. In contrast,
where causal SNPs are successively screened out during the estimation using BCGD, too
many SNPs with spurious effects are selected.
The relative advantage of SGL-CGD over SGL-BCGD on all performance measures
starts to decrease around γ = 0.1, as SGL-BCGD becomes better able to detect all causal
pathways and SNPs, irrespective of the screening effect.
4.2.3 Weight tuning
SGL-CGD will be subject to the same biases arising for example from variations in the
number and size of pathway genes, as was the case with the previous GL-based P-GLAW
method. We therefore employ a similar weight-tuning strategy as before in which we iter-
atively adapt the pathway weight vector, w to achieve a near uniform empirical pathway
selection frequency distribution, Π∗, over R permutations of the phenotype vector, each
with λ tuned to select a single pathway.
For SGL-CGD with a univariate response, the weight tuning algorithm can be signifi-
cantly simplified by noting that there is no need to fit the model to estimate each βl. This
is for the following reasons. Firstly, with a univariate phenotype we don’t perform PsRRR,
so that no estimate for the full genotype vector β is required for estimating phenotype co-
efficients. Secondly, as discussed in the previous section, under the pathway independence
assumption, each βˆl has no influence on any other βˆk, k 6= l. Thus with a fixed value for α,
and with λ tuned to select a single pathway, we need only establish which pathway enters
the model first, as λ is reduced from its maximal value, λmax. From (4.18), at phenotype
permutation r, the pathway Cˆr selected with permuted phenotype yr is then given by
Cˆr = {arg max
l
λminl }
where
λminl =
||S(X′lyr, λminl )||2
(1− α)wl .
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Weight tuning then proceeds in exactly the same way as described under P-GLAW (Sec-
tion 2.4). This ability to skip the full model estimation process results in a considerable
reduction in computation time.
4.2.4 Pathway, SNP and gene ranking
As with the previous methods, we rank selected variables using a resampling strategy in
which we fit the model B times, each time using a random subsample of the full dataset of
size N/2, drawn without replacement. The procedure for pathway ranking is exactly the
same as that described for GL-based models.
For SNP and gene ranking, we denote the set of SNPs selected at sample b (in the
unexpanded variable space) by Sˆ(b), where
Sˆ(b) = {j : βˆj 6= 0, j ∈ Gl, l ∈ {1, . . . , L}},
and follow the same procedure for SNP and gene ranking as described at the end of Section
3.3.2. Note that in the case of SNPs that overlap multiple pathways, the same SNPs may
be selected in more than one pathway.
Our proposed ‘pathways sparse group lasso with adaptive weights’ (P-SGLAW) method
combines the various elements described in Section 4.2, namely estimation of the SGL
model (4.19) using SGL-CGD, together with the procedure for weight tuning to remove
bias, and the resampling strategy for ranking pathways, SNPs and genes in order of impor-
tance. In the next section we apply this method to an application study using real data.
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4.3 P-SGLAW application study: Identification of pathways, SNPs
and genes associated with high-density lipoprotein cholesterol
In this section we describe an investigation of pathways, SNPs and genes associated with
high-density lipoprotein cholesterol (HDL-C) levels in two separate cohorts of Asian adults.
HDL-C is sometimes referred to as ‘good cholesterol’, since high levels of HDL-C have
previously been linked to a reduced incidence of cardiovascular disease (Gordon et al.,
1989), and it is also thought to protect patients from the development and progression of
artherosclerotic disease and associated morbidity (Toth, 2005).
4.3.1 Subjects, genotypes and phenotypes
The analysis is carried out using two datasets supplied by colleagues at the National Uni-
versity of Singapore, that have previously been used to search for novel variants associated
with type 2 diabetes mellitus (T2D) in Asian populations. The first (discovery) cohort
is from the Singapore Prospective Study Program, hereafter referred to as ‘SP2’, and the
second (replication) dataset is from the Singapore Malay Eye Study or ‘SiMES’. Detailed
information on both datasets can be found in Sim et al. (2011), but we briefly outline some
salient features here.
Both datasets comprise whole genome data for T2D cases and controls, genotyped on
the Illumina HumanHap 610 Quad array. For the present study we use controls only, since
variation in lipid levels between cases and controls can be greater than the variation within
controls alone. The use of both cases and controls in our analysis might then lead to a
confounded analysis, where any associations could be linked to T2D status or some other
spurious factor.
The SP2 dataset consists entirely of ethnic Chinese, and shows no evidence of popula-
tion stratification. The SiMES dataset comprises ethnic Malays, and shows some evidence
of cryptic relatedness between samples. For this reason, the first two principal components
of a PCA for population structure are used as covariates in our analysis of this dataset.
Again full details of the stratification analysis can be found in Sim et al. (2011) and associ-
ated supplementary information.
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A summary of information pertaining to genotypes for each dataset, both before and
after imputation and pathway mapping, is given in Table 4.2, along with a list of phenotypes
and covariates.
Table 4.2: Genotype and phenotype information corresponding to the SP2 and SiMES datasets used
in the study.
SP2 Simes
Sample size N = 1, 040 N = 1, 099
Genotypes
Before imputation
SNPs available for analysis(1) 542, 297 557, 824
SNPs with missing genotypes(2) 152, 372 282, 549
Post imputation
SNPs available for analysis(3) 492, 639 515, 503
Phenotypes/covariates
quantitative trait (phenotype)(4) HDL-C HDL-C
covariates gender, age, age2, gender, age, age2,
BMI(5) BMI, PC1, PC2(6)
(1)after first round of quality control (Sim et al., 2011) and removal of monomorphic SNPs
(2)maximum 5% missing rate per SNP
(3)after imputation and removal of SNPs with MAF< 0.01
(4)mg/dL
(5)body mass index (kg/m2)
(6)principal components relating to cryptic relatedness
4.3.2 Genotype imputation
After the initial round of quality control, genotypes for both datasets have a maximum SNP
missingness of 5%. Since our method cannot handle missing values, we perform ‘missing
holes’ SNP imputation, so that all missing SNP calls are estimated against a reference panel
of known haplotypes.
SNP imputation proceeds in two stages. First, imputation requires accurate estimation
of haplotypes from diploid genotypes. This process, known as phasing, is performed using
SHAPEIT v1 (http://www.shapeit.fr). This uses a hidden Markov model to infer haplotypes
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from sample genotypes using a map of known recombination rates across the genome (De-
laneau, Marchini, and Zagury, 2012). The recombination map must correspond to genotype
coordinates in the dataset to be imputed, so we use recombination data from HapMap phase
II, corresponding to genome build NCBI b36 (http://hapmap.ncbi.nlm.nih.gov/downloads/
recombination/2008-03 rel22 B36/).
Following the primary phasing stage, SNP imputation is performed using IMPUTE
v2.2.2 (http://mathgen.stats.ox.ac.uk/impute/impute v2.html). IMPUTE uses a reference
panel of known haplotypes to infer unobserved genotypes, given a set of observed sample
haplotypes (Howie, Marchini, and Stephens, 2011). The latest version (IMPUTE 2) uses
an updated, efficient algorithm, so that a custom reference panel can be used for each
study haplotype, and for each region of the genome, enabling the full range of reference
information provided by HapMap3 (The 1000 Genomes Project Consortium, 2011) to be
used. Following IMPUTE 2 guidelines, we use HapMap3 reference data corresponding to
NCBI b36 (http://mathgen.stats.ox.ac.uk/impute/data download hapmap3 r2.html) which
includes haplotype data for 1,011 individuals from Africa, Asia, Europe and the Americas.
SNPs are imputed in 5MB chunks, using an effective population size (Ne) of 15,000, and a
buffer of 250kb to avoid edge effects, again as recommended for IMPUTE 2.
The phasing and imputation process is complex and computationally intensive. For this
reason we implement a pipeline in Python, with phasing and imputation for each chromo-
some conducted in parallel across multiple nodes in a computing cluster. This enables full
genome imputation that would otherwise take days, to be completed in a matter of hours.
4.3.3 Pathway mapping
Following imputation, SNPs for both datasets are mapped to KEGG canonical pathways
from the MSigDB database (http://www.broadinstitute.org/gsea/msigdb/index.jsp), as de-
scribed in the previous AD study (Section 3.5.4). Details of the pathway mapping process
are given in Figures 4.7 and 4.8.
Note that there is a difference in the number of SNPs available for the pathway mapping
between the two datasets, and this results in a small discrepancy in the total number of
mapped genes (SP2: 4,734 mapped genes; SiMES: 4,751). However, both datasets map
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Figure 4.7: SP2 dataset. SNP to pathway mapping.
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Figure 4.8: SiMES dataset. SNP to pathway mapping.
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to all 185 KEGG pathways, and a large majority of mapped genes and SNPs overlap both
datasets. Detailed information on the pathway mapping process for the two datasets is
presented in Table 4.3.
Table 4.3: SNP and gene to pathway mappings for the SP2 and SiMES datasets.
SP2 SiMES
Total SNPs mapping to pathways 75,389 78,933
Total SNPs mapping to pathways in both datasets (intersection) 74,864
Total mapped genes 4,734 4,751
Total genes mapping to pathways in both datasets (intersection) 4,726
Total mapped pathways 185 185
Minimum number of genes mapping to single pathway 11 11
Maximum number of genes mapping to single pathway 63 63
Minimum number of SNPs mapping to single pathway 66 67
Maximum number of SNPs mapping to single pathway 5,759 6,058
Minimum number of pathways mapping mapping to a single SNP 1 1
Maximum number of pathways mapping mapping to a single SNP 45 45
4.3.4 Results
We perform pathways-driven SNP selection on both datasets, using the P-SGLAW method
described previously. We present results for each dataset separately below.
SP2 Dataset
For the SP2 dataset we consider two separate scenarios for the regularisation parameters
λ and α. For the two scenarios we set the sparsity parameter, λ = 0.95, but consider two
values for α, namely α = 0.95, 0.85. We test each scenario over 1000 N/2 subsamples.
We also compare the resulting pathway and SNP selection frequency distributions with
null distributions, again over 1000 N/2 subsamples, but with phenotype labels permuted,
so that no SNPs can influence the phenotype.
The parameter α controls how the regularisation penalty is distributed between the `2
(pathway) and `1 (SNP) norms of the coefficient vector. Each scenario therefore entails
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different numbers of selected pathways and SNPs, and this information is presented in
Table 4.4.
Table 4.4: Separate combinations of the P-SGLAW regularisation parameters, λ and α used for anal-
ysis of the SP2 dataset. For each λ, α combination, the mean (±SD) number of selected pathways
and SNPs across all 1000 subsamples is reported.
λ = 0.95 λ = 0.95
α = 0.85 α = 0.95
empirical
selected pathways 7.9± 6.1 4.8± 4.1
selected SNPs 1551± 1294 160± 185
null
selected pathways 9.1± 7.2 5.0± 4.55
selected SNPs 1656± 1401 155± 194
Comparisons of empirical and null pathway selection frequency distributions for each
scenario are presented in Figure 4.9. The same comparisons for SNP selection frequencies
are presented in Figure 4.10. In these plots, null distributions (coloured blue) are ordered
along the x-axis according to their corresponding ranked empirical selection frequencies
(marked in red). This is to help visualise any potential biases that may be influencing
variable selection (see below).
To interpret these results, we begin by noting from Table 4.4 that many more SNPs are
selected with α = 0.85, resulting in higher SNP selection frequencies, compared to those
obtained with α = 0.95 (see Figure 4.10). This is as expected, since a lower value for α
implies a reduced `1 penalty on the SNP coefficient vector, resulting in more SNPs being
selected. Perhaps surprisingly, given that the `2 group penalty (1 − α)λ is increased, the
number of selected pathways is also greater. This must reflect the reduced `1 penalty, which
allows a greater number of SNPs to contribute to a putative selected pathway’s coefficient
vector. This in turn increases the number of pathways that pass the threshold for selection.
This raises the question of what might be considered to be an optimal choice for the
regularisation-distributional parameter α, since different assumptions about the number
of SNPs potentially influencing the phenotype may affect the resulting pathway and SNP
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Figure 4.9: Empirical and null pathway selection frequency distributions for all 185 KEGG path-
ways with the SP2 dataset. For each scenario, pathways are ranked along the x-axis in order of their
empirical pathway selection frequency, pipathl1 >, . . . , > pi
path
lL
. (a) α = 0.85. (b) α = 0.95.
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(a)
(b)
Figure 4.10: Empirical and null SNP selection frequency distributions with the SP2 dataset. For
each scenario, SNPs are ranked along the x-axis in order of their empirical pathway selection fre-
quency, piSNPj1 > pi
SNP
j2
> . . .. (a) α = 0.85. (b) α = 0.95. Note fewer SNPs are selected with
nonzero empirical selection frequency with α = 0.95, so that the x-axis range in (b) is reduced.
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rankings. To answer this, we turn our attention to the pathway and SNP selection frequency
distributions for each α value in Figures 4.9 and 4.10. At the lower value of α = 0.85 (top
plots in Figures 4.9 and 4.10), empirical pathway and SNP selection frequency distributions
appear to be biased, in the sense that there is a suggestion that pathways and SNPs with
the highest empirical selection frequencies also tend to be selected with a higher frequency
under the null, where there is no association between genotype and phenotype. This re-
lationship appears to be diminished with α = 0.95, when fewer SNPs are selected by the
model. We investigate this further by plotting empirical vs. null selection frequencies as a
sequence of scatter plots in Figure 4.11, and we report Pearson correlation coefficients and
p-values for these in Table 4.5.
Table 4.5: SP2 dataset: Pearson correlation coefficients (r)and p-values for the data plotted in Figure
4.11. n denotes the number of predictors considered. For SNPs, coefficients describe correlations
for all predictors selected with nonzero empirical selection frequencies only, since a large number
of SNPs are not selected by the model at any subsample.
α = 0.85 α = 0.95
n r p-value n r p-value
pathways 185 0.66 1.3× 10−24 185 0.26 2.9× 10−4
SNPs 62, 965 0.37 0 30, 027 0.11 1.2× 10−84
These provide further evidence of increased correlation between empirical and null
selection frequency distributions at the lower α value for both pathways and SNPs, again
suggesting increased bias in the empirical results, in the sense that certain pathways and
SNPs tend to be selected with a higher frequency, irrespective of whether or not a true
signal may be present. Further qualitative evidence of reduced bias with α = 0.95 is
suggested by the clearer separation of empirical and null distributions at the higher α value
in Figures 4.9 and 4.10. For example, the maximum empirical pathway selection frequency
is reduced by a factor of 0.29 (0.35 to 0.25) as α is increased from 0.85 to 0.95, whereas the
maximum pathway selection frequency under the null is reduced by a factor of 0.81 (0.29
to 0.054). Similarly for SNPs, the maximum empirical SNP selection frequency is reduced
by a factor of 0.37 (0.52 to 0.33), whereas the maximum SNP selection frequency under
the null is reduced by a factor of 0.9 (0.11 to 0.011).
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Figure 4.11: SP2 dataset: Scatter plots comparing empirical and null selection frequencies presented
in Figures 4.9 and 4.10. (a) and (b): Pathway selection frequencies with α = 0.85, 0.95 respec-
tively. (c) and (d): SNP selection frequencies for the same α values. For clarity, SNP selection
frequencies are plotted for the top 1000 SNPs (by empirical selection frequency) only. Correspond-
ing correlation coefficients (for all ranked SNPs) are presented in Table 4.5. Note that pathway and
SNP selection frequencies are much higher at the lower α value (left hand plots), since many more
variables are selected (see Table 4.4.
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The increased bias with α = 0.85 is most likely due to the selection of too many
SNPs, in the sense that many selected SNPs do not exhibit real phenotypic effects. These
extra SNPs effectively add noise to the model, in the form of multiple weak, spurious
signals. This in turn will add bias to the resulting selection frequency distributions, tending
to favour, for example, SNPs that overlap multiple pathways, and the pathways that contain
them. As α is increased, we would expect this biasing effect to be reduced, until a point
where too few SNPs are selected, when there is then a risk that some of the true signal may
be lost.
Note that the reduced but still significant correlations between empirical and null selec-
tion frequency distributions at α = 0.95 in Table 4.5 are not unexpected. These may reflect
the complex overlap structure between pathways, meaning that pathways (and associated
SNPs) with a relatively high degree of overlap with other pathways, due for example to
the presence of so called ‘hub genes’, are more likely to harbour true signals, as well as
spurious ones (Lehner et al., 2006; Carter et al., 2004; Jeong et al., 2001).
Taking all the above into consideration, we choose to report results with α = 0.95,
where there is less evidence of bias due to the selection of too many SNPs. The top 30
pathways, ranked by selection frequency are presented in Table 4.6, and the top 30 ranked
SNPs, together with corresponding genes to which they are mapped are presented in Table
4.7.
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Table 4.7: SP2 dataset: Top 30 SNPs and genes, respectively ranked by SNP and gene selection fre-
quency. Genes falling in the top 30 ranks of the consensus gene set, Ψgene244 , obtained by comparing
gene ranking results from both SP2 and SiMES datasets (see Table 4.13), are marked with a ∗.
SNP RANKING GENE RANKING
Rank SNP piSNP Mapped gene(s) Gene pigene # mapped SNPs
1 rs2257167 0.33 IFNAR1 IFNAR1 0.33 11
2 rs2254315 0.32 IFNAR1 IL12B 0.30 9
3 rs1041868 0.32 IFNAR1 PIAS2 0.30 7
4 rs7364085 0.31 IFNAR1 TIRAP 0.22 5
5 rs2850021 0.31 IFNAR1 RAC1 0.21 10
6 rs2253413 0.31 IFNAR1 LAMA2∗ 0.19 111
7 rs2243590 0.31 IFNAR1 ADCY2∗ 0.19 94
8 rs2834204 0.31 IFNAR1 PIK3R1 0.19 28
9 rs3181224 0.30 IL12B PARK2 0.19 460
10 rs512868 0.28 PIAS2 IL2RA 0.19 55
11 rs641366 0.24 PIAS2 PRKCA∗ 0.19 123
12 rs2032215 0.22 PIAS2 ITGB8 0.18 27
13 rs8177375 0.22 TIRAP TCF7L1 0.18 55
14 rs10893493 0.21 TIRAP CD80∗ 0.18 21
15 rs4890341 0.20 PIAS2 GRIN3A 0.18 60
16 rs2303361 0.19 RAC1 PRKCB∗ 0.18 83
17 rs7873495 0.17 GRIN3A PPP3R2 CACNA1C∗ 0.17 180
18 rs1323653 0.17 IL2RA TGFB3 0.16 7
19 rs11762117 0.16 ITGB8 PRKACB 0.16 16
20 rs3807955 0.16 ITGB8 KRAS∗ 0.16 21
21 rs10462842 0.15 ADCY2 VAV3 0.16 97
22 rs10215885 0.15 ITGB8 IL5RA 0.15 38
23 rs3807936 0.15 ITGB8 ITGA1∗ 0.15 77
24 rs530205 0.15 PIAS2 VAV2∗ 0.15 85
25 rs3823974 0.15 ITGB8 EGFR∗ 0.14 61
26 rs2074425 0.15 ITGB8 TPO 0.14 50
27 rs6725799 0.15 TCF7L1 CACNA2D3∗ 0.14 283
28 rs2301727 0.15 ITGB8 RYR2∗ 0.14 214
29 rs10486391 0.14 ITGB8 NOS1 0.14 49
30 rs3779505 0.14 ITGB8 RFWD2 0.13 31
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SiMES Dataset
For the replication SiMES dataset, we repeat the above analysis design, but consider only
the ‘low bias’ scenario where λ = 0.95 and α = 0.95. Once again we test each sce-
nario over 1000 N/2 subsamples, and compare the resulting pathway and SNP selection
frequency distributions with null distributions generated over 1000 N/2 subsamples with
phenotype labels permuted. Pathway and SNP selection frequency distributions are pre-
sented in Figure 4.13. An investigation of pathway and SNP selection bias is presented
in the form of scatter plots illustrating potential correlation between empirical and null se-
lection frequencies in Figure 4.12, with corresponding Pearson correlation coefficients and
p-values presented in Table 4.8. The top 30 ranked pathways, and SNPs and genes are
presented in Tables 4.9 and 4.10 respectively.
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Figure 4.12: SiMES dataset: Scatter plots comparing empirical and null pathway (left) and SNP
(right) selection frequencies presented in Figure 4.13. For clarity, SNP selection frequencies are
plotted for the top 1000 SNPs (by empirical selection frequency) only.
Table 4.8: SiMES dataset: Pearson correlation coefficients (r)and p-values for the data plotted
in Figure 4.12. n denotes the number of predictors considered. For SNPs, coefficients describe
correlations for all predictors selected with nonzero empirical selection frequencies only, since a
large number of SNPs are not selected by the model at any subsample.
n r p-value
pathways 185 −0.094 0.20
SNPs 20, 006 0.058 2.63× 10−16
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Figure 4.13: Empirical and null pathway (top) and SNP (bottom) selection frequency distributions
for the SiMES dataset. α = 0.95. For both empirical (red) and null (blue) distributions, variables
(pathways and SNPs) are ranked along the x-axis in order of their empirical selection frequencies.
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Table 4.10: SiMES dataset: Top 30 SNPs and genes, respectively ranked by SNP and gene selection
frequency. Genes falling in the top 30 ranks of the consensus gene set, Ψgene244 , obtained by com-
paring gene ranking results from both SP2 and SiMES datasets (see Table 4.13), are marked with a
∗.
SNP RANKING GENE RANKING
Rank SNP piSNP Mapped gene(s) Gene pigene # mapped SNPs
1 rs2636698 0.31 PPA2 PPA2 0.31 16
2 rs2726503 0.31 PPA2 PDSS2 0.26 59
3 rs2713829 0.31 PPA2 GABARAPL1 0.18 11
4 rs2636726 0.31 PPA2 ATP6V0A4 0.15 35
5 rs2713834 0.31 PPA2 ITGB1 0.13 14
6 rs2726471 0.31 PPA2 CACNA1C∗ 0.11 186
7 rs2636713 0.31 PPA2 PRKCB∗ 0.11 84
8 rs2726516 0.31 PPA2 FYN 0.11 46
9 rs2636739 0.31 PPA2 BCL2∗ 0.10 61
10 rs2713861 0.31 PPA2 PAK7∗ 0.10 127
11 rs2636751 0.31 PPA2 DGKB 0.10 233
12 rs2298733 0.30 PPA2 LAMA2∗ 0.10 118
13 rs6568474 0.26 PDSS2 NDUFA4 0.10 7
14 rs9386622 0.26 PDSS2 DGKH 0.10 70
15 rs6924886 0.26 PDSS2 ADCY2∗ 0.09 104
16 rs759440 0.25 PDSS2 LIPC 0.09 69
17 rs11759792 0.23 PDSS2 SLC8A1∗ 0.09 240
18 rs10457161 0.20 PDSS2 EGFR∗ 0.09 74
19 rs12821011 0.18 GABARAPL1 PRKAG2 0.09 118
20 rs11053685 0.18 GABARAPL1 CACNA1D 0.09 83
21 rs4764324 0.18 GABARAPL1 ITGA11∗ 0.09 63
22 rs4764327 0.18 GABARAPL1 IGF1R∗ 0.09 100
23 rs9373924 0.18 PDSS2 SDHC 0.09 9
24 rs10845074 0.18 GABARAPL1 CACNA2D3∗ 0.08 294
25 rs9320215 0.17 PDSS2 RYR2∗ 0.08 221
26 rs10845073 0.17 GABARAPL1 ITGA1∗ 0.08 77
27 rs4946826 0.16 PDSS2 ALDH7A1 0.08 23
28 rs6938393 0.15 PDSS2 MGST3∗ 0.08 40
29 rs13202332 0.13 PDSS2 ALDH2 0.08 12
30 rs9480754 0.13 PDSS2 SDHB 0.08 13
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Comparison of ranked pathway lists
We now consider the problem of comparing rankings (pathways, genes and SNPs) obtained
for each dataset. To do this we require some measure of distance between each pair of lists.
Ideally this measure should place more emphasis on differences between highly-ranked
variables, since we expect the association signal, and hence agreement between the ranked
lists, to be strongest there. By the same reasoning, we expect there to be little or no agree-
ment between variables at lower rankings, where selection frequencies are low. Indeed a
consideration of empirical and null selection frequency distributions (Figures 4.9 (b) and
4.13, top) suggests that only the very top ranked variables are likely to reflect any true
signal, so that we would additionally like our distance metric to be able to accommodate
consideration of the top-k variables only, with k < p, where p is the total number of vari-
ables ranked in either dataset. One complication with top-k lists is that they are partial, in
the sense that unlike complete (k = p) lists, a variable may occur in one list, but not the
other.
In order to consider this problem, we introduce the following notation. We denote
the complete set of ranked predictors by L = {1, . . . , p}, and begin by assuming that
all variables are ranked in both datasets. We denote the rank of each variable in list 1 by
τ(i), i = 1, . . . , p, so that τ(5) = 1 if variable 5 is ranked first and so on. The corresponding
ranks for list 2 are denoted by σ(i), i = 1, . . . , p. A suitable metric describing the distance
between two top-k rankings is the Canberra distance (Jurman et al., 2008),
Ca(k, τ, σ) =
p∑
i=1
|min{τ(i), k + 1} −min{σ(i), k + 1}|
min{τ(i), k + 1}+ min{σ(i), k + 1} . (4.24)
This has the properties that we require, in that the denominator ensures more emphasis is
placed on differences in the ranks of highly ranked variables in either dataset. Furthermore,
this distance measure allows comparisons between partial, top-k lists, since a variable oc-
curring in one top-k list but not the other is assigned a ranking of k + 1 in the list from
which it is missing. Note also that a variable i that is not in either of the top-k ranks, that is
τ(i), σ(i) > k, makes no contribution to Ca(k, τ, σ).
In order to gauge the extent to which the distance measure (4.24) differs from that
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expected between two random lists, we require a value for the expected Canberra distance
between two random lists, which we denote E[Ca(k, p)]. Jurman et al. (2008) derive an
expression for this quantity, and we use this to compute the normalised Canberra distance,
Ca∗(k, τ, σ) =
Ca(k, τ, σ)
E[Ca(k, p)]
. (4.25)
Note that this has a lower bound of 0, corresponding to exact agreement between the
lists. For two random lists, the upper bound will generally be close to 1, although it can ex-
ceed 1, particularly for small k, since the expected value for random lists is not necessarily
the highest value.
We illustrate the variation of the normalised Canberra distance (4.25) between SP2 and
SiMES pathway rankings in the left hand plot in Figure 4.14 (blue curve). We consider all
possible top-k lists, k = 1, . . . , 185 since all 185 pathways are ranked in both datasets. In
the same plot, we also show
Ca∗pi(k, τ, σ) =
1
Z
Z∑
pi=1
Ca(k, τ, σpi)
E[Ca(k, p)]
k = 1, . . . , 185 (4.26)
obtained by comparing empirical SP2 rankings (τ) against Z = 10, 000 permutations of the
SiMES pathway rankings, σpi, pi = 1, . . . , 10, 000 (green curve). This latter curve confirms
that the expected value, E[Ca(k, p)], is indeed a good measure of Ca in the random case
where there is no agreement between rankings.
Using the same permuted rankings, σpi, we next test the null hypothesis that the ob-
served normalised Canberra distance, Ca∗(k, τ, σ), is not significantly different from that
between τ and a random list σpi, by computing a p-value as
p∗(k) =
1
Z
Z∑
pi=1
ICa∗(k,τ,σ)≤Ca∗(k,τ,σpi),
for k = 1, . . . , 185. We then obtain FDR q-values using the Benjamini-Hochberg procedure
(Benjamini and Hochberg, 1995) and illustrate these for each k in the right hand plot of
Figure 4.14. FDR is controlled at a nominal 5% level for 19 ≤ k ≤ 71, indicating that the
distance between the top-k pathway rankings for both datasets is significantly different
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Figure 4.14: Comparison of top-k SP2 and SiMES pathway rankings. Left hand plot: Variation of
normalised Canberra distance, Ca∗ with k (4.25) (blue curve). Corresponding mean values over
Z = 10, 000 permutations of SiMES rankings (4.26) (green curve). Right hand plot: FDR q-values
(blue curve). Dotted green line shows the threshold for FDR control at the 5% level.
from the random ranking case for a wide range of possible values of k. The distance
Ca∗ between SP2 and SiMES pathway rankings however attains its minimum value when
k = 25 with q(25) = 0.037, so that on this measure, the two pathway rankings are in closest
agreement when we consider the top 25 pathways in each ranked list only. Some intuitive
understanding of why this might be so can be gained by considering the empirical vs. null
pathway selection frequency distributions for each dataset in Figures 4.9 (b) and 4.13 (top).
Here we see that the separation between empirical and null selection frequencies is most
clear for values of k below around 30 for SP2, and around 15 for SiMES.
If we assume that the two pathway rankings are indeed in closest agreement when
k = 25, then one means of obtaining a consensus set of important pathways is to consider
their intersection,
Ψpath25 = {i : τ−1(i) ≤ 25} ∩ {j : σ−1(j) ≤ 25},
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from which we can obtain a set of average rankings as
ψpath25 =
{τ(z) + σ(z)
2
: z ∈ Ψpath25
}
.
Both the intersection set, Ψpath25 , and ordered average rankings, ψ
path
25 for the two datasets
under consideration are shown in Table 4.11. We additionally mark the consensus set Ψ25path
with asterisks in Tables 4.6 and 4.9.
Table 4.11: Consensus set of pathways, Ψpath25 , for SP2 and SiMES datasets with k = 25. Consensus
pathways are ordered by their average rank in ψpath25 .
Pathway Average rank (ψpath25 )
Dilated Cardiomyopathy 4.5
Hypertrophic Cardiomyopathy 7.5
T Cell Receptor Signaling Pathway 11.0
Terpenoid Backbone Biosynthesis 11.0
Arrhythmogenic Right Ventricular Cardiomyopathy 12.0
Ribosome 13.0
Ppar Signaling Pathway 18.5
Comparison of ranked gene and SNP lists
A number of factors complicate the comparison of ranked gene and SNP lists across both
datasets. Firstly, sets of mapped SNPs and genes differ slightly between the two datasets
(see Table 4.2). Secondly, even if we consider only those variables mapped in both datasets,
different, though overlapping sets of variables are ranked in each. Thirdly, ranked variables
are not independent (Jurman et al., 2008). For example, genes may be grouped into path-
ways, so that a reordering of genes within a pathway might be considered less significant
than a reordering of genes mapping to different pathways. Similarly a reordering of SNPs
mapping to a single gene might be considered less significant than a reordering of SNPs
mapping to different genes.
In order to compute a distance measure between pairs or ranked lists, we therefore
make two simplifying assumptions. First, we consider only variables ranked in one or both
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datasets. This seems reasonable, since we can necessarily only compile a distance measure
from variables that are ranked in one or both datasets. Second, we assume that variables are
independent. This makes our distance measure conservative, in the sense that it will treat
all reordering of SNPs or genes equally, irrespective of any potential functional relationship
between them.
With these assumptions in mind, we begin by denoting the set of all p∗ variables (genes
or SNPs) that are ranked in either dataset by L = {1, . . . , p∗}. We further denote the corre-
sponding sets of ranked variables for SP2 and SiMES datasets by Lτ and Lσ respectively.
We then have the following set relations: Lτ ,Lσ ⊂ L; Lτ 6= Lσ; and |Lτ | 6= |Lσ|.
We now extend the previous Canberra distance measure to encompass the above set
relations. We begin, as before, by defining two ranked lists corresponding to the rankings
of all the variables inL for each dataset, although this time we must account for the fact that
not all variables in L are ranked in both. We denote SP2 rankings by τ(i), i = 1, . . . , p∗,
where τ(i) is the rank of variable i if i ∈ Lτ , and τ(i) = p∗ otherwise. SiMES rankings are
defined in the same way, and denoted by σ(i), i = 1, . . . , p∗.
Applying this revised ranking scheme, we can then define a top-k normalised Canberra
distance (4.24) as
Ca∗(k, τ, σ) =
Ca(k, τ, σ)
E[Ca(k, p∗)]
. (4.27)
for any k ≤ min{|Lτ |, |Lσ|}. The restriction on k follows from the fact that we cannot
distinguish between top-k rankings for all k > min{|Lτ |, |Lσ|}.
i. Gene rankings
Information summarising the relationship between the two ranked lists of genes is given in
Table 4.12.
We consider normalised Canberra distances, Ca∗(k, τ, σ), for k = 1, . . . , 500 only, and
plot these in Figure 4.15 (left, blue curve), along with Ca∗pi(k, τ, σ) (4.26) for Z = 10, 000
permutations of the SiMES pathway rankings, σpi, pi = 1, . . . , 10, 000 (green curve). Once
again this latter curve confirms that the expected value, E[Ca(k, p∗)], is indeed a good
measure of Ca in the random case where there is no agreement between rankings. We also
plot FDR q-values using the same procedure as described previously for pathways. FDR is
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Table 4.12: Summary of genes analysed and ranked in SP2 and SiMES datasets.
SP2 SiMES
number of genes mapped to pathways 4,734 4,751
number of genes mapping to both datasets 4,726
number of ranked genes (|Lτ |, |Lσ|) 3,430 2,815
number of genes ranked in either dataset (p∗) 3,913
number of genes ranked in both datasets (|Lτ | ∩ |Lσ|) 2,332
controlled at a nominal 5% level for all k > 13 in the region tested (1 ≤ k ≤ 500). The
distance Ca∗ between SP2 and SiMES pathway rankings attains its minimum value when
k = 244, so that on this measure, the two gene rankings are in closest agreement when we
consider the top 244 pathways in each ranked list only.
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Figure 4.15: Comparison of top-k SP2 and SiMES gene rankings, for k = 1, . . . , 500. Left hand
plot: Variation of normalised Canberra distance, Ca∗ with k (4.27) (blue curve), and corresponding
mean values over 10,000 permutations of SiMES rankings (4.26) (green curve). Right hand plot:
FDR q-values (blue curve). Dotted green line shows the threshold for FDR control at the 5% level.
Following the same strategy as implemented for pathways, we then form the consensus
set, Ψgene244 , and average rankings ψ
gene
244 . The consensus set contains 84 genes, and we list
the top 30 genes ordered by their average rank in the two datasets, in Table 4.13.
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Table 4.13: Top 30 consensus genes ordered by their average rank, ψgene244 .
Rank Gene Average rank (ψgene244 )
1 LAMA2 9.0
2 ADCY2 11.0
3 CACNA1C 11.5
4 PRKCB 11.5
5 PRKCA 21.0
6 EGFR 21.5
7 ITGA1 24.5
8 CACNA2D3 25.5
9 RYR2 26.5
10 IGF1R 30.5
11 PAK7 36.5
12 ADCY8 37.5
13 VAV2 41.0
14 SLC8A1 41.5
15 CACNB2 42.5
16 CACNA2D1 43.0
17 ITGA9 44.0
18 KRAS 47.5
19 MAPK10 50.5
20 CACNA1S 51.0
21 VAV3 54.0
22 PLCG2 55.5
23 BCL2 57.0
24 CD80 60.0
25 ITGA11 60.5
26 CTNNA2 61.0
27 ALDH1B1 61.5
28 MGST3 63.0
29 NEDD4L 63.0
30 PRKAG2 66.0
ii. SNP rankings
Information summarising the relationship between the two ranked lists of SNPs is given in
Table 4.14. In contrast to both pathway and gene rankings, it is apparent that relatively few
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ranked SNPs overlap both datasets – 8,151 out of 41,452 SNPs that are ranked in either
dataset. This results in values for Ca∗(k) that are close to 1, corresponding to the random
list case, over a wide range of possible values for k (data not shown).
For this reason, we compute a simple summary measure
ψSNP =
{τ(j) + σ(j)
2
: j ∈ Lτ ∩ Lσ
}
(4.28)
and report only the top ranking SNPs using this measure in Table 4.15.
Table 4.14: Summary of SNPs analysed and ranked in SP2 and SiMES datasets.
SP2 SiMES
number of SNPs mapped to pathways 75,389 78,933
number of SNPs mapping to both datasets 74,864
number of ranked SNPs (|Lτ |, |Lσ|) 30,027 20,006
number of SNPs ranked in either dataset (p∗) 41,452
number of SNPs ranked in both datasets (|Lτ | ∩ |Lσ|) 8,581
4.4 Discussion
We began this chapter by outlining a strategy for pathways-driven SNP selection, using the
sparse group lasso, that aims to maximise the power to select causal SNPs, possibly of low
effect size, that might otherwise be missed if pathways information is ignored. In a simula-
tion study we were then able to demonstrate that where causal SNPs are enriched within a
single causal pathway, SGL does indeed have greater SNP selection power, compared to an
alternative sparse regression model, the lasso, that disregards pathways information. These
results mirror previous findings that support the intuition that a sparse selection penalty that
promotes dual-level sparsity is better able to recover the true model in these circumstances
(Friedman, Hastie, and Tibshirani, 2010; Simon et al., 2012).
We then argued from a theoretical standpoint that where SNPs can map to multiple
pathways, a modification (SGL-CGD) of the SGL-BCGD estimation algorithm that treats
pathways as independent, may offer greater sensitivity for the detection of causal SNPs and
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Table 4.15: Top 30 SNPs ranked in both SP2 and SiMES datasets, ranked in order of mean ranking,
ψSNP (4.28).
rank SNP ψSNP mapped gene(s)
1 rs897799 133.0 COX6B2 IL11
2 rs2126953 203.0 ITGA1
3 rs7714110 213.0 ADCY2
4 rs6924886 274.5 PDSS2
5 rs2447867 275.5 ITGA1
6 rs9386622 283.0 PDSS2
7 rs6568474 283.5 PDSS2
8 rs10446497 349.5 PAK2
9 rs6583177 385.5 PAK2
10 rs4765961 429.0 CACNA1C
11 rs759440 457.0 PDSS2
12 rs10457161 465.0 PDSS2
13 rs10462842 479.5 ADCY2
14 rs9373932 529.0 PDSS2
15 rs12206487 532.0 LAMA2
16 rs743567 543.0 MYH7
17 rs12472674 543.0 CTNNA2
18 rs11759792 557.5 PDSS2
19 rs9373924 566.0 PDSS2
20 rs319070 623.0 PDSS2
21 rs751877 630.0 ADCY4 LTB4R RIPK3
22 rs2047698 714.0 PDGFD
23 rs4804505 727.5 PDE4A KEAP1
24 rs12672417 764.0 SMURF1
25 rs7766689 800.5 LAMA2
26 rs157694 860.0 MAP3K7
27 rs554192 878.0 NEDD4L
28 rs2746543 896.5 SDHB
29 rs742257 942.0 LAMB3
30 rs1798619 944.5 PAK2
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pathways. A potential concern is that this gain in power may be accompanied by an inflated
number of false positives. However, in a simulation study with overlapping pathways we
found that SGL-CGD demonstrated relative gains in both sensitivity and specificity, com-
pared to SGL-BCGD. This gain in specificity was unexpected, and appears to arise directly
from treating pathways as independent in the model estimation process. As with GL, the
ability of SGL to recover the true model is likely to be affected by the complexity of the
pathway overlap structure (Percival, 2012), although we expect that the gains in power and
sensitivity achieved with the independence assumption will also be apparent with real data.
As with the methods introduced in preceding chapters, P-SGLAW combines the SGL
model and SGL-CGD estimation algorithm with a weight-tuning algorithm to reduce selec-
tion bias, and a resampling technique designed to provide a robust measure of SNP, gene
and pathway importance. As such, the latter is expected to confer advantages, in terms
of the down ranking of unimportant predictors, previously observed for the lasso (Mein-
shausen and Bu¨hlmann, 2010; Chatterjee and Lahiri, 2011). Once again it would be inter-
esting to explore this further using simulations derived from real pathway and genotype
data.
We do however develop a heuristic measure of ranking performance in our P-SGLAW
application study identifying SNPs and pathways associated with high-density lipoprotein
cholesterol levels (Section 4.3). By comparing empirical pathway and SNP rankings with
null rankings obtained by permuting phenotype labels, we gain some confidence that path-
way and SNP signals captured in the top rankings can be distinguished from those arising
from noise or spurious associations. Interestingly, when the same comparison between em-
pirical and null rankings is made with a reduced value for the regularisation parameter, α,
there is evidence of selection bias, in the sense that pathways and SNPs tend to be highly
ranked both empirically and under the null. Since a smaller α corresponds to a greater
number of SNPs being selected at each subsample, this would seem to suggest that too
many SNPs are being selected. In this case, pathway and SNP rankings may in part reflect
spurious associations, with a bias towards SNPs overlapping multiple pathways.
Turning to the study results, we conduct two separate analyses on independent discov-
ery and replication datasets. Since subjects from both datasets are genotyped on the same
platform, the large majority of SNPs mapping to pathways in one dataset do so also in the
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other dataset. Thus 99.3% of SNPs mapping to pathways in the SP2 dataset are similarly
mapped in the SiMES dataset. For the SiMES dataset, the corresponding figure is 94.8%.
As expected, the concordance of gene coverage is even greater. Thus 99.8% of mapped
genes in the SP2 dataset are also mapped in the SiMES dataset, and 99.5% of mapped
genes in the SiMES dataset are also mapped in SP2.
On the assumption that similar patterns of genetic variation are likely to impact HDLC
levels in both cohorts, this gives us an opportunity to validate results from each dataset
by comparing rankings. Where there are common mechanisms affecting phenotypes in
both cohorts however, we would expect to observe the most concordance between the two
studies at the pathway level, followed by genes, and lastly SNPs. Indeed this increased
heterogeneity at the SNP, and to a lesser extent at the gene level is one motivation for
adopting a pathways approach in the first place (Holmans et al., 2009; Hirschhorn, 2009;
Cantor, Lange, and Sinsheimer, 2010).
We obtain consensus pathway and gene rankings by considering only the top k ranks
in each dataset, with k obtained as the value that minimises the distance between the two
rankings. We additionally derive a significance measure for each top-k distance by compar-
ing empirical distances against a null distribution obtained by permuting ranks in one list.
We note that this can only be an approximation of the true null, since in reality rankings
for both datasets may be influenced by the extent to which genes and SNPs overlap multi-
ple pathways. However, some support for the reasonableness of this approximation can be
gained from our earlier analysis, showing that the correlation between empirical and null
pathway and SNP rankings is low, so that rankings under the null are indeed approximately
random.
Considering the consensus pathway rankings in Table 4.11, three out of the seven con-
sensus pathways (ranked 1, 2 and 5), are related to cardiomyopathy. These three pathways
are the only cardiomyopathy-related pathways amongst the 185 KEGG pathways used in
our analysis, so it is noteworthy that all three fall within the consensus pathway rankings.
The link between HDLC levels and cardiomyopathy is already well established (Ansell
et al., 2005; Gordon et al., 1989; Toth, 2005; Freitas et al., 2009; Gaddam et al., 2011).
Furthermore, numerous references in the literature also describe the links between lipid
metabolism and T cell receptor (consensus pathway ranking 3) and PPAR signaling (rank 7)
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(Janes et al., 2000; Calder and Yaqoob, 2007; Staels et al., 1998; Bensinger and Tontonoz,
2008).
Turning to a consideration of the top 30 consensus genes and SNPs presented in Tables
4.13 and 4.15 (and see also pathway ranking tables 4.6, 4.9 and 4.11, and extended results
in supplementary information). We found that many are enriched in one of several gene
families:
1. L-type calcium channel genes, including CACNA1C, CACNA1S, CACNA2D1, CACNA2D3
and CACNB2
2. Adenylate cyclase genes, including ADCY2, ADCY4 and ADCY8
3. Integrin and laminin genes, including ITGA1, ITGA9, ITGA11, LAMA2, and LAMA3
4. MAPK signaling pathway genes, including MAPK10 and MAP3K7
5. Immunological pathway genes, including PAK2, PAK7, PRKCA, PRKCB, VAV2 and
VAV3
These genes are highly enriched in several high ranking pathways from both datasets.
Notably, the focal adhesion pathway alone has 12 gene hits, as does the dilated cardiomy-
opathy pathway. Cardiomyopathy pathways as a whole have 30 genes hits (several of the
genes overlap more than one cardiomyopathy pathway). 10 of these genes feature in the
MAPK signaling pathway, while GnRH (8 genes), T and B cell receptor (8), calcium (7),
ErbB (5), and Wnt signling (4) pathways also contain several genes in the list. To elu-
cidate the biological relevance of these gene families and the connections between them,
we investigated their known functional links with cardiovascular phenotypes (not restricted
to HDLC) by referencing the KEGG and Genetic Association (http://geneticassociationdb.
nih.gov) databases.
Voltage dependent L-type calcium channel gene family
The genes in this family encode the subunits of the human voltage dependent L-type cal-
cium channel (CaV1). The α-1 subunit (encoded by CACNA1C, A1S, A2D1 and A2D3 in
our study) determines channel function in various tissues. CaV1 function has significant
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impact on the activity of heart cells and smooth muscles. For example, patients with mal-
functioning CaV1 develop arrhythmias and shortened QT interval (Splawski et al., 2004;
Antzelevitch et al., 2007; Templin et al., 2011). Furthermore, CACNA1C polymorphisms
have been associated with variation in blood pressure in Caucasian and East Asian pop-
ulations by pharmacogenetic analysis. In 120 Caucasians, 3 SNPs in this gene were sig-
nificantly associated with the response to a widely applied antihypertensive CaV1 blocker
(Bremer et al., 2006). Kamide et al. (2009) also found that polymorphisms in CACNA1C
were associated with sensitivity to an antihypertensive in 161 Japanese patients. The CaV1
β subunit encoding CACNB2 has also been associated with blood pressure (Levy et al.,
2009).
This gene family was mapped to several pathways in our study, with the KEGG dilated
cardiomyopathy pathway achieving highest rank both within individual datasets, and in the
consensus pathway rankings. Dilated cardiomyopathy is the most common form of car-
diomyopathy, and features enlarged and weakened heart muscles. Although high levels of
serum HDLC lowers the risk of heart disease (Castelli, 1988; Toth, 2005), there is still no
direct evidence that CaV1 is involved in HDLC metabolism.
Adenylate cyclase gene family
Three adenylate cyclases genes, ADCY2, ADCY4 and ADCY8 were highly ranked in our
study. Currently, there are no reported associations of these genes with cardiovascular dis-
ease or lipid levels. Adenylate cylcase genes catalyse the formation of cyclic adenosine
monophosphate (cAMP) from adenosine triphosphate (ATP), while cAMP servers as the
second messenger in cell signal transduction. Note that ADCY2 is insensitive to calcium
concentration, suggesting that any association of this gene family with HDLC levels may
not be due to any interactions with the CaV1 gene family.
Among high ranking pathways, ADCY2 and ADCY8 feature in the dilated cardiomy-
opathy pathway. Although ADCY4 was not in the top 30 consensus genes, rs751877 in
this gene was among the top 30 consensus SNPs.
Integrin and laminin gene families
We found 3 genes encoding integrin subunits in our study. Integrins hook to the extracellu-
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lar matrix (ECM) from the cell surface, and are also important signal transduction receptors
which communicate aspects of the cell’s physical and chemical environment (Nermut et al.,
1988). Interestingly, laminins are the major component of the ECM, and are relevant to the
shape and migration of almost every type of tissue. Both of these two families of genes
are therefore highly relevant to the survival and shape of heart muscles. A recent GWAS
conducted in a Japanese population confirmed a previous association between ITGA9 and
blood pressure in European populations (Takeuchi et al., 2010).
Integrin family genes and LAMA2 were selected primarily within high-ranking car-
diomyopathy, focal adhesion and ECM receptor signaling pathways, with once again the di-
lated cardiomyopathy pathway achieving the highest ranks. However, evidence for LAMA3
association is weaker, since it was not in the top 30 consensus genes, although a SNP from
the LAMB3 (laminin β-3) gene was ranked 29 in the consensus SNP list.
MAPK signaling pathway
TAK1 (MAP3K7) and JNK3 (MAPK10) are kinases which regulate cell cycling. They
activate or depress downstream transcription factors which mediate cell proliferation, dif-
ferentiation and inflammation.
JNK activity has been associated with obesity in a mouse model, where the absence
of JNK1 (MAPK8), a protein in the same family as MAPK10, protects against the obesity-
induced insulin resistance (Hirosumi et al., 2002). The negative correlation between HDLC
level and obesity has been well accepted (Howard, Ruotolo, and Robbins, 2003).
Immunological pathways
PAK (PAK2 and PAK7) genes feature in the high ranking T cell signaling pathway in both
SP2 and SiMES datasets. PRKC (including PRKCA and PRKCB), along with VAV (VAV2
and VAV3) genes also feature in various high ranking immunological pathways including T
cell signaling, Pathogenic Escherichia Coli Infection and Natural Killer Cell Mediated Cy-
totoxicity. Genes from all 3 of these families are frequently top ranked in these pathways.
PAK and VAV are activated by antigens, and regulate the T cell cytoskeleton, indicating
a possible impact on T cell shape and mobility. In a candidate gene association analysis,
PRKCA was reported to be associated with HDLC at a nominally significant level, but was
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not significant after adjusting for multiple testing (Lu et al., 2008).
In summary, genes enriched in the above gene clusters and pathways may be relevant
to heart muscle cell signal transduction, shape and migration, and may thus have functional
relevance to the onset of cardiovascular diseases. Many highly ranked genes in our study
are also involved in neurological pathways. For example polymorphisms in CACNA1C
have been associated with bipolar disorder, schizophrenia and major depression (Ferreira
et al., 2008; Moskvina et al., 2009; Green et al., 2010). This points to an interesting hy-
pothesis that serum HDLC levels might be regulated not only by metabolism but also by
neurological pathways, although the elucidation of any putative biological mechanism un-
derlying such an association obviously exceeds the scope of this study.
Besides the gene families and associated pathways discussed above, a notable feature
of the top 30 consensus SNP ranking results presented in Table 4.15 is the inclusion of 9
SNPs mapping to the PDSS2 gene. PDSS2 achieves its high ranking in the consensus SNP
list, through its inclusion in the highly ranked terpenoid backbone biosynthesis pathway in
SiMES, and this gene is in fact the second highest consensus ranking gene with this dataset.
In contrast, this gene is ranked low (216) in the SP2 dataset, which explains why it fails to
make the top 30 consensus gene rankings. PDSS2 encodes subunit 2 of prenyl diphosphate
synthase, which determines the length of the isoprenoid chain of coenzyme Q10 (CoQ10)
(Saiki et al., 2005). A deficiency in biosynthesis of CoQ10 has previously been associated
with delayed motor development and abnormal renal function, with excess serum lipids
(Sobreira et al., 1997).
Despite the well established links between lipid metabolism and PPAR signaling noted
above, no genes in this high-ranked pathway fall in the top 30 gene rankings for either
dataset (see Tables 4.6 and 4.15). This could be because the association signal in this path-
way is more widely distributed, compared to other high ranking pathways, perhaps indicat-
ing heterogeneity in genetic causal factors within our sample, so that different genes and
SNPs are highlighted in different subsamples. This would result in reduced gene selection
frequencies. Also, genes that overlap multiple putative causal pathways are more likely to
be selected in a given subsample, meaning that associated genes mapping to pathways with
relatively few overlaps may have lower selection frequencies. This may be the case with
genes in the PPAR signaling pathway, whose 63 genes map to an average 2.7 ± 1.8 path-
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ways. As a comparison, the 84 genes in the top-ranked dilated cardiomyopathy pathway
map to an average 7.2± 3.8 pathways.
Our study failed to highlight HDLC-associated SNPs identified in previous GWAS (see
for example www.genome.gov/gwastudies for an up to date list). A primary reason for this
is that the large majority of SNPs identified in previous studies do not map to pathways in
our study, either because they fall in intergenic regions, or because they do not feature on
the Illumina arrays used here. In addition our method is designed to highlight distributed,
small SNP effects that accumulate across gene pathways, and so will likely fail to identify
those SNPs with significant marginal effects targeted by GWAS.
As noted above, for those SNPs that are ranked in our study, we expect there to be con-
siderably less concordance between SNP ranking results for the two datasets, compared
with pathway and gene rankings, and this is indeed the case. This reduced concordance
may be due to increased heterogeneity of genetic risk factors at the SNP level between the
two datasets. Another important source of variation in SNP selection frequencies is LD
between SNPs. The within-pathway lasso penalty will tend to select one of a group of
highly correlated SNPs at random, reducing SNP selection frequencies within LD blocks
harbouring causal SNPs. An alternative approach would be to consider a different penalty
within selected pathways, for example the elastic net (Zou and Hastie, 2005), which se-
lects groups of correlated variables jointly, although this comes at the cost of introducing a
further regularisation parameter to be tuned.
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Chapter 5
Sparse regression methods for pathway
and SNP selection: Conclusions and
further work
In the preceding chapters we have considered a range of strategies and models for the detec-
tion of pathways, genes and SNPs associated with univariate and multivariate quantitative
traits.
For the modelling of a univariate quantitative trait, we developed a method, P-GLAW,
that combines all SNPs and pathways together in a single penalised regression model, and
imposes a group-sparsity constraint to drive pathway selection. We demonstrated through
simulations over a wide range of scenarios, that this multivariate approach was better able
to identify implicated pathways, compared to an alternative method based on combining
univariate SNP statistics. We then extended this method to the case of a multivariate quan-
titative trait by applying a group lasso penalty in a sparse reduced-rank regression (sRRR)
model previously applied to the problem of identifying SNPs. We used the resulting PsRRR
method in an imaging genetic analysis modelling a high-dimensional multivariate pheno-
type characteristic of structural changes in the brains of patients with AD. Our study identi-
fied a number of pathways previously implicated in the disease, and in a follow up analysis
we performed sRRR with a lasso penalty to identify important SNPs and genes within pre-
viously selected pathways. Here we were able to identify a number of SNPs and genes
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previously implicated in AD, alongside other putative candidates. Finally, returning to the
case of a univariate trait, we explored a method, P-SGLAW, that enforces sparsity at both
the pathway and SNP level, and is therefore able to perform simultaneous pathway and
SNP selection. We demonstrated by simulation that where pathways information is impor-
tant, this dual-level sparse selection model is better able to recover underlying true sparsity,
compared to the simple lasso that disregards such information. We then argued that in the
case of overlapping pathways, a modification to the estimation algorithm that assumes that
pathways are independent may improve model selection performance, and again demon-
strated this in a simulation study. Finally we applied our method to a study of pathways,
SNPs and genes associated with high-density lipoprotein cholesterol levels.
We have highlighted various theoretical and practical issues and problems surrounding
the development and implementation of each of these methods in previous chapters. Here
we take a broader view, and focus on points that are relevant to the methods as a whole, as
well as considering possible future areas of investigation.
Beginning with the models themselves, each can be broadly classified as enforcing
either group-wise sparse (P-GLAW and PsRRR) or dual-level sparse (P-SGLAW) solutions
to the problem of modelling quantitative traits with genetic predictors. The former makes
the assumption that all SNPs within an implicated pathway may influence the phenotype,
whereas the latter assumes that this influence is restricted to only a subset of all SNPs
within a pathway. As such, for pathways selection the former might be expected to be
more sensitive to widely distributed pathway signals than the latter. A further interesting
contrast can be drawn between a competitive approach to the modelling of pathways (P-
GLAW), as against a non-competitive approach (P-SGLAW) that treats each pathway as
independent in the estimation algorithm. This distinction arises primarily because of the
fact that pathways overlap. Again pathway selection performance with each approach is
expected to vary, depending on the nature of the pathways signal, and in particular on
the distributions of overlapping causal genes. We have argued that the non-competitive
approach is best-suited to the detection of important SNPs. However this may be at the
expense of pathway selection performance. A compromise may be to take the ‘two-step’
approach to SNP selection described in the PsRRR AD application study. Ultimately the
choice of model may depend on which assumptions seem most appropriate to the data, as
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well as the particular research question being investigated.
For the modelling of a multivariate trait, at least two outstanding issues with our pro-
posed PsRRR method warrant further work. Firstly, we make the simplifying assump-
tion that phenotypes are uncorrelated by setting the covariance matrix for the phenotype,
Γ = IQ. This has previously been shown to be a reasonable assumption when working
with high dimensional imaging genetic data (Vounou, Nichols, and Montana, 2010). How-
ever, while we describe a simulation study with a lasso based penalty on the phenotype
in Section 3.4.3, a natural extension to the current model would be to impose a suitable
regularisation penalty to account for structure in the phenotype, for example by using the
elastic net, a ROI-based sparse group lasso, or other more complex hierarchical penalty
(Jenatton et al., 2011). Secondly, in this work we have only considered the rank-1 solution
for our PsRRR model. We therefore capture only the first latent factor summarising the
relationship between genotypes and phenotypes. Vounou, Nichols, and Montana (2010)
describe a procedure for capturing further latent factors by regressing out the effects of
important predictors from each successive rank estimation. The situation here is compli-
cated by a number of factors including the presence of overlapping SNPs, the typically
large number of SNPs mapping to selected pathways, and the need to recalibrate weights.
It would nonetheless be interesting to explore the possibility of estimating further ranks
by regressing out the effects of pathways selected above a nominal threshold. Finally we
note interesting work in imaging genetics has recently been done on combining imaging
modalities to detect genetic associations with multi-modal phenotypes (Wang et al., 2012).
This mirrors parallel theoretical and applied work on multi task learning using sparse rep-
resentations (Kim and Xing, 2012; Yang, Kim, and Xing, 2009; Puniyani, Kim, and Xing,
2010), and offers a number of interesting avenues for the extension of the current model.
All the methods developed here are subject to potential bias, in the sense that where
there is no association between genotypes and phenotypes, pathways may not be selected
with an equal probability. Such biases reflect differences in the statistical properties of
each pathway, for example variations in pathway size, number of genes, patterns of LD
between SNPs, and correlations between pathways. A related problem discussed widely in
the sparse modelling literature is the issue of consistency in variable selection, that is the
ability to recover the true underlying sparsity. A number of methods have been proposed
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to improve variable selection consistency for both the lasso and the group lasso, including
the use of adapted weights that reflect certain statistical properties of the predictor vari-
ables (Zou, 2006; Wang and Leng, 2008), and for the lasso, a method that applies small
perturbations to the regularisation parameter λ (Meinshausen and Bu¨hlmann, 2010). Our
bias correction strategy uses adapted weights, but is data-driven, on the grounds that it is
not clear a priori which particular properties may be most relevant to the problem of bias.
We demonstrate through simulations that this strategy gives clear benefits in terms of group
selection consistency. Our iterative weight tuning procedure is however quite computation-
ally intensive, and it would be interesting to compare our results with some of the proposed
alternatives, which may be easier to implement.
Another means of potentially improving consistency in model selection is through the
use of bootstrapping or resampling techniques, and these have been widely demonstrated
to provide a robust measure of variable importance in finite samples (Wang et al., 2010;
Chatterjee and Lahiri, 2011). This type of approach can also provide a solution to the dif-
ficult problem of choosing the correct regularisation, λ, where it has been demonstrated to
give superior model selection performance when compared to alternative methods such as
cross validation, for determining the correct amount of model sparsity (Meinshausen and
Bu¨hlmann, 2010). We use a subsampling approach to rank variables, and demonstrate its
effectiveness for ranking pathways using P-GLAW in a simulation study. We expect these
advantages to extend to the case of dual level sparsity, although it would be interesting to
investigate this further using real data. We do not explore the issue of determining a selec-
tion frequency threshold for the control of false positives here. This has been investigated
in the context of lasso selection (Meinshausen and Bu¨hlmann, 2010), but the direct applica-
tion of existing theory to the present case is not feasible, since overlapping pathways make
clear distinctions between causal and noise variables problematic. In the P-SGLAW appli-
cation study described in Section 4.3, we do however compare empirical pathway and SNP
selection frequency distributions against those obtained using permuted phenotype labels.
These comparisons give some indication of which, amongst the top-k ranked variables, are
likely to be important. There may be scope for formalising this comparison by for example
comparing the shapes of empirical and null distributions or deriving an exact permutation
test.
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There are other potentially interesting areas to explore with regard to the subsampling
method used here. For example, standard approaches consider only the set of variables
selected at each subsample, and ignore potentially relevant information captured in the co-
efficient estimates themselves. The use of this additional information would result in a set
of ranked lists, one for each subsample, and the joint consideration of these lists has the
potential to provide a more robust measure of variable importance, by taking account of
the relative importance of each variable for each subsample. Various techniques for aggre-
gating ranked, partial lists (including those that we used for comparing variable rankings
between datasets in the study described in Section 4.3) have been proposed (Sculley, 2007;
Kolde et al., 2012; Jurman et al., 2012), and we have begun to investigate these in the
context of variable selection. For imaging genetic analysis using PsRRR with sparse selec-
tion of genotypes and phenotypes, it would also be interesting to consider joint selection
probabilities for voxels and pathway selection. This has the potential to boost power by
observing patterns of covariation between voxels (or voxel clusters) and pathways.
As with all PGAS techniques, our methods rest on the use of prior information on
the functional interaction of genes within pathways. Our methods can however be easily
adapted to accommodate other ways of grouping SNP data, for exampling using protein
interaction networks (Wu, Feng, and Stein, 2010), or GO and other ontologies (Jensen and
Bork, 2010).
Despite great efforts, pathway assembly is still in its infancy, and the relative sparsity
of gene-pathway annotations reflects the fact that our understanding of how the majority
of genes functionally interact is at an early stage. As a consequence, annotations from
different pathways databases often vary (Soh et al., 2010), so that the choice of pathways
database can impact PGAS results (Elbers et al., 2009; Cantor, Lange, and Sinsheimer,
2010). Results are also subject to bias resulting from SNP to gene mapping strategies, so
that for example SNP to gene mapping distances will affect the number of unmapped SNPs
falling within gene ‘deserts’ (Eleftherohorinou et al., 2009); SNPs may map to relatively
large numbers of genes in gene rich areas of the genome; and the mapping of a SNP to its
closest gene may obscure a true functional relationships with a more distant gene (Wang
et al., 2009b). Indeed recent research from the ENCODE project indicates that functional
elements may in fact be densely distributed throughout the genome (Bernstein et al., 2012;
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Sanyal et al., 2012), and this information has the potential to radically alter future path-
ways analysis. These issues, together with the fact that PGAS methods are by construction
designed to highlight distributed, moderate to small SNP effects, emphasise the point that
pathways analysis should be seen as complementary to studies searching for single mark-
ers (Wang, Li, and Hakonarson, 2010). This observation is further reinforced in our PsRRR
application study, where a number of genes previously implicated in AD do not map to
known pathways in our study. These genes and their associated SNPs, many of which are
well validated, are therefore excluded, so that a significant part of the known AD-associated
genetic signal is missing.
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Chapter 6
False positives in neuroimaging genetics
using cluster size inference with
Voxel-based morphometry data
While our focus in preceding chapters has been on multivariate methods, mass univariate
modelling, whereby each genetic predictor is tested against each voxel, is still the prevailing
paradigm in imaging genetics (Potkin et al., 2009a). As previously discussed, a major issue
with this approach is the need to apply a severe correction for multiple testing, owing to
the very large number of tests performed, with a resulting detrimental affect on power. One
approach to reducing the scale of this correction is simply to reduce the number of tests.
However, this generally requires assumptions to be made concerning candidate genes or
brain regions, or involves the discarding of potentially informative data (see Section 1.3).
An alternative strategy is to recognise that structure present in both imaging and genetic
data means that the tests are not strictly independent. This means that the effective number
of tests is reduced, rendering a Bonferroni-corrected threshold over conservative.
In the genetic domain, multiple testing corrections that account for SNP-SNP depen-
dencies are well established (Johnson et al., 2010). An important source of structure in the
imaging domain arises from spatial dependencies between voxels, leading to localised pat-
terns of widespread correlation. These correlations are introduced by the image acquisition
process itself, by physiological signal not included in the model, by image resampling dur-
Cluster size inference 175
ing re-alignment, or by explicit smoothing applied in image pre-processing (Frackowiak
et al., 2003). Random field theory (RFT) is a widely used multiple testing method for de-
termining corrected significances while accounting for these spatial dependencies between
voxels (Worsley et al., 1996b). RFT however rests on a number of assumptions regarding
the underlying imaging data (Ashburner et al., 2006), and these correction techniques must
therefore be tested on representative empirical data before their efficacy can be firmly es-
tablished. In a recent study Meyer-Lindenberg et al. (2008) measured rejection (i.e. false
positive) rates in an imaging genetic study using voxel-wise inference against a pre-selected
set of ‘null’ SNPs considered to have no effect on brain structure or function. Subjects in-
cluded patients with schizophrenia, as well as healthy controls. Gene effects on both brain
structure (derived from structural MRI scans using voxel-based morphometry), and brain
function (using fMRI response to cognitive tests) were considered. The study looked at
rejection rates both across the brain as a whole, and for specific regions of interest. Signif-
icance thresholds were adjusted for comparisons across multiple voxels using both family-
wise error (FWER) and false discovery rate (FDR) corrections. At a nominal significance
level of 0.05, they found empirical rejection rates ranging from 0.2–4.1%, suggesting that
for the methods studied, false positive rates are well controlled, and that inferences are if
anything conservative.
Voxel-wise and cluster size tests
Within the MULM framework, a variety of different approaches have been used to identify
significant signals (or ‘activation’) in the brain. In voxel-wise tests, differences in activation
are assessed at each individual voxel, so that locations where there is a strong association
between voxel intensity and a disease phenotype for example, are labelled as significant.
In cluster size tests on the other hand, an arbitrary cluster-forming threshold is applied to
define connected components, with significance then being assessed on the basis of the size
of clusters of contiguous super-threshold voxels. Cluster size tests can be relatively more
sensitive than voxel-wise tests for spatially extended signals (Friston et al., 1996; Poline et
al., 1997; Moorhead et al., 2005), since they make use of the spatial nature of the signal and
require a less severe multiple testing correction (there are always fewer clusters than vox-
els). This necessarily comes at the cost of reduced localising power, as rejecting the cluster
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null hypothesis just implies that one or more voxels within the cluster are significant.
As with voxel-wise tests, cluster size tests must account for the fact that neighbouring
voxels are correlated, even without any experimentally-induced activation. RFT is used to
assign p-values to each cluster in the statistic image accounting for smoothness and search
volume. However, RFT rests on a number of assumptions, and simulation studies have
shown that the performance of this technique depends on the choice of cluster-forming
threshold, and on the use of sufficiently smooth images (Hayasaka and Nichols, 2003).
Inferences using cluster size are also subject to confounding effects arising from ‘non-
stationarity’—i.e., from local variations in noise smoothness. Under non-stationarity, even
when there is no signal present clusters will be larger in ‘smoother’ regions, and smaller in
‘rougher’ ones. Methods that fail to take such local non-stationarity into account will pro-
vide unreliable inferences, with areas of extended smoothness producing large clusters and
increased incidence of false positives, and conversely rough areas demonstrating greater
incidence of false negatives (Hayasaka et al., 2004). One approach to tackling this problem
is to adjust cluster sizes according to local smoothness using non-stationary RFT methods
(Worsley, 2002).
Hayasaka et al. (2004) compared stationary and non-stationary RFT cluster size infer-
ence methods in the identification of activated areas using simulated and PET data sets.
They found that the stationary RFT method was anticonservative1 under non-stationarity,
but that the non-stationary RFT test performed well only for smooth images under high
degrees of freedom. While that work suggested the use of corresponding nonparametric
nonstationary cluster size permutation tests, here we are motivated to use parametric RFT
in the imaging genetics context, as testing massive numbers of SNPs may make permuta-
tion tests impractical.
In this chapter we investigate rejection (type I error) rates for voxel-wise and cluster
size neuroimaging genetic inference on a dataset comprising 181 MRI images and associ-
ated genotype information from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
online database. We follow a similar experimental design to that of Meyer-Lindenberg et
al. (2008), although we restrict our analysis to genotypic effects on whole-brain structure,
1Anticonservative tests produce p-values that are too small, giving rise to rejection (false positive) rates
that are higher than the nominal (expected) rate for the test.
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using voxel-based morphometry (VBM). We supplement our real data with simulated data
evaluations to aid in the interpretation of the real VBM data results.
VBM is a technique used to derive quantitative information on the distribution of par-
ticular types of brain tissue, for example grey and white matter, from structural MRI scans.
Voxel-wise images are first processed using a series of techniques, required for example to
extract (‘segment’) the required feature, for example grey matter concentration, from the
raw image; to correct for subject movement; and to correct for differences in large-scale
brain morphology, thus enabling images taken from different subjects to be compared. Ad-
ditional smoothing is also generally applied at the image pre-processing stage to improve
the signal to noise ratio, and to decrease sensitivity to any misalignment between subjects
(Ashburner and Friston, 2000; Frackowiak et al., 2003).
6.1 Imaging data
6.1.1 ADNI images
181 T1-weighted 3D structural MRI scans from subjects with mild cognitive impairment
(MCI) were obtained from the ADNI database (see Jack et al. (2008) for image acquisi-
tion details). SPM5’s unified segmentation and normalisation (http://www.fil.ion.ucl.ac.
uk/spm/software/spm5) was used to obtain gray matter (GM) images in standard space,
modulated to account for volume changes in the warping to the MNI atlas. Modulated GM
images were smoothed with 6mm and 12mm Gaussian kernels 2. 12mm smoothing is the
de-facto standard in VBM studies (Ashburner and Friston, 2000), and was used by Meyer-
Lindenberg et al. (2008). A second set of images with 6mm smoothing enables the perfor-
mance of RFT at relatively low smoothness to be assessed. A grey matter analysis mask
was constructed by thresholding the mean grey matter image at 0.025. All pre-processing
and smoothing was carried out using SPM5.
2Smoothing with a Gaussian kernel has the effect that each voxels intensity is a weighted average of
surrounding local voxels, with the weighting following a Gaussian function
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6.1.2 Simulated images
Stationary and non-stationary random images were generated using FSL (http://www.fmrib.
ox.ac.uk/fsl/). 3D simulated images had the same voxel size (2mm3) as MNI-warped ADNI
images, and were also masked with the real data analysis mask.
Stationary realisations were generated using white noise images convolved with 6mm
and 12mm 3D Gaussian smoothing kernels. Non-stationary realisations were generated
from white noise images smoothed with 3 different Gaussian kernels extending over dis-
tinct, adjacent 3D regions of the image volume. “6mm” non-stationary images were com-
posed of a central region smoothed with a 9mm kernel, with intermediate and outer regions
smoothed with 6 and 4mm kernels respectively. “12mm” images were made up of regions
smoothed with 12, 8, and 18mm kernels (see Figure 6.1). Final images were smoothed with
a 1.5mm kernel to eliminate discontinuities at the boundaries between different regions, re-
sulting in final non-stationary smoothnesses of 4.3, 6.2 and 9.1mm FWHM for “6mm”, and
8.1, 12.1 and 18.1 for “12mm”. All images were truncated from a larger initial volume to
avoid edge artefacts. Finally, to match the real data under consideration, only voxels within
the real-image grey matter mask were used.
6.2 Genotype data
In their study of genetic effects on brain structure, Meyer-Lindenberg et al. (2008) selected
720 ‘null’ SNPs, found to have no significant association with disease phenotype (at the 5%
level) in separate case-control and family-based analyses. The results of the subsequent
neuroimaging genetic analysis were considered to set an upper bound on null rejection
rates, since individual SNPs may still influence brain structure after all. To establish a lower
bound, the authors repeated their analysis, but with the genotype-phenotype relationship
removed by permuting genotypes across subjects. 4 such permutations were analysed. In
the present study, 700 selected ‘null’ SNPs are used, with 10 subsequent permutations.
ADNI subjects’ genotype information, assayed using the Illumina 610-Quad BeadChip
microarray, was obtained from the ADNI website. Each genotype file contains informa-
tion pertaining to 620,901 SNPs and copy number variations (CNVs). 700 ‘null’ SNPs
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(a)
(b)
(c)
(d)
Figure 6.1: Non-stationary image simulation. (a) Schematic illustrating extent of 3 different smooth-
ness regions. (b) as (a) with ADNI image brain mask applied. (c) Realisation of non-stationary im-
age with outer, middle and inner regions smoothed with 8, 12 and 18mm FWHM Gaussian smooth-
ing kernels. (d) as (c) with final 1.5mm smoothing kernel and ADNI mask applied.
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were selected as follows. Firstly, all CNVs were excluded and only SNPs from chromo-
some 3 were considered. Chromosome 3 was chosen since none of 4 prime candidate
AD-associated genes (APOE, PSEN1, PSEN2 and SORL1 at the time of the study) are
located on this chromosome. Of the remaining 39,928 SNPs, those with a minor allele
frequency of less than 5% were excluded, as were any SNPs with a Bonferroni-corrected
Hardy Weinberg equilibrium p-value < 0.05/700. From the remaining 18,285 SNPs, 700
uniformly-spaced (by rank order in position) SNPs were selected, in order to minimise any
possible linkage disequilibrium effects. Finally, as per standard practice, an adjustment
was made to those SNPs (310 in total) with low numbers (< 10) of homozygous alleles,
merging the rare homozygous and heterozygous groups. This is to minimise any potential
biasing effects in the regression, and is equivalent to fitting a dominant or recessive model
at the SNPs in question.
6.3 Statistical inference
Voxel-wise and cluster size tests for association between genotype and grey matter in-
tensity were performed under the General Linear Model (GLM) (Friston et al., 1995) us-
ing SPM5. Non-stationary tests were carried out using Hayasaka’s non-stationary toolbox
for SPM (http://fmri.wfubmc.edu/cms/NS-General). The non-stationary toolbox corrects
for expected variation in cluster size in non-stationary images under the null, using RFT
(Hayasaka et al., 2004; Worsley et al., 1999). Note that we did not compare our results with
standard permutation tests (Hayasaka et al., 2004). Permutation methods are guaranteed to
be valid under the null hypothesis, and our prime motivation in this study was to address the
accuracy of RFT methods in a large data (i.e. imaging genetics) setting where permutation
might not be practical computationally.
For the real (ADNI) image dataset, genotype effects were measured by modelling mod-
ulated grey matter intensity as a response to SNP allele frequency, with subject age and sex
as nuisance covariates. Each SNP was analysed separately, with SNP significance deter-
mined from t and F -tests, corrected for multiple comparisons using family-wise error and
false discovery rate. For cluster size tests, cluster-forming thresholds, αc, of 0.001, 0.01
and 0.05 under both stationary and non-stationary assumptions were considered. Overall
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rejection rates express the proportion of the 700 SNPs found to cause any significant activa-
tion. All tests were repeated a total of 10 times with genotype-phenotype labels permuted
to remove any possible remaining association.
Equivalent tests on simulated images were conducted with the same SNP and covariate
(age, sex) data, so that degrees of freedom for all tests were the same as those on the ADNI
dataset. These tests were performed without permutation since there can be no association
between genotype and phenotype with random images.
6.3.1 Non-stationary cluster size inference
While the RFT non-stationary cluster size test is described in detail elsewhere (Hayasaka
et al., 2004), we review it again here to facilitate later discussion. Under the GLM, the
intensity y(v) at voxel location v is expressed as a linear combination of regressors
y(v) = Xβ(v) + (v) (6.1)
where, in a study with N subjects and P regressors, X is an (N × P ) design matrix, β(v)
is a P -dimensional vector of parameters to be estimated, and (v) is an N -vector of error
terms, assumed to be independent and normally distributed.
With cluster size tests, significant clusters are formed from contiguous voxels whose t
or F -statistic exceed a fixed cluster-forming threshold, uc (or equivalently, an uncorrected
significance level αc that uniquely determines uc). Briefly, the non-stationary toolbox cor-
rects for image non-stationarity by measuring the ‘smoothness’ at each voxel, a quantity
that is related to the variance of the spatial partial derivatives of the model errors,  in (6.1).
From this a measure of image smoothness, measured in FWHM is obtained. FWHM refers
to the ‘full-width at half-maximum’ of a Gaussian kernel required to smooth a random
(white noise) image into equivalent smoothness of the data at hand; note that isotropy is
not assumed, and FWHM is fully specified by (FWHMx, FWHMy, FWHMz). A related
quantity is the ‘resolution element’ or RESEL (Worsley, 2002), a ‘virtual’ voxel of size
FWHMx × FHWMy × FHWMz. The RESEL count Nres is the number of RESELs that fit
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into the search volume,
Nres =
V
FWHMx × FHWMy × FHWMz (6.2)
where V is the number of voxels in the image. When stationarity (i.e. uniform smoothness
across the image) is assumed, FWHM is calculated by pooling FWHM across the entire
image volume3. Under non-stationarity, FWHM is estimated at each voxel v, giving a
RESEL measure as well. The size of this local RESEL, 1/[FWHMx(v) × FHWMy(v) ×
FHWMz(v)], is denoted RPV(v) for RESELs per voxel at voxel v. In this way a voxel’s
effective volume, relative to image smoothness, is obtained. The next step is to calculate the
smoothness-adjusted cluster size, S ′, by summing effective voxel volumes over a cluster:
S ′ =
∑
v∈C
RPV(v)
where C denotes the set of voxel indices in the cluster. This procedure is equivalent to
measuring cluster size in a distorted image, where space has been warped in such a way so
as to ensure that stationarity holds (Worsley et al., 1999).
Finally, the probability of obtaining clusters of a given size S ′ under the null is cal-
culated, corrected for multiple comparisons. This probability is derived from the image’s
Euler Characteristic, ρ(αc), a topological property which approximates the expected num-
ber of clusters or ‘blobs’ in a thresholded image of given smoothness. In the stationary
case, the expected cluster size under the null is
E(S) =
E(Nv)
E(C)
(6.3)
where E(Nv) is the expected number of suprathreshold voxels (= V αc), and E(C) is the
expected number of clusters (= V ρ(αc)). This expression also holds for S ′ but suprathresh-
old voxels must be measured in RESELs, i.e. E(Nv) = Nresαc. The expected cluster size
is then used to estimate the null distribution of S (or S ′) and obtain uncorrected p-values,
3Precisely the roughness measure is pooled and then converted to FWHM in order to minimise bias; see
(Worsley et al., 1999) for details
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which are then converted to either FWER-corrected p-values or FDR-corrected p-values
(Chumbley and Friston, 2009) that account for searching the brain for significant clusters.
The use of RFT in cluster size tests rests on a number of assumptions (Hayasaka and
Nichols, 2003). These include:
• Lattice approximation - images are assumed to be derived from a smooth (continu-
ous) random field sampled at regular points on a lattice; sampling is assumed to be
fine enough to capture the local features of the field
• Image smoothness - images are smooth at the voxel scale; equivalently, total search
volume is small compared to the size of a resel
• Uniform smoothness (for stationary tests only)
• High cluster-forming thresholds - RFT’s estimate of cluster size distribution under
the null is derived asymptotically, under the assumption that the cluster-forming
threshold αc is sufficiently high
These assumptions present particular practical difficulties for those using cluster size tests,
since low thresholds with as little smoothing as possible - the very conditions under which
RFT performs worst - tend to maximise sensitivity and localising power (Hayasaka and
Nichols, 2003).
6.4 Results
6.4.1 ADNI images
Full cluster and voxel-wise results with FWER correction are presented in Table 6.1. Re-
sults with FDR correction are presented in Table 6.2. Relevant whole brain, voxel-wise
rejection rates reported by Meyer-Lindenberg et al. (2008) are also included for compari-
son.
Results from tests with permuted genotype-phenotype labels (FWER corrected results
only) were broadly similar to those with observed, unpermuted labels, indicating that for
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% Rejection Rates
6mm smoothing 12mm smoothing M-L et al.2
αc Observed Permuted1 Observed Permuted1 Observed Permuted3
t-tests
cluster size
stationary 0.001 10.7 9.2±1.1 3.4 3.6±0.7 - -
0.01 23.3 24.8±2.2 9.4 9.4±1.5 - -
0.05 47.4 46.7±1.8 20.7 18.6±1.5 - -
non-stationary 0.001 10.0 8.1±1.0 3.9 3.8±0.8 - -
0.01 19.9 21.2±1.6 9.1 9.3±1.5 - -
0.05 45.0 43.2±2.2 20.1 18.4±1.6 - -
voxel-wise - 3.4 2.7±0.6 3.0 2.7±0.6 1.9 1.1±0.4
F -tests
cluster size
stationary 0.001 13.0 10.3±1.6 4.4 3.8±1.1 - -
0.01 30.9 29.6±2.1 11.9 10.7±1.7 - -
0.05 60.4 60.6±1.7 26.1 24.5±2.5 - -
non-stationary 0.001 11.6 9.1±1.2 4.7 4.5±1.2 - -
0.01 25.6 25.1±2.1 11.4 10.9±1.7 - -
0.05 57.6 55.6±2.0 25.6 23.9±2.2 - -
voxel-wise - 3.6 2.6±0.7 3.0 2.9±0.7 - -
1Mean rejection rate±SD across 10 permutations
2Results reported in Meyer-Lindenberg et al. (2008). These refer to whole-brain t-tests
using structural (VBM)data with 12mm smoothing only
3Mean rejection rate±SD for 4 permutations
Table 6.1: FWER-corrected results - real (ADNI) images
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% Rejection Rates1
αc 6mm smoothing 12mm smoothing M-L et al.
t-tests
cluster size
stationary 0.001 12.7 2.7 -
0.01 31.4 8.0 -
0.05 51.6 17.7 -
non-stationary 0.001 10.7 2.6 -
0.01 26.9 7.9 -
0.05 48.1 16.0 -
voxel-wise - 3.3 1.9 1.8
F -tests
cluster size
stationary 0.001 15.9 2.9 -
0.01 41.1 11.6 -
0.05 75.7 25.4 -
non-stationary 0.001 13.6 3.3 -
0.01 35.9 11.1 -
0.05 70.3 24.4 -
voxel-wise - 2.9 1.6 -
1Rejection rates for unpermuted data only were considered for FDR-corrected tests
Table 6.2: FDR-corrected results - real (ADNI) images
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the purposes of the present study, chromosome 3 SNP effects on brain structure were neg-
ligible.
The key finding was that rejection rates were poorly controlled for all cluster size tests,
except for those performed on 12mm smoothed images with the highest (most stringent)
cluster-forming threshold, αc = 0.001. In this latter instance, FWER-corrected rejection
rates approached the desired nominal 5% level, with a 3.8±0.8% rejection rate for a t-test
with non-stationary correction under permutation, and 4.5±1.2% under the corresponding
F -test. FDR-corrected results were broadly similar to FWER-corrected results for αc =
0.01 and 0.001.
FWER and FDR-corrected voxel-wise tests were conservative for both 6 and 12mm
smoothed images, in agreement with results for FWER-corrected voxel-wise t-tests on
12mm smoothed images reported by Meyer-Lindenberg et al. (2008).
In general, cluster size tests became more anticonservative at lower thresholds (decreas-
ing uc, increasing αc), and this effect was exacerbated for low smoothness images. Image
smoothness had a pronounced effect on all results, with tests performed on 6mm smoothed
images having substantially higher rejection rates than those performed on images with
12mm smoothing. The degree of smoothing, however, showed little effect on voxel-wise
rejection rates.
Cluster size tests corrected for image non-stationarity were generally closer to nominal
than those assuming stationarity. Finally, F -tests were generally more anticonservative
than equivalent t-tests.
6.4.2 Simulated images
Rejection rates for tests on simulated, random Gaussian images are presented in Table
6.3. For stationary (constant smoothness) 6 and 12mm FWHM Gaussian images, both
stationary and non-stationary cluster size t-tests are highly conservative at higher thresholds
(αc = 0.001, 0.01), but are anti-conservative at the lowest threshold (αc = 0.05). F -tests
are conservative at all thresholds. As with stationary images, non-stationary cluster size
t-tests are conservative at αc = 0.001, 0.01, and anti-conservative at αc = 0.05, whereas
F -tests are conservative at all thresholds. As might be expected, stationary cluster size t
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% Rejection Rates
6mm smoothing 12mm smoothing
αc Stationary Non-stationary1 Stationary Non-stationary2
t-tests
cluster size
stationary 0.001 0.5 5.5 2.3 8.2
0.01 1.0 11.7 1.6 13.0
0.05 13.0 35.9 6.9 21.9
non-stationary 0.001 0.6 1.1 2.7 2.6
0.01 0.9 0.3 1.4 1.9
0.05 9.3 10.7 6.4 7.4
voxel-wise
FWE - 3.7 3.6 5.1 4.3
FDR - 4.7 4.0 2.9 2.7
F -tests
cluster size
stationary 0.001 0.3 5.6 2.9 7.7
0.01 0.4 10.7 0.9 10.9
0.05 2.1 20.3 2.4 20.4
non-stationary 0.001 0.4 0.7 3.1 2.7
0.01 0.4 0.1 0.9 2.3
0.05 1.1 1.4 2.2 2.1
voxel-wise
FWE - 2.6 2.7 3.6 3.1
FDR - 2.0 3.4 1.4 1.3
1Images constructed from concentric regions smoothed with 4, 6 and 9mm Gaussian kernels
2As above with 8, 12 and 18mm Gaussian kernels
Table 6.3: Results - simulated images
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and F -tests on both “6mm” and “12mm” FWHM non-stationary images perform poorly.
Voxel-wise tests are generally conservative, or close to nominal for both stationary and
non-stationary images at 6 and 12mm.
6.5 Discussion
This study provides the first analysis of false positive rates in an imaging genetics study
of VBM data using cluster size inference. Images from a group of 181 subjects with mild
cognitive impairment were tested against a set of 700 ‘null’ SNPs. The analysis presented
here suggests that rejection rates under both stationary and non-stationary assumptions are
poorly controlled at low cluster-forming thresholds or for images with low smoothness.
Null SNPs were selected from chromosome 3, with the simple rationale that none of
the genes reported to have the strongest link with AD at the time of this study were present
on this chromosome. Since this is a somewhat crude measure for selecting SNPs with
no effect on grey matter distribution, we tested this assumption by comparing our results
with those obtained with permuted data, so that any possible SNP effects were removed
through breaking the association between genotype and phenotype. We found that rejection
rates obtained using permuted SNPs were not significantly different from those obtained
without permutation (considering a 95% confidence interval at ±2 sd), indicating that, for
the purposes of this study, SNP effects on brain structure are indeed negligible.
We begin by considering the results obtained with the ADNI image dataset.
Effect of cluster-forming threshold, αc
The choice of cluster-forming threshold, αc was found to have a significant effect on clus-
ter size inference rejection rates. For images smoothed with a 12mm Gaussian kernel, both
stationary and non-stationary tests were found to be well-controlled or conservative at the
most stringent threshold (αc = 0.001). However, tests became increasingly anticonserva-
tive at lower thresholds uc (higher αc) for both 12mm and 6mm smoothed images.
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A possible explanation for the poor performance at low uc is bias in RFT’s estimate of
the expected number of clusters, E(C) (Figure 6.2). If E(C) is over-estimated, expected
cluster size is under-estimated (see Eqn. (6.3)), meaning that more clusters of a given size
are labelled as significant. This over-estimation of E(C) may reflect the inability of the
Euler Characteristic, ρ(αc), to accurately estimate the number of clusters at low thresholds,
where clusters are more numerous and tend to coalesce to form topologically complex pat-
terns (Taylor and Worsley, 2008).
12mm vs. 6mm smoothing kernels
The application of a wide range of Gaussian smoothing kernels in VBM is evident in the
literature — e.g. 4mm (Schwartz et al., 2010), 8mm (Folley et al., 2010) and 10mm (Shen
et al., 2010), as well as the ‘standard’ 12mm (Rosen et al., 2010; Ueda et al., 2010). How-
ever guidelines on the particular choice of smoothing kernel have been described as ‘vague’
(Hayasaka and Nichols, 2003), and there is a suggestion that kernel widths should be de-
termined empirically (Worsley et al., 1996a). Notably, with the use of high-dimensional
warping methods like DARTEL (Ashburner, 2007), there appears to be trend towards lower
smoothing kernels. Improved intersubject alignment means there is a reduced need for
smoothing to ‘blur out’ warping errors. For example, Bergouignan et al. (2009) use 12mm
smoothing with SPM’s standard normalisation and 8mm with DARTEL.
In the present study, differing amounts of smoothing were found to have a pronounced
effect on rejection rates. Tests on images smoothed with a 6mm Gaussian kernel were
highly anticonservative at all thresholds including the highest (αc = 0.001), and were
consistently more anticonservative when compared with 12mm smoothing results.
Poor performance for low smoothness images is in fact to be expected under the lattice
assumption of random field theory (Hayasaka and Nichols, 2003). As image smoothness
decreases, this lattice approximation breaks down, since the underlying variation is poorly-
captured by discrete, voxel-wise sampling. This means that continuous RFT results are
modelling unobserved, large intensity changes between sampled voxels. While previous
reports have suggested 3 voxel FWHM smoothing (i.e. 6mm FWHM smoothing for the
2mm voxels considered here) is sufficient (Nichols and Hayasaka, 2003), for the ADNI
data this is insufficient, as we find an over-estimation of the expected number of clusters,
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with the gap between expected and observed values, E(C)− C, generally greater at 6mm
than at 12mm (see Figure 6.2).
Stationary vs. non-stationary tests
Non-stationary cluster-wise rejection rates were generally similar, or slightly better-controlled
than those assuming stationarity, suggesting that there is at least some non-stationarity
present in the images. For non-stationary images, stationary tests would also be expected
to perform worse at lower thresholds where clusters are larger and more likely to encom-
passes extra-smooth regions, and this is indeed the case. A heuristic measure of image
non-stationarity was obtained by plotting the distribution of voxel-wise FWHM, obtained
from the RPV image produced by SPM (FWHM=RPV−1/3). A completely stationary im-
age would be expected to have constant FWHM across the entire image volume. Any
pronounced departure from this suggests non-stationarity. An analysis of 12mm and 6mm
FWHM images (see Figure 6.3) finds a spread of around 7mm to 17mm and SD of 2.6mm
for 12mm smoothed images, (4mm to 8mm and SD of 1.0mm for 6mm images).
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Figure 6.3: Distribution of voxel-wise FWHM for ADNI images smoothed with 6mm (left) and
12mm (right) Gaussian smoothing kernels. Voxel-wise FWHM gives an indication of local smooth-
ness and corresponds to the ‘full-width at half-maximum’ of a Gaussian kernel required to produce
a random (white noise) image of equivalent smoothness. A perfectly stationary image would have
constant FWHM at all voxels. In contrast, a highly non-stationary image would have a large spread
in FWHM, as is seen here.
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While this spread of FWHM could be attributed to sampling variation, the theoretical
SD of the FWHM estimator can be computed by simulation (see Appendix B of Hayasaka
et al. (2004)). We find theoretical SDs of 0.696mm for 12mm smoothed stationary images,
and 0.348mm for 6mm images, which are much smaller than our observed values. While
these theoretical SDs under stationarity again depend on the accuracy of the RFT results,
they provide further evidence of substantial image non-stationarity.
T vs. F image results
The t and F image cluster size results cannot be directly compared. While the single
degree-of-freedom F test we used is exactly equal to the square of the t test used, the set
of clusters generated will be different for two reasons. First, the one-sided α level used to
define a t statistic threshold will not equal the square root of the F statistic threshold of
the same α level (an F ’s level corresponds to the t’s two-sided alpha level). Further, the
F image has the clusters arising from negative t values. Thus there will be both more and
different clusters in the F images for the same data and αc.
These caveats aside, the rejection rates on the real data were largely similar for the same
αc’s, with valid performance found only for 12mm smoothed data with αc = 0.001.
Simulated images
In marked contrast to tests performed on the ADNI image dataset, non-stationary cluster
size tests on simulated stationary and non-stationary random images were found to be valid
(conservative) at both high and moderate cluster-forming thresholds (αc = 0.001, 0.01),
irrespective of image smoothness.
Other studies using simulated images produced from stationary and non-stationary,
Gaussian random fields have also considered the effect of varying both the cluster-forming
threshold and image smoothing kernel. With stationary simulated images, Hayasaka and
Nichols (2003, Figure 2) found that cluster size tests were conservative over the same range
of image smoothness with αc = 0.001, 0.01, in agreement with our results. Using similar
non-stationary simulated data, Hayasaka et al. (2004) also found that non-stationary clus-
ter size tests were conservative with images of low smoothness (comparable to our 6mm
non-stationary images), and with 20 subjects, but only considered αc = 0.01.
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The large discrepancy in cluster size inference rejection rates between real and sim-
ulated image data over a range of thresholds and smoothing kernels suggests that there
are features of the real VBM data that may be incompatible with the RFT method. This
may for example be due to the inherent non-normality of VBM data, or to patterns of non-
stationarity in real images that are more complex than those simulated here. Non-normality
of VBM data has been reported before, but only when considering the accuracy of voxel-
wise significance (Viviani et al., 2007; Salmond et al., 2002). This other work found that
imbalanced group comparisons required 12mm FWHM smoothing to accurately control
voxel-wise false-positives, though balanced group comparisons were accurate with smaller
kernel sizes. As genotypes are rarely equally frequent, the imbalanced results are most
relevant to this setting.
We performed a number of additional simulations in order to investigate the role of
non-normality in cluster size inference. VBM data is hard bounded between 0 and 1, and
modulated VBM nearly so. A Shapiro-Wilks test for normality at each voxel, using the
spmd5beta diagnostic toolbox (http://www.sph.umich.edu/$\sim$nichols/SPMd/) reveals
that both 6mm and 12mm smoothed images are indeed highly non-normal. This deviation
is particularly marked for 6mm images, with around 45% of voxels exceeding a nominal
5% Shapiro-Wilks threshold. In contrast, the stationary Gaussian noise-derived simulated
images describe above show no significant deviation from normality. To test the effect of
introducing non-normality to our simulations, we generated a set of images by first thresh-
olding Gaussian noise images smoothed with 6mm and 8mm kernels, to produce ‘patchy’,
binary images. These were then smoothed with 6mm and 12mm kernels to produce images
with a range of deviations from non-normality that mimicked or exceeded the deviations
from normality exhibited by the real VBM data, as measured with a Shapiro-Wilks test. Re-
gression of these images against all 700 SNPs produced similar results to those described
above, with conservative results at high and moderate cluster-forming thresholds with both
6mm and 12mm smoothing.
To test the effect of more complex patterns of non-stationarity, we segmented FWHM
images derived from 6mm and 12mm smoothed ADNI images to produce a set of topo-
logically complex masks corresponding to regions of high, medium and low ‘smooth-
ness’. Non-stationary simulated images were then generated by filling each masked region
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with differently smoothed Gaussian noise, as described in section 6.1.2. Once again, a
full analysis produced conservative results, with rejection rates below a nominal 5% for
αc = 0.001, 0.01 for both 6mm and 12mm smoothed images.
One final set of simulated images was produced by again generating complex, non-
stationary FWHM-segmented masks, this time filled with non-normal, Gaussian noise-
derived data, as described above. Rejection rates were again well controlled, in marked
contrast to results obtained using real ADNI data.
6.6 Conclusion
We found that RFT nonstationary cluster size tests on real VBM data perform poorly at low
cluster-forming thresholds and for images with low smoothness. In a second analysis with
synthetic image data generated using Monte Carlo simulations, we found performance was
instead excellent, if conservative. The contradictory results indicate there are features of
the real VBM data that are incompatible with the RFT method.
We suggest two possible reasons for this difference in performance. First, as grey matter
segmented data is hard bounded between 0 and 1, and modulated VBM data nearly so, the
data may exhibit non-normality, violating a foundational assumption of the RFT method.
Second, while we simulated nonstationarity, the pattern of nonstationarity observed in real
VBM is substantially more complex (Figure 6.4). However, further tests using simulated
images with both significant deviations from normality, and with more complex patterns of
non-stationarity still produced conservative results, so that we were unable to find evidence
that either aspect of real VBM data is responsible for the poor performance observed with
real image data.
There are many ways to characterise deviations from normality in image data, and it
may be that the VBM data deviates from normality in ways which we have been unable to
capture in our simulations. The same is true of our attempts to model the true complexity
of nonstationarity. Additionally, while RFT assumes that images can be warped to approxi-
mate stationarity, for VBM these hypothetical warps could be so convoluted so as to render
the constituent approximations inaccurate.
Fortunately, an alternative to parametric, RFT-based cluster size inference is available
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Figure 6.4: 12mm VBM image non-stationarity. The figure illustrates the variation in image
smoothness measured in FWHM, derived from the SPM RPV image. There is a wide variation,
ranging from 3.8 to 27.7mm.
— a nonparametric permutation test where the data itself is used to derive an empirical
cluster size distribution under the null (Hayasaka et al., 2004). While this approach carries
a greater computational burden, the false positive rates are exact (Hayasaka and Nichols,
2003), and the permutation approach should be reasonable for studies examining only a
small number of SNPs.
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Appendix A
Review of Existing Pathways Methods
In the following review we briefly describe a selection of existing PGAS analysis methods.
We divide these into univariate-based methods that rely on SNP-wise association tests,
and multivariate-based methods that depend on multivariate or multilocus modelling. The
number of methods is now large and growing, particularly in the univariate category (see
Wang, Li, and Hakonarson (2010); Fridley and Biernacka (2011); Khatri, Sirota, and Butte
(2012) for reviews). We therefore select a small number of methods to give a sense of some
of the issues involved. A short summary of key features for each method is given at the end
in Table A.1.
A.1 Univariate-based methods
The majority of existing PGAS methods begin with multiple univariate tests of association,
in which each SNP in the study is scored, for example using χ2 statistics in case-control
studies, or t-statistics or p-values from regression-based tests in the case of quantitative
traits. A wide variety of techniques are then used to combine univariate statistics into
pathway scores. All methods employ strategies for dealing with the problem of differing
correlation structures (LD) within genes and pathways, and also with variations in gene
and pathway size. Without a correction for LD, signals within pathways containing large
groups of highly correlated SNPs, for example residing within large genes, will have in-
flated numbers of high-scoring SNPs, and so bias pathway scores. To account for this, most
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methods compare observed pathway scores against null distributions formed from multiple
permutations of phenotype labels, which has the added advantage of also correcting for
variation in gene and pathway size.
For the combination of univariate SNP statistics, a group of methods build on the Gene-
set Enrichment Analysis (GSEA) technique, first proposed for the pathway analysis of gene
expression data (Subramanian et al., 2005). GSEA methods attempt to determine the degree
to which high ranking SNPs or genes are over-represented in a given gene set or pathway,
in comparison with a null dataset formed from multiple permutations of phenotype labels.
Consider for example the situation where H genes are partitioned into L groups or
pathways, Gl, (l = 1, . . . , L), each containing Hl genes. The GenGen method (Wang, Li,
and Bucan, 2007) first assigns a score to gene Wk, (k = 1, . . . , H), by taking the highest
statistic value (e.g. χ2) of all SNPs mapped to that gene. Gene scores are then sorted into
a ranked list, r(1), . . . , r(H), where r(1) is the gene score corresponding to the gene showing
greatest association with the phenotype. An enrichment score, ES(l) for pathway l, is then
given by
ES(l) = max
1≤t≤H
{ ∑
Wk∗∈Gl,k∗≤t
|r(k∗)|γ
HR
−
∑
Wk∗ /∈Gl,k∗≤t
1
H −Hl
}
(A.1)
where HR =
∑
Wk∗∈Gl |r(k∗)|γ . When γ = 0, the enrichment score depends only on gene
rank, whereas scores are weighted by gene score when γ = 1. (A.1) is a Kolmogorov-
Smirnov-type running sum that measures the extent to which high ranking genes are en-
riched in Gl, compared to a randomly selected set of genes. ES(l) will be high when a large
part of the association signal is to be found in genes in Gl.
As a next step, a correction for the influence of both LD and the number of SNPs
mapped to each gene on pathway enrichment scores is obtained as follows. Calculation of
the pathway enrichment score is repeated with phenotype labels permuted, to give a distri-
bution of enrichment scores, ES(l, pi), (pi = 1, . . . , Npi), generated from Npi permutations.
From this, a normalised enrichment score NES(l) is calculated as a Z score,
NES(l) =
ES(l)−mean(ES(l, pi))
SD(ES(l, pi))
When multiple pathways are tested, a measure of pathway significance corrected for mul-
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tiple testing is obtained using an FDR procedure. The FDR for pathway l∗ is calculated
as
pFDR(l∗) =
% of all (l, pi) with NES(l, pi) ≥ NES(l∗)
% of observed l with NES(l) ≥ NES(l∗)
where the numerator is the proportion of false discoveries, obtained by measuring the num-
ber of permuted datasets having an NES greater than that observed for pathway l∗; and the
denominator is the proportion of results declared positive, i.e. the proportion of pathways
having an NES greater than or equal to that observed for pathway l∗.
GSEA-SNP (Holden et al., 2008) follows a similar strategy to GenGen, this time using
individual SNP scores, rather than gene scores.
A different approach is used in the PLINK set-based test, part of the popular PLINK
genome data analysis toolset (Purcell et al., 2007). Here pathway scores are obtained by
taking the mean, marginal p-value of a pre-determined maximum number of ‘independent’
SNPs within the pathway, defined as those whose pairwise LD is below a certain threshold
value. Consider P mapped SNPs, j = 1, . . . , P , once again partitioned into L groups or
pathways, Gl, (l = 1, . . . , L), each containing Pl SNPs. A measure of significance for
pathway l is then obtained using the following algorithm:
1. rank SNP p-values, obtained from multiple univariate QTTs (see Section 1.1), in
order of decreasing significance, s(1), . . . , s(Pl), where s(1) is the SNP p-value corre-
sponding to the SNP in pathway l showing greatest association with the phenotype
(i.e. having the smallest p-value)
2. form the set G∗l ⊂ Gl, containing P ∗l independent SNPs as follows:
(a) let D = Gl and G∗l = ∅
(b) add the top-ranked SNP, j∗ from D, to G∗l . Denote the number of SNPs in G∗l
by N∗l .
(c) remove fromD, SNP j∗, and all SNPs, k whose pairwise LD, r2(j∗, k) passes a
threshold R. Here r2(j∗, k) is the r2 coefficient measuring correlation between
SNPs j∗ and k (Hedrick and Kumar, 2001)
(d) repeat steps (b) and (c) until N∗l = P
∗
l
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3. form the pathway statistic,
u(l) =
1
P ∗l
∑
j∗∈G∗l
s(j∗)
4. repeat steps 1. to 3. Npi times, each time permuting phenotype labels, to obtain a null
distribution for the pathway statistic u(l, pi), (pi = 1, . . . , Npi)
5. the empirical pathway p-value is then calculated as the proportion of all permutations
with u(l, pi) ≤ u(l)
6. as a final step, where more than one pathway is tested, a correction for multiple
testing can be applied
Other strategies for combining univariate SNP scores include the rank truncated prod-
uct method proposed by Yu et al. (2009), which uses the truncated product of top-ranking
univariate p-values to determine pathway scores; the SNP ratio test (O’Dushlaine et al.,
2009), where the proportion of SNPs passing a predefined significance threshold within a
given pathway is used to determine pathway significance, and the Aligator method (Hol-
mans et al., 2009), which also sets a threshold for SNP significance, but defines as signifi-
cant any gene containing at least one significant SNP. Eleftherohorinou et al. (2009) assess
pathway significance by summing univariate SNP statistics across a pathway and compar-
ing this with a parametised null distribution obtained through permutation. In a separate
second stage, SNPs driving the pathway effect in significant pathways are selected using
lasso logistic regression.
One interesting way to distinguish PGAS methods is by focusing on the type of null
hypothesis being tested. With the PLINK set-based test for example, pathway significance
is determined with reference to a null distribution formed from SNPs within the pathway
under consideration. PGAS methods testing null hypotheses of this type can be classified
as self-contained (Wang, Li, and Hakonarson, 2010), and are clearly useful in studies fo-
cussing on candidate genes and pathways. In contrast, with the GenGen method, ES(l) in
(A.1) is calculated by comparing enrichment for genes within pathway l, to other mapped
genes not in l. Such methods have been described as competitive, and this approach might
be expected to give better control of false positives, although at the cost of lower power,
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since the self-contained null hypothesis is more restrictive (Goeman and Bu¨hlmann, 2007;
Wang, Li, and Hakonarson, 2010).
Univariate-based PGAS studies have identified numerous pathways, previously impli-
cated in a wide range of diseases, as well as providing new candidate pathways for future
consideration. However, despite their obvious advantages for detecting small, coordinated
signals in PGAS, such methods have a number of disadvantages and potential weaknesses.
First of all, many methods require the generation of null distributions of univariate test
statistics through permutation, making them computationally intensive for genome wide
datasets. Also, permutation methods assume that the permuted units - subjects, SNPs or
genes - are independent and identically distributed. SNP-SNP and gene-gene interactions,
together with uncorrected relatedness between subjects may therefore introduce bias, de-
pending on the techniques being used (Wang, Li, and Hakonarson, 2010). Each of the
methods considered here uses different strategies for combining univariate statistics to as-
sess pathways significance, so that each method may highlight different pathways depend-
ing on the distribution and effect sizes of causal SNPs within genes and pathways. Power
may also suffer when testing multiple pathways due to the application of stringent multiple
testing corrections.
A.2 Multivariate methods
In contrast to univariate-based methods, multivariate PGAS methods in which SNPs are
modelled jointly have only recently begun to emerge. Potential benefits of a multivariate
approach include the capacity to model covariates, and the prospect of increased power
and better control of false positives, since small SNP effects may be revealed when other,
stronger effects have been accounted for, and similarly false signals can be weakened by
the inclusion of stronger signals from true causal associations (Hoggart et al., 2008).
Pathways of Distinction Analysis (Braun and Buetow, 2011) uses distance metrics
between SNPs within pathways to assess whether cases are more similar to other cases
than to controls, and vice versa. This multilocus approach directs attention away from SNPs
exhibiting independent main effects towards a focus on epistatic interactions, whereby joint
interactions play a much larger part in driving pathway significance.
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The use of sparse regression models in PGAS is a relatively recent development. As
with univariate-based tests, these must take variations in gene and pathway size, and LD
when establishing pathway significance. Once again permutation methods are often em-
ployed to correct for this, along with various techniques to reduce correlation within genes
or pathways prior to model fitting. Here we review a few examples, focussing on the regres-
sion models used, rather than on other aspects such as the different permutation methods
employed for establishing significance.
Gene set ridge regression in association studies or GRASS (Chen et al., 2010) uses a
novel combination of methods including penalised regression to determine pathway sig-
nificance in case control studies. They begin by mapping groups of SNPs to genes, Wk
(k = 1, . . . , Hl)), in a singe pathway of interest, Gl. The dimensionality of each gene is
then reduced by characterising within-gene variation as a set of orthogonal ‘eigenSNPs’,
obtained by PCA. This is justified on a number of grounds including the desirability of
reducing redundant information in a gene due to LD, and of reducing undesirable effects
due to correlation that can arise when using lasso-based models (Zou and Hastie, 2005).
Individual eigenSNP coefficients are obtained through the following objective function
βˆ = arg min
β
{
L(β) + λ
Hl∑
k=1
(||βk||1)2
}
(A.2)
where β is the vector of eigenSNP coefficients for all SNPs in Gl and βk = (βk1 , . . . , βkSk )
is the parameter vector corresponding to eigenSNPs in Wk, and L(β) is the logistic loss
function (2.13). Here, the penalty promotes sparsity amongst eigenSNPs by applying a
lasso penalty within each gene, while retaining all genes in the model through the imposi-
tion of a ridge penalty among genes. λ is determined using Akaike’s information criterion
(AIC) (Akaike, 1974). Gene level association is estimated from ||βˆk||2, from which a stan-
dardised value
β˜k =
||βˆk||2 − µβˆk
σβˆk
by permuting phenotype labels. Finally a pathway score is obtained as
T = ||β˜||2 =
√
β˜1 + . . .+ β˜Hl
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from which a pathway p-value is obtained as the proportion of permuted datasets with a
T score greater than the observed value. The optimisation (A.2) is described as a form of
‘group ridge’ regression, in that it affords smooth shrinkage of grouped eigenSNP predic-
tors. Note that the assumption is that all genes in a pathway will contribute to the pathway
association signal.
In contrast Zhao et al. (2011) impose an additional layer of sparsity at the gene level,
on the assumption that this is not the case. Once again this method is implemented for
case-control data with a logistic loss function. In a similar way to GRASS, the method
begins by summarising genetic variation in each gene using PCA, but this time only the
first principal component (FPC) is used for the subsequent analysis. Gene selection then
proceeds by solving the optimisation
βˆ = arg min
β
{
L(β) + λ
Hl∑
k=1
||βk||1
}
where the βk, k = 1, . . . , Hl are coefficients corresponding to the FPCs for each gene in
pathway l. For a given value of λ, this produces a set, S(λ) = {k : βk 6= 0} of genes
selected by the model. The method proceeds by selecting multiple such sets, each with a
different value of λ, with the ‘best’ subset S∗ selected using the AIC criterion. A pathway
likelihood ratio (LR) statistic is then obtained by comparing a logistic likelihood function
with β = βˆ against the null with βˆ = 0. Finally a pathway p-value is obtained by compar-
ing the pathway LR statistic against those obtained from multiple permuted datasets.
We conclude this section by describing the penalised regression method proposed by
(Zhou et al., 2010). While not strictly a PGAS method, it provides an interesting example of
penalised regression since it combines `2 and `1 penalties, with SNPs grouped into genes, to
drive simultaneous SNP and gene selection, with a particular emphasis on the identification
of rare variants. They apply their method in a small application study comprising 148 SNPs
and 17 genes, and this is thus an early example of the application of the sparse group lasso
model (see Chapter 4) to SNP data. SNPs are mapped to H genes, Wk (k = 1, . . . , H)),
each containing Sk SNPs, with the parameter vector corresponding to SNPs inWk, denoted
byβk = (βk1 , . . . , βkSk ). SNPs not mapped to genes are however still retained in the model.
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The objective function is then given by
βˆ = arg min
β
{
L(β) + λg
H∑
k=1
||βk||2 + λs
P∑
j=1
||βj||1
}
Sparsity at the SNP level is encouraged through the use of the `1 (lasso) penalty. The `2
(group lasso) penalty encourages sparsity at the gene level, and aids the detection of rare
variants residing within selected genes, since the ridge penalty relaxes the constraint on
SNP coefficients within those genes. The regularisation penalties, λg and λs are adjusted
to ensure that each SNP experiences the same overall penalty, irrespective of whether it
is mapped to a gene or not. Thus if a SNP j that is mapped to a gene experiences a
penalty λg||βk||2 + λs|βj|, an unmapped SNP experiences an equal penalty λ|βj|, where
λ = λg + λs.
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